0001144204-14-047741.txt : 20140807 0001144204-14-047741.hdr.sgml : 20140807 20140807163037 ACCESSION NUMBER: 0001144204-14-047741 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140807 DATE AS OF CHANGE: 20140807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 141024314 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 10-Q 1 v384196_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

001-33357

(Commission file number)

PROTALIX BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Florida		65-0643773
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)

2 Snunit Street
Science Park
POB 455
Carmiel, Israel		20100
(Address of principal executive offices)		(Zip Code)

	+972-4-988-9488
	(Registrant’s telephone number, including area code)

	N/A
	(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “large accelerated filer” and “accelerated filer” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

On August 1, 2014, approximately 93,664,898 shares of the Registrant’s common stock, $0.001 par value, were outstanding.

FORM 10-Q

TABLE OF CONTENTS

		Page

	PART I – FINANCIAL INFORMATION
	Cautionary Statement Regarding Forward-Looking Statements	ii
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets – As of June 30, 2014 (Unaudited) and December 31, 2013	1
	Condensed Consolidated Statements of Operations (Unaudited) – For the Six Months and the Three Months Ended June 30, 2014 and 2013	2
	Condensed Consolidated Statement of Changes in Capital Deficiency (Unaudited) – For the Six Months Ended June 30, 2014 and 2013	3
	Condensed Consolidated Statements of Cash Flows (Unaudited) – For the Six Months Ended June 30, 2014 and 2013	4
	Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16
Item 4.	Controls and Procedures	17

	PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	18
Item 6.	Exhibits	19

Signatures		20

Except where the context otherwise requires, the terms, “we,” “us,” “our” or “the Company,” refer to the business of Protalix BioTherapeutics, Inc. and its consolidated subsidiaries, and “Protalix” or “Protalix Ltd.” refers to the business of Protalix Ltd., our wholly-owned subsidiary and sole operating unit.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

The statements set forth under the captions “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and other statements included elsewhere in this Quarterly Report on Form 10-Q, which are not historical, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms “anticipate,” “believe,” “estimate,” “expect,” “can,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and words or phrases of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.

Examples of the risks and uncertainties include, but are not limited to, the following:

risks related to the commercialization efforts for taliglucerase alfa in the United States, Israel, Brazil, Canada, Australia and other countries;

the risk of significant delays in the commercial introduction of taliglucerase alfa in the United States, Brazil, Israel, Canada, Australia and other markets as planned;

risks related to the acceptance and use of taliglucerase alfa or any of our product candidates, if approved, by physicians, patients and third-party payors;

the supply of drug product pursuant to our supply arrangement with Fundação Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MOH;

risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement which may result in the termination of such agreement which may have a material adverse effect on our company;

the risk that we will not be able to develop a successful sales and marketing organization for taliglucerase alfa in Israel or for any other product candidate in a timely manner, if at all;

failure or delay in the commencement or completion of our preclinical studies and clinical trials which may be caused by several factors, including: unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; slower than expected rates of patient recruitment; inability to monitor patients adequately during or after treatment; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; or lack of sufficient funding to finance our clinical trials;

the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy, that our product candidates will not have the desired effects or include undesirable side effects or other unexpected characteristics;

our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services;

delays in the approval or the potential rejection of any application filed with or submitted to the regulatory authorities reviewing taliglucerase alfa outside of the United States, Israel, Brazil, Canada, Australia and other countries in which taliglucerase alfa is already approved;

our ability to establish and maintain strategic license, collaboration and distribution arrangements, and to manage our relationships with Pfizer Inc., Fiocruz and any other collaborator, distributor or partner;

risks relating to our ability to finance our research programs, the expansion of our manufacturing capabilities and the ongoing costs in the case of delays in regulatory approvals for taliglucerase alfa outside of the United States, Israel, Brazil, Canada, Australia and other countries in which taliglucerase alfa is already approved;

delays in our preparation and filing of applications for regulatory approval of our other product candidates in the United States, the European Union and elsewhere;

our expectations with respect to the potential commercial value of our product and product candidates;

the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories and, therefore, will be subject to potential marketing and commercialization restrictions;

the impact of development of competing therapies and/or technologies by other companies;

any lack of progress of our research and development activities and our clinical activities with respect to any product candidate;

the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;

potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance coverage;

risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our 2018 convertible notes, or any other indebtedness;

the possibility of infringing a third party’s patents or other intellectual property rights;

the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property rights against third parties;

risks relating to biosimilar legislation and/or healthcare reform in the United States or elsewhere; and

the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.

Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.

These forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013, and are described from time to time in the reports we file with the U.S. Securities and Exchange Commission, or the Commission.

iii

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

PROTALIX BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
(Unaudited)

	June 30, 2014			December 31, 2013

ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	71,144		$	86,398
Accounts receivable - Trade		2,097			2,091
Other assets		1,988			1,457
Inventories		7,135			7,957
Total current assets		82,364			97,903

FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT		1,721			1,578
PROPERTY AND EQUIPMENT, NET		12,438			13,711
DEFERRED CHARGES		128			141
Total assets	$	96,651		$	113,333

LIABILITIES NET OF CAPITAL DEFICIENCY

CURRENT LIABILITIES:
Accounts payable and accruals:
Trade	$	3,592		$	5,254
Other		16,305			12,073
Deferred revenues		7,282			9,369
Total current liabilities		27,179			26,696

LONG TERM LIABILITIES:
Convertible notes		67,255			67,048
Deferred revenues		39,514			41,796
Liability in connection with collaboration operation					2,371
Liability for employee rights upon retirement		2,493			2,368
Total long term liabilities		109,262			113,583
Total liabilities		136,441			140,279

COMMITMENTS

CAPITAL DEFICIENCY		(39,790	)		(26,946	)
Total liabilities net of capital deficiency	$	96,651		$	113,333

The accompanying notes are an integral part of the condensed consolidated financial statements.

PROTALIX BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share data)
(Unaudited)

	Six Months Ended						Three Months Ended
	June 30, 2014			June 30, 2013			June 30, 2014			June 30, 2013
REVENUES	$	9,121		$	5,832		$	2,425		$	2,264
COMPANY’S SHARE IN COLLABORATION AGREEMENT		948			1,200			261			800
COST OF REVENUES		(5,678	)		(2,289	)		(1,605	)		(1,318	)
GROSS PROFIT		4,391			4,743			1,081			1,746
RESEARCH AND DEVELOPMENT EXPENSES (1)		(15,228	)		(15,744	)		(7,076	)		(7,990	)
Less – grants and reimbursements		4,199			3,963			2,114			1,532
RESEARCH AND DEVELOPMENT EXPENSES, NET		(11,029	)		(11,781	)		(4,962	)		(6,458	)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)		(5,277	)		(4,285	)		(1,566	)		(2,182	)
OPERATING LOSS		(11,915	)		(11,323	)		(5,447	)		(6,894	)
FINANCIAL EXPENSES		(1,789	)		(22	)		(874	)		(9	)
FINANCIAL INCOME		240			187			202			66
FINANCIAL INCOME (EXPENSES) – NET		(1,549	)		165			(672	)		57
NET LOSS FOR THE PERIOD	$	(13,464	)	$	(11,158	)	$	(6,119	)	$	(6,837	)
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:	$	(0.15	)	$	(0.12	)	$	(0.07	)	$	(0.07	)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE – BASIC AND DILUTED:		92,754,640			92,241,505			92,820,897			92,297,522
(1) Includes share-based compensation		591			1,589			163			719
(2) Includes share-based compensation		(14	)		910			(256	)		413

The accompanying notes are an integral part of the condensed consolidated financial statements.

PROTALIX BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY

(U.S. dollars in thousands, except share data)

(Unaudited)

						Additional
	Common			Common		paid–in		Accumulated
	Stock (1)			Stock		Capital		deficit			Total
	Number of shares			Amount

Balance at December 31, 2012		93,489,809		$	93	$	180,145	$	(183,595	)	$	(3,357	)
Changes during the six-month period ended June 30, 2013:
Share-based compensation related to stock options							645					645
Share-based compensation related to restricted stock award, net of forfeitures of 1,667 shares		(1,667	)				1,854					1,854
Exercise of options granted to employees		21,480			1		29					30
Net loss for the period									(11,158	)		(11,158	)
Balance at June 30, 2013		93,509,622		$	94	$	182,673	$	(194,753	)	$	(11,986	)
Balance at December 31, 2013		93,551,098		$	94	$	184,345	$	(211,385	)	$	(26,946	)
Changes during the six-month period ended June 30, 2014:
Share-based compensation related to stock options							190					190
Share-based compensation related to restricted stock award							387					387
Exercise of options granted to employees (includes net exercise)		55,362			*		43					43
Net loss for the period									(13,464	)		(13,464	)
Balance at June 30, 2014		93,606,460		$	94	$	184,965	$	(224,849	)	$	(39,790	)

* Represents amount less than thousand

(1) Common Stock, $0.001 par value; Authorized – as of June 30, 2014 and 2013 - 150,000,000 shares.

The accompanying notes are an integral part of the condensed consolidated financial statements.

PROTALIX BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars in thousands)

(Unaudited)

	Six Months Ended
	June 30, 2014			June 30, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(13,464	)	$	(11,158	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Share based compensation		577			2,499
Depreciation and write down of fixed assets		1,628			1,818
Financial income, net (mainly exchange differences)		(133	)		(120	)
Changes in accrued liability for employee rights upon retirement		102			93
Gain on amounts funded in respect of employee rights upon retirement		(25	)		(14	)
Amortization of debt issuance costs and debt discount		220
Changes in operating assets and liabilities:
Decrease in deferred revenues (including non-current portion)		(4,369	)		(4,207	)
Increase in accounts receivable and other assets		(397	)		(406	)
Decrease (increase) in inventories		822			(3,152	)
Increase (decrease) in accounts payable and accruals (including long term )		180			(3,048	)
Net cash used in operating activities	$	(14,859	)	$	(17,695	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	$	(371	)	$	(1,341	)
Investment in restricted deposit		(93	)
Amounts funded in respect of employee rights upon retirement, net		(101	)		(71	)
Net cash used in investing activities	$	(565	)	$	(1,412	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of options	$	31		$	30
Net cash provided by financing activities	$	31		$	30
EFFECT OF EXCHANGE RATE CHANGES ON CASH	$	139		$	168
NET DECREASE IN CASH AND CASH EQUIVALENTS		(15,254	)		(18,909	)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		86,398			52,035
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	71,144		$	33,126

The accompanying notes are an integral part of the condensed consolidated financial statements.

PROTALIX BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars in thousands)

(Unaudited)

(Continued) - 2

	Six Months Ended
	June 30, 2014		June 30, 2013

SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Purchase of property and equipment	$	170	$	304
Exercise of options granted to employees	$	12

The accompanying notes are an integral part of the condensed consolidated financial statements.

PROTALIX BIOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

General

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company’s proprietary ProCellEx^® protein expression system (“ProCellEx”). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (“EMA”) application process in the European Union. The Company’s two subsidiaries are referred to collectively herein as the “Subsidiaries.”

On May 1, 2012, the U.S. Food and Drug Administration (“FDA”) approved taliglucerase alfa for injection, the Company’s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the “Israeli MOH”) in September 2012, by the Brazilian Ministry of Health (the “Brazilian MOH”) in March 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.

Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO™ by Pfizer Inc. (“Pfizer”), the Company’s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the “Pfizer Agreement”). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO™.

Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA’s approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.

PROTALIX BIOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the “Brazil Agreement”) with Fundação Oswaldo Cruz (“Fiocruz”), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of 2014.

During the six months ended June 30, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.

To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.’s behalf in connection with the supply of taliglucerase alfa to Fiocruz.

Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.

In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d’Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.

In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.

PROTALIX BIOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.

Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.

Net loss per share

Basic and diluted loss per share (“LPS”) are computed by dividing net loss by the weighted average number of shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”) outstanding for each period.

Diluted LPS does not include 7,413,383 and 18,844,777 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the six months ended June 30, 2013 and 2014, respectively, and 7,356,464 and 18,778,154 shares of Common Stock for the three months ended June 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.

NOTE 2 - INVENTORIES

Inventory at June 30, 2014 and December 31, 2013 consisted of the following:

	June 30,		December 31,
	2014		2013
	(U.S. dollars in thousands)
Raw materials	$	1,845	$	2,342
Work in progress		133		92
Finished goods		5,157		5,523
Total inventory	$	7,135	$	7,957

PROTALIX BIOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 2 - INVENTORIES (continued):

During the six months ended June 30, 2014, the Company recorded approximately $1.6 million for write-down of inventory under cost of revenues.

NOTE 3 – FAIR VALUE MEASUREMENT

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.

The fair value of the convertible notes as of June 30, 2014 is approximately $70.2 million based on a level 2 measurement.

NOTE 4 – STOCK TRANSACTIONS

During the six months ended June 30, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.

NOTE 5 – SUBSEQUENT EVENTS

On July 24, 2014, the Company’s Board of Directors approved the grant of a 10-year option to purchase 150,000 shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $3.37 per share. The options vest over a three-year period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two year period, subject to certain terms and conditions. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company’s 2006 Stock Incentive Plan. The Company estimated the fair value of the option on the date of grant using the Black-Scholes option-pricing model to be approximately $293,000.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2013. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx^® protein expression system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, biobetter and biosimilar versions of recombinant therapeutic proteins, based on our plant cell-based expression technology, that primarily target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe ProCellEx will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent versions of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic proteins. We are now also applying the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins, with the first two product candidates being glucocerebrosidase and antiTNF fusion protein, and we are performing research focused on the expression, and subsequently the oral delivery, of antibodies in plant cells.

On May 1, 2012, the U.S. Food and Drug Administration, or the FDA, approved for sale our first commercial product, taliglucerase alfa for injection, which is being marketed in the United States and Israel under the brand name ELELYSO, as an enzyme replacement therapy, or ERT, for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved by the Brazilian National Health Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria, or ANVISA) in March 2013, by the Israeli Ministry of Health, or the Israeli MOH, in September 2012, by the Australian Therapeutic Goods Administration (TGA) in May 2014, by Health Canada in May 2014 and by the applicable regulatory authorities in Uruguay, Mexico and Chile. Taliglucerase alfa will be marketed under the name UPLYSO in Brazil and certain other Latin American countries. Taliglucerase alfa is our proprietary, recombinant form of glucocerebrosidase, or GCD, that is produced or expressed through ProCellEx. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein to be approved by the FDA or by the regulatory authorities with jurisdiction over any substantial market. Gaucher disease is a rare and serious lysosomal storage disorder with severe and debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that is naturally found in human cells.

Since May 2012, taliglucerase alfa has been marketed in the United States by Pfizer Inc., or Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but we retained those rights in Israel and in Brazil. We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities for the continued development efforts for taliglucerase alfa outside of Israel. Protalix Ltd. has been marketing taliglucerase alfa in Israel since 2013 and in Brazil since January 2014.

On June 18, 2013, we entered into a Supply and Technology Transfer Agreement, or the Brazil Agreement, with Fiocruz, for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The initial term of the technology transfer is seven years. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the term. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, we are not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa.

The Brazil Agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases, will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.

To facilitate the arrangement with Fiocruz, we and Pfizer agreed to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection with the supply of taliglucerase alfa to Fiocruz.

We will pay a fee equal to 5% of the net proceeds generated in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.

We are cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has been approved, marketing authorization applications have been filed in other countries.

In addition to naive and switch studies in adults which were successfully completed, we conducted a 12-month clinical trial of naïve and switchover pediatric patients, which was successfully completed in 2012. Based on the data from this study, an application for a supplement to the NDA for ELEYSO, allowing a pediatric use indication to be added to the product label, has recently been submitted by Pfizer to the FDA. The regulatory approvals in Australia and Canada in May 2014 are the first approvals which include pediatric indications. Patients in the extension trials are still being treated with taliglucerase alfa.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Israel and Chile. In France, Gaucher patients are being treated with taliglucerase alfa through an Autorisation Temporaire d’Utilisation (ATU), or Temporary Authorization for Use, a regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. In addition taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in certain countries. Hundreds of patients, in the aggregate, have been treated with taliglucerase alfa.

In addition to taliglucerase alfa, we are developing an innovative product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:

(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in a phase I/II clinical trial for which the first patient was treated in December 2012. We expect to complete patient recruitment and report interim results by the end of 2014, and to report final results during the first half of 2015.

(2) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells, currently the subject of a phase IIa clinical trial treating 10 Gaucher patients for 28 days. Enrollment of required patients for this trial is ongoing and we expect to complete patient recruitment and report results during 2014.

(3) PRX-106, our oral antiTNF product candidate which is being developed as an orally-administered treatment for immune mediated disorders using plant cells as a natural capsule for the expressed protein. We are currently conducting preclinical studies on oral antiTNF for several attractive indications, and we expect to initiate a phase I clinical trial of oral anti TNF for the oral treatment of autoimmune diseases in 2014.

(4) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of cystic fibrosis, to be administered by inhalation. We held a pre-IND meeting with the FDA in 2012, and plan to file an IND with the FDA following the completion of toxicology studies around year end, 2014.

Except for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which we licensed to Pfizer, we hold the worldwide commercialization rights to all of our proprietary development candidates. We have built an internal marketing team designed to serve the Israeli and Brazilian market for taliglucerase alfa and we intend to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition, we continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutes.

Critical Accounting Policies

Our significant accounting policies are more fully described in Note 1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to our significant accounting policies since the Annual Report on Form 10-K for the year ended December 31, 2013.

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Results of Operations

Three months ended June 30, 2014 compared to the three months ended June 30, 2013

Revenues

We recorded revenues of $2.4 million during the three months ended June 30, 2014, an increase of approximately $161,000, or 7%, compared to revenues of $2.3 million for the three months ended June 30, 2013. Revenues for the three months ended June 30, 2014 included $1.5 million in Israel. Revenues also represent a pro rata amortization of the $65.0 million upfront and milestone payments of $1.1 million in each quarterly period.

Our share in the Collaboration Agreement

We recorded revenue of $261,000 as our share of net income from the collaboration under the Pfizer Agreement during the three months ended June 30, 2014, compared to $800,000 for the three months ended June 30, 2013. Our share in the collaboration agreement recorded during the three months ended June 30, 2014 represents our 40% share of the net income generated during the period, which was primarily the result of revenues generated by Pfizer in the United States which exceeded the expenses during such period. Under the terms and conditions of the Pfizer Agreement, we record income or loss equal to 40% of the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based on reports we receive from Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable period.

Cost of Revenues

Cost of revenues was $1.6 million for the three months ended June 30, 2014 and $1.3 million for the three months ended June 30, 2013. Cost of revenues for the three months ended June 30, 2014 and June 30, 2013 consists mainly certain fixed costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser extent, the direct cost of products we sold in Israel and Brazil for which revenues were recognized during the period.

Research and Development Expenses, Net

Research and development expenses were $7.0 million for the three months ended June 30, 2014, a decrease of $914,000, or 11%, from $8.0 million for the three months ended June 30, 2013. The decrease resulted primarily from a decrease of $556,000 in the share based component of costs related to salaries expense. The decrease also resulted from an increase in grants equal to $1.3 million from the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor compared to the total grants of approximately $568,000 during the three months ended June 30, 2013.

We expect research and development expenses for our various development programs to continue to be our primary expense.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $1.6 million for the three months ended June 30, 2014, a decrease of $616,000, or 28%, from $2.2 million for the three months ended June 30, 2013. The decrease resulted primarily from a decrease of approximately $669,000 in share-based compensation expenses primarily due to the expected departure of our chief executive officer during 2014.

Financial Expenses and Income

Financial expenses was $672,000 for the three months ended June 30, 2014, compared to financial income of $57,000 for the three months ended June 30, 2013. Financial expenses resulted primarily from interest expense of $776,000 for the 4.5% convertible note which was partially offset by financial income which resulted primarily from interest earned on short term deposits.

Six months ended June 30, 2014 compared to the six months ended June 30, 2013

Revenues

We recorded revenues of $9.1 million during the six months ended June 30, 2014, an increase of $3.3 million, or 56%, compared to revenues of $5.8 million for the six months ended June 30, 2013. Revenues for the six months ended June 30, 2014 include $3.5 million of products sold in Brazil, $2.5 million in Israel and $1.4 million in connection with products we delivered at cost to Pfizer under the Pfizer Agreement. Revenues also represent a pro rata amortization of the $65.0 million upfront and milestone payments of $1.1 million in each quarterly period.

Our share in the Collaboration Agreement

We recorded revenue of $948,000 as our share of net income from the collaboration under the Pfizer Agreement during the six months ended June 30, 2014, a decrease of $252,000, or 21%, compared to revenue of $1.2 million for the six months ended June 30, 2013. Our share in the collaboration agreement recorded during the six months ended June 30, 2014 represents our 40% share of the net income generated during the period, which was primarily the result of revenues generated by Pfizer in the United States which exceeded the expenses during such period. Under the terms and conditions of the Pfizer Agreement, we record income or loss equal to 40% of the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based on reports we receive from Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable period.

Cost of Revenues

Cost of revenues was $5.7 million for the six months ended June 30, 2014, an increase of $3.4 million, or 148%, compared to cost of revenues of $2.3 million for the six months ended June 30, 2013. Cost of revenues for the six months ended June 30, 2014 consists of the costs of the $1.0 million of products we delivered at cost to Pfizer under the Pfizer Agreement, write-down of inventory of $1.6 million, and certain fixed costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser extent, the direct cost of products we sold in Israel and Brazil for which revenues were recognized during the period.

Research and Development Expenses, Net

Research and development expenses were $15.2 million for the six months ended June 30, 2014 and $15.7 million for the six months ended June 30, 2013.

We expect research and development expenses for our various development programs to continue to be our primary expense.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $5.3 million for the six months ended June 30, 2014, an increase of $992,000, or 23%, from $4.3 million for the six months ended June 30, 2013. The increase resulted primarily from sales and marketing expenses of approximately $1.3 million, primarily in connection with sales in Brazil, which was partially offset by a decrease of $106,000 in salaries expense.

Financial Expenses and Income

Financial expenses were $1.5 million for the six months ended June 30, 2014, compared to financial income of $165,000 for the six months ended June 30, 2013. Financial expenses resulted primarily from interest expense of $1.6 million for the 4.5% convertible note which was partially offset by financial income which resulted primarily from interest earned on short term deposits.

Liquidity and Capital Resources

Sources of Liquidity

As a result of our significant research and development expenditures which supersedes our product sales revenue, we have not been profitable and have generated operating losses since our inception with the exception of the quarter ended June 30, 2012 due to the $25.0 million milestone payment we received from Pfizer in connection with FDA approval of taliglucerase alfa in that period. To date, we have funded our operations primarily with proceeds equal to $31.3 million from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd., and an additional $14.1 million in connection with the exercise of warrants issued in connection with the sale of such shares, through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50 million in connection with an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we generated gross proceeds of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of our common stock.

In addition to the foregoing, on September 18, 2013, we completed a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, or the Notes, including $9.0 million aggregate principal amount of Notes related to the offering’s initial purchaser’s over-allotment option, which was exercised in full.

In November 2009, Pfizer paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.’s meeting a certain milestone. Protalix Ltd. also received a milestone payment of $25.0 in connection with the FDA’s approval of taliglucerase alfa in May 2012. Protalix Ltd. is also entitled to payments equal to 40% of the net profits earned by Pfizer on its global sales of taliglucerase alfa (except in Israel and Brazil). In calculating net profits there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold. Pfizer has also paid Protalix Ltd. $8.3 million in connection with the successful achievement of certain milestones under the Clinical Development Agreement between Pfizer and Protalix Ltd.

We believe that the funds currently available to us as are sufficient to satisfy our capital needs for the foreseeable future.

Cash Flows

Net cash used in operations was $14.9 million for the six months ended June 30, 2014. The net loss for the six months ended June 30, 2014 of $13.5 million was further increased by a decrease of $4.4 million in deferred revenues, but was partially offset by depreciation expense of $1.6 million and a decrease of $822,000 in inventories. Net cash used in investing activities for the six months ended June 30, 2014 was $565,000 and consisted primarily of purchases of property and equipment.

Net cash used in operations was $17.7 million for the six months ended June 30, 2013. The net loss for the six months ended June 30, 2013 of $11.2 million was further increased by a decrease of $4.2 million in deferred revenues, a decrease of $3.0 million in accounts payable and an increase of $3.2 million in inventories, but was partially offset by share based compensation of $2.5 million and $1.8 million in depreciation. Net cash used in investing activities for the six months ended June 30, 2013 was $1.4 million and consisted primarily of purchases of property and equipment.

Future Funding Requirements

We expect to continue to incur significant expenditures in the near future. However, we anticipate that we will generate revenues to offset such losses as Pfizer’s commercialization efforts for taliglucerase alfa in the United States and as our commercialization efforts for taliglucerase alfa in Brazil and Israel progress, and as taliglucerase alfa is launched by Pfizer in other countries in which taliglucerase alfa was recently approved. We also anticipate that we will generate additional revenues after additional anticipated marketing approvals of taliglucerase alfa are granted in new countries. We expect to continue to incur significant research and development expenses, including expenses related primarily to the clinical trials of PRX-102 and oral glucocerebrosidase and the advancement of our other product candidates into clinical trials.

We believe that our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for the foreseeable future. We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required to use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials.

Our future capital requirements will depend on many factors, including the progress of Pfizer’s commercialization efforts for taliglucerase alfa in the United States and other countries, the progress of our commercialization efforts for taliglucerase alfa in Brazil and Israel and, if anticipated marketing approvals of taliglucerase alfa are granted in other jurisdictions, the progress of Pfizer’s global commercialization efforts for taliglucerase alfa, the progress and results of our clinical trials, the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the number and development requirements of other product candidates that we pursue and the costs of commercialization activities, including product marketing, sales and distribution.

We may need to finance our future cash needs through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements. We currently do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate. We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable. Any sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.

Effects of Inflation and Currency Fluctuations

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the six and three months ended June 30, 2014 or the six and three months ended June 30, 2013.

Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the six and three months ended June 30, 2014 or the six and three months ended June 30, 2013.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements as of each of June 30, 2014 and June 30, 2013.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Currency Exchange Risk

The currency of the primary economic environment in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic environment to be the currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S. dollars, approximately 50% of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.

A portion of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:

	Six months ended June 30,				Year ended December 31,
	2014		2013		2013
Average rate for period		3.481		3.667		3.611
Rate at period end		3.438		3.618		3.471

To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.

Interest Rate Risk

Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in internal controls

There were no changes to our internal controls over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended June 30, 2014 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not involved in any material legal proceedings.

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

There were no unregistered sales of equity securities during the three months ended June 30, 2014.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

File Number

Exhibit

Date

Filed
Herewith

3.1

Amended and Restated Articles of Incorporation of the Company

S-4

333-48677

3.4

March 26, 1998

3.2

Article of Amendment to Articles of Incorporation dated June 9, 2006

8-A

001-33357

3.2

March 9, 2007

3.3

Article of Amendment to Articles of Incorporation dated December 13, 2006

8-A

001-33357

3.3

March 9, 2007

3.4

Article of Amendment to Articles of Incorporation dated December 26, 2006

8-A

001-33357

3.4

March 9, 2007

3.5

Article of Amendment to Articles of Incorporation dated February 26, 2007

8-A

001-33357

3.5

March 9, 2007

3.6

Amended and Restated Bylaws of the Company

10-K

001-33357

3.6

February 28, 2013

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer

32.2

18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer

101.INS

XBRL INSTANCE FILE

101.SCH

XBRL SHEMA FILE

101.CAL

XBRL CALCULATION FILE

101.DEF

XBRL DEFINITION FILE

101.LAB

XBRL LABEL FILE

101.PRE

XBRL PRESENTATION FILE

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		PROTALIX BIOTHERAPEUTICS, INC.
		(Registrant)

Date: August 7, 2014	By:	/s/ David Aviezer
		David Aviezer, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

Date: August 7, 2014	By:	/s/ Yossi Maimon
		Yossi Maimon Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)

EX-31.1 2 v384196_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, David Aviezer, certify that:

I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2014

/s/ David Aviezer
David Aviezer, Ph.D. President and Chief Executive Officer

EX-31.2 3 v384196_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, Yossi Maimon, certify that:

I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;

(a)

(b)

(c)

(d)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2014

/s/ Yossi Maimon
Yossi Maimon Chief Financial Officer, Treasurer

EX-32.1 4 v384196_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

PROTALIX BIOTHERAPEUTICS, INC.

CERTIFICATION

In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: August 7, 2014

/s/ David Aviezer
David Aviezer, Ph.D. President and Chief Executive Officer

EX-32.2 5 v384196_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

PROTALIX BIOTHERAPEUTICS, INC.

CERTIFICATION

In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: August 7, 2014

/s/ Yossi Maimon
Yossi Maimon Vice President and Chief Financial Officer

EX-101.INS 6 plx-20140630.xml XBRL INSTANCE DOCUMENT 0001006281 2014-06-30 0001006281 2013-12-31 0001006281 2014-04-01 2014-06-30 0001006281 2013-04-01 2013-06-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001006281 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001006281 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0001006281 us-gaap:RetainedEarningsMember 2013-12-31 0001006281 us-gaap:CommonStockMember 2012-12-31 0001006281 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001006281 us-gaap:RetainedEarningsMember 2012-12-31 0001006281 2012-12-31 0001006281 us-gaap:CommonStockMember 2013-06-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2013-06-30 0001006281 us-gaap:RetainedEarningsMember 2013-06-30 0001006281 2013-06-30 0001006281 us-gaap:CommonStockMember 2013-12-31 0001006281 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001006281 us-gaap:CommonStockMember 2014-06-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0001006281 us-gaap:RetainedEarningsMember 2014-06-30 0001006281 2009-10-01 2009-12-31 0001006281 plx:ScenarioTwoMember 2009-10-01 2009-12-31 0001006281 plx:ScenarioThreeMember 2012-01-01 2012-06-30 0001006281 plx:ProtalixBioTherapeuticsIncorporationMember 2014-06-30 0001006281 plx:PfizerIncorporationMember 2014-06-30 0001006281 plx:ProtalixLtdMember 2013-06-18 0001006281 plx:ProtalixLtdMember 2013-06-01 2013-06-18 0001006281 2013-01-01 2013-06-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0001006281 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-06-30 0001006281 us-gaap:CommonStockMember 2013-01-01 2013-06-30 0001006281 us-gaap:RetainedEarningsMember 2013-01-01 2013-06-30 0001006281 2014-01-01 2014-06-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0001006281 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-06-30 0001006281 us-gaap:CommonStockMember 2014-01-01 2014-06-30 0001006281 us-gaap:RetainedEarningsMember 2014-01-01 2014-06-30 0001006281 plx:EmployeeMember 2014-01-01 2014-06-30 0001006281 2014-08-01 0001006281 us-gaap:SubsequentEventMember 2014-07-23 2014-07-24 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure plx:item

-13464000

-11158000

577000

2499000

1628000 1818000

133000

120000

102000

93000

25000 14000

220000

-4369000

-4207000

397000

406000

-822000

3152000

180000

-3048000

-14859000

-17695000

371000

1341000

93000

101000

71000

-565000

-1412000

31000

139000

168000

-15254000

-18909000

86398000

52035000

71144000

33126000

170000 304000 12000

30000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 3 FAIR VALUE MEASUREMENT   The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.   The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:   Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.   Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.   Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.   In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.   The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.   <font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The fair value of the convertible notes as of June 30, 2014 is approximately $70.2 million based on a level 2 measurement. </div>

70200000

PLX

7135000

7957000

82364000

97903000

1721000

1578000

12438000

13711000

128000

141000

96651000

113333000

3592000

5254000

16305000

12073000

7282000

9369000

27179000

26696000

67255000

67048000

39514000

41796000

2371000

2493000

2368000

109262000

113583000

136441000

140279000

-39790000

-26946000

96651000

113333000

2097000

2091000

1988000

1457000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 4 STOCK TRANSACTIONS   During the six months ended June 30, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000. </div>

55362

56122

43000

60000000

5000000

25000000 0.40 0.60 40000000

3500000

0.001

7413383

18844777

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" ; font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td> </td> </tr> </table> </div> </div> <div> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" ; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td style=" width: 0.3in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"> </td> <td style=" width: 0.25in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">a.</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">General</td> </tr> </table> </div> </div>   Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the Company), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx® protein expression system (ProCellEx). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (EMA) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the Subsidiaries.   On May 1, 2012, the U.S. Food and Drug Administration (FDA) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the Israeli MOH) in September 2012, by the Brazilian Ministry of Health (the Brazilian MOH) in June 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.   Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO by Pfizer Inc. (Pfizer), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the Pfizer Agreement). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.   Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.   On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the Brazil Agreement) with Fundação Oswaldo Cruz (Fiocruz), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of 2014.   During the six months ended June 30, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.   To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.   Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.   In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.   Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.   An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.   In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.   In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.   Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.   </div> <div> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td style=" width: 0.3in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"> </td> <td style=" width: 0.25in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">b.</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">Basis of Presentation</td> </tr> </table> </div> </div>   The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.   These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.   </div> <div> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td style=" width: 0.3in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"> </td> <td style=" width: 0.25in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">c.</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">Net loss per share</td> </tr> </table> </div> </div>   Basic and diluted loss per share (LPS) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $0.001 per share (the Common Stock) outstanding for each period.   Diluted LPS does not include 7,413,383 and 18,844,777 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the six months ended June 30, 2013 and 2014, respectively, and 7,356,464 and 18,778,154 shares of Common Stock for the three months ended June 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.   </div> </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td style=" width: 0.3in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"> </td> <td style=" width: 0.25in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">b.</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">Basis of Presentation</td> </tr> </table> </div> </div>   The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.   These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.   </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td style=" width: 0.3in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"> </td> <td style=" width: 0.25in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">c.</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">Net loss per share</td> </tr> </table> </div> </div>   Basic and diluted loss per share (LPS) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $0.001 per share (the Common Stock) outstanding for each period.   Diluted LPS does not include 7,413,383 and 18,844,777 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the six months ended June 30, 2013 and 2014, respectively, and 7,356,464 and 18,778,154 shares of Common Stock for the three months ended June 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.   </div>

1600000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Inventory at June 30, 2014 and December 31, 2013 consisted of the following:   <div class="CursorPointer"> <table align="left" cellpadding="0" cellspacing="0" style=" border-collapse: collapse; font: 10pt times new roman, times, serif; width: 85%; clear: both; margin-left: 1in;"> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" text-align: center; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; text-align: center; width: 15%;">June 30,</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; text-align: center; width: 15%;">December 31,</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; text-align: center; width: 70%;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" text-align: center; border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">2014</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" text-align: center; border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">2013</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="6" style=" text-align: center; border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">(U.S. dollars in thousands)</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Raw materials</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">1,845</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">2,342</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Work in progress</td> <td style=" font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">133</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">92</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Finished goods</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">5,157</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">5,523</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Total inventory</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 2.80pt double; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" border-bottom: #000000 2.80pt double; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">7,135</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: #000000 2.80pt double; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 2.80pt double; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" border-bottom: #000000 2.80pt double; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">7,957</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> </table> </div>   </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 2 - INVENTORIES   <div> Inventory at June 30, 2014 and December 31, 2013 consisted of the following:   <div class="CursorPointer"> <table align="left" cellpadding="0" cellspacing="0" style=" border-collapse: collapse; font: 10pt times new roman, times, serif; width: 85%; clear: both; margin-left: 1in;"> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" text-align: center; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; text-align: center; width: 15%;">June 30,</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; text-align: center; width: 15%;">December 31,</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; text-align: center; width: 70%;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" text-align: center; border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">2014</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="2" style=" text-align: center; border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">2013</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td colspan="6" style=" text-align: center; border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">(U.S. dollars in thousands)</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Raw materials</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">1,845</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">2,342</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Work in progress</td> <td style=" font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">133</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" text-align: right; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">92</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Finished goods</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">5,157</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 1pt solid; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">5,523</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> <tr style=" vertical-align: bottom; font-size: 10pt;"> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Total inventory</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 2.80pt double; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" border-bottom: #000000 2.80pt double; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">7,135</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: #000000 2.80pt double; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> <td style=" border-bottom: #000000 2.80pt double; text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td> <td style=" border-bottom: #000000 2.80pt double; text-align: right; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; vertical-align: bottom; white-space: nowrap; font-size: 10pt;">7,957</td> <td style=" text-align: left; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"> </td> </tr> </table> </div>   </div> During the six months ended June 30, 2014, the Company recorded approximately $1.6 million for write-down of inventory under cost of revenues. </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" width="100%" style=" ; margin-bottom: 0pt;"> <tr style=" vertical-align: top; font-size: 10pt;"> <td style=" width: 0.3in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"> </td> <td style=" width: 0.25in; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">a.</td> <td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;">General</td> </tr> </table> </div> </div>   Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the Company), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx® protein expression system (ProCellEx). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (EMA) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the Subsidiaries.   On May 1, 2012, the U.S. Food and Drug Administration (FDA) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the Israeli MOH) in September 2012, by the Brazilian Ministry of Health (the Brazilian MOH) in June 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.   Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO by Pfizer Inc. (Pfizer), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the Pfizer Agreement). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.   Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.   On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the Brazil Agreement) with Fundação Oswaldo Cruz (Fiocruz), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of 2014.   During the six months ended June 30, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.   To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.   Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.   In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.   Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.   An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.   In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.   In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.   Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.   </div> 280000000

7356464

18778154

12500000

1845000

2342000

133000

92000

5157000

5523000

293000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 5 SUBSEQUENT EVENTS  On July 24, 2014, the Company's Board of Directors approved the grant of a 10-year option to purchase 150,000 shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $3.37 per share. The options vest over a three-year period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two year period, subject to certain terms and conditions. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's 2006 Stock Incentive Plan. The Company estimated the fair value of the option on the date of grant using the Black-Scholes option-pricing model to be approximately $293,000. </div>

150000

3.37

50000

P3Y

P10Y

8 P2Y

-183595000

-3357000

645000

1854000 1854000

21480

1000

29000

30000

-11158000

93509622

94000

182673000

-194753000

-11986000

93551098

94000

184345000

-211385000

190000

387000 387000

55362

43000

-13464000

93606460

94000

184965000

-224849000

93489809

93000

180145000

-1667

1667

150000000

0.001

150000000

9121000

5832000

948000 1200000

5678000

2289000

4391000

4743000

15228000

15744000

4199000 3963000 11029000 11781000

5277000

4285000

-11915000

-11323000

1789000

240000

-1549000

165000

-0.15

-0.12

92754640

92241505

591000

1589000

-14000

910000

1605000

1318000

1081000

1746000

7076000

7990000

2114000 1532000 4962000 6458000

1566000

2182000

-5447000

-6894000

874000

202000

-672000

57000

-6119000

-6837000

-0.07

92820897

92297522

163000

719000

-256000

413000

2425000

2264000

261000 800000

187000

22000

66000

9000

PROTALIX BIOTHERAPEUTICS, INC. 0001006281 10-Q 2014-06-30 false --12-31 Accelerated Filer 2014 Q2 93664898 Represents amount less than thousand

EX-101.SCH 7 plx-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY link:presentationLink link:calculationLink link:definitionLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 102 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 103 - Disclosure - FAIR VALUE MEASUREMENT link:presentationLink link:calculationLink link:definitionLink 104 - Disclosure - STOCK TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy) link:presentationLink link:calculationLink link:definitionLink 302 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - STOCK TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - FAIR VALUE MEASUREMENT (Details) link:presentationLink link:calculationLink link:definitionLink 105 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 plx-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 plx-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 plx-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD Accounts receivable - Trade Accounts Receivable, Net, Current Other Receivables, Net, Current Other assets Inventories Inventory, Net Total inventory Assets, Current Total current assets FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT Defined Benefit Plan, Assets for Plan Benefits, Noncurrent PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment, Net Deferred Costs, Noncurrent DEFERRED CHARGES Assets Total assets Long-term Debt, Excluding Current Maturities Liability in connection with collaboration operation COMMITMENTS Commitments and Contingencies Trade Accounts Payable, Trade, Current Other Accounts Payable, Other, Current Deferred revenues Deferred Revenue, Current Liabilities, Current Total current liabilities Convertible Debt, Noncurrent Convertible notes Deferred revenues Deferred Revenue, Noncurrent Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent Liability for employee rights upon retirement Liabilities, Noncurrent Total long term liabilities Liabilities Total liabilities CAPITAL DEFICIENCY Stockholders' Equity Attributable to Parent Beginning Balance Ending Balance Liabilities and Equity Total liabilities net of capital deficiency REVENUES Revenues Cost of Revenue GROSS PROFIT Gross Profit Research and Development Expense Selling, General and Administrative Expense Operating Income (Loss) OPERATING LOSS Other Nonoperating Expense Other Nonoperating Income FINANCIAL INCOME Nonoperating Income (Expense) FINANCIAL INCOME (EXPENSES) - NET Net Income (Loss) Attributable to Parent Net loss Net loss for the period NET LOSS FOR THE PERIOD Earnings Per Share, Basic and Diluted BASIC AND DILUTED BASIC AND DILUTED Weighted Average Number of Shares Outstanding, Basic and Diluted Allocated Share-based Compensation Expense Share-based compensation Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Equity Components [Axis] Accumulated Deficit [Member] Retained Earnings [Member] Beginning Balance (in shares) Ending Balance (in shares) Shares, Outstanding Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation related to stock options Exercise of options granted to employees (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of options granted to employees Stock Issued During Period, Value, Stock Options Exercised Common Stock [Member] Additional paid-in Capital [Member] Additional Paid-in Capital [Member] Common Stock, par value Common Stock, Par or Stated Value Per Share Common stock, par value per share Common Stock, Authorized Common Stock, Shares Authorized Share-based Compensation Share based compensation Foreign Currency Transaction Gain (Loss), Unrealized Pension and Other Postretirement Benefit Expense Changes in accrued liability for employee rights upon retirement Amortization of Financing Costs Amortization of debt issuance costs and debt discount Decrease in deferred revenues (including non-current portion) Increase (Decrease) in Deferred Revenue Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (decrease) in accounts payable and accruals (including long term ) Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Payments to Acquire Property, Plant, and Equipment Increase (Decrease) in Restricted Cash Payments for (Proceeds from) Other Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Exercise of options Proceeds from Stock Options Exercised Cash proceeds from exercise of options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash and Cash Equivalents NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Net loss per share Earnings Per Share, Policy [Policy Text Block] Pfizer Agreement, upfront payment received Proceeds from Collaborators Proceeds from Sale of Other Assets Revenue from sale of products Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive Scenario [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Inventory Disclosure [Text Block] INVENTORIES Schedule of Inventory, Current [Table Text Block] Inventory Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Net of Reserves Work in process Inventory, Finished Goods, Net of Reserves Finished goods Inventory write-down Inventory Write-down Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENT STOCK TRANSACTIONS Stockholders' Equity Note Disclosure [Text Block] Common stock issued in connection with exercise of options Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Option Indexed to Issuer's Equity [Axis] Amendment Flag Current Fiscal Year End Date Document Period End Date Arrangements and Non-arrangement Transactions [Domain] Trading Symbol Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable and accruals: Accounts Payable and Accrued Liabilities, Current [Abstract] Adjustments required to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Common stock issued for cash, issuance costs Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Assets, Current [Abstract] CURRENT ASSETS: ASSETS Assets [Abstract] Class of Stock [Line Items] Cost of Revenue [Member] Cost of Sales [Member] Convertible notes Debt, Policy [Policy Text Block] Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED: Earnings Per Share [Abstract] LOSS PER SHARE OF COMMON STOCK: Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Equity Component [Domain] FAIR VALUE MEASUREMENT [Abstract] CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income Statement Location [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] INVENTORIES [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Liabilities, Noncurrent [Abstract] LONG TERM LIABILITIES: Liabilities and Equity [Abstract] LIABILITIES NET OF CAPITAL DEFICIENCY CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Option Indexed to Issuer's Equity, Type [Domain] Scenario, Unspecified [Domain] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Stock by Class [Table] Supply Commitment, Remaining Minimum Amount Committed Total supply commitment Statement [Table] Statement [Line Items] CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY) [Abstract] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Common stock issued for cash (net of issuance costs) (in shares) Stock Issued During Period, Shares, New Issues Common stock issued for cash (net of issuance costs) Stock Issued During Period, Value, New Issues STOCK TRANSACTIONS [Abstract] SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: [Abstract] Cashless Exercise Of Stock Options Cash due from broker assisted exercises of employee stock options. Exercise of options granted to employees Collaborative Arrangement Profit Share Percentage Collaborative arrangement profit sharing percentage. Pfizer Agreement, future revenues and expense sharing percentage Depreciation Amortization And Asset Impairment The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value. Depreciation and write down of fixed assets Document And Entity Information [Abstract] Employee And Nonemployee [Member] Employee And Nonemployee [Member]. Certain Employees and Non-employees [Member] Employee [Member] Employee [Member]. Certain Employee [Member] EX-101.PRE 11 plx-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!CDA+4IP$``"H.```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EUU/PC`4AN]-_`]+;PWK MBHIH&%SX<:DDX@^HZQE;V-JF+0C_WJY\Q)`)(9)X;M9L[3GOLW/QIN]@M*RK M:`'&EDJFA,4)B4!F2I1RFI*/R4NG3R+KN!2\4A)2L@)+1L/+B\%DI<%&OEK: ME!3.Z0=*;59`S6VL-$B_DRM3<^=?S91JGLWX%&@W27HT4]*!=!W7]"##P1/D M?%ZYZ'GI/Z])#%261(_K@XU62KC659EQYTGI0HH]E$F+90JS\L,A,KFM9]` M;+4!+FP!X.HJ#FM<\U)NN0_HA\.6AH6=&:3YO]#X1(XN$HYK)!PW2#AND7#T MD'#<(>'H(^&X1\+!$BP@6!R58;%4AL53&19395A_T8^-TM9G M&P.G3V$;7IKJCO:-P+@2=O&E+0;L%'TN.EUP+X=`D[P$B!9M&I+>\!L``/__ M`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4 M"_'L)MI<3_3_MCAQ M(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+ M`P04``8`"````"$`,=XF:WX!``"[#```&@`(`7AL+U]R96QS+W=O]L\/\Q88JR0I6B5 MQ)SMT;#5\OYN\8*ML.XE4S>]25P6:7)66]L_"^*G:B09VDZX?H\!UM>Y$S69<[TNG3U-_O>5;Z=6VVW38%/JGCO4-HK)?BG MTCM3(UJ75.@*;4&,@BJX&,E!,;#I!T8L.AV4QB6S6AK,K< M@1#N^VO=N8"G'CXL^>$)E(B@H^P'YZ3#AXZS1(J)[0]I#T1'0[(9AVP6[\K? M1HW)KHFM!F@Y02?I'W`@)>G,(WL%H66B\S$5+)&!(&4EO??G_H%M/B./4*0IJ/[\3?J^MU(:PW5M5-JI:K79Z5>+0"0]1#E M6I>7MEVG.2MH?:1*)F%GH:J":EA6+W9=5HQF=AJP06;;Q19M"PC6@#OM4"6H+4.,ZY9 M-D0GL%0KMO.@6I8W2RY@]V+@#)`]ZD0^5E;&%G0I=`+RMNC@EW?L>:?-+QLK MYIRMZH]#S=):/W&9J57S4[#VO5L-@,"JW7KBF;ZG6"Y<9\KB+!Q'8,R%UG5)8>;"F=N0]Q$"2;1 M.(SB<$S@+I[C(#10&BT=C'<@3)P`VH,),S!06K\/(/,?!71T MFHX-F./OD?$,&'"_TW3R/1@0TK$Y-6#::APN"H1T,&<&S-D^FQC?1?@6!WZ4 M$#\()K,HP=$=>83(`FPZ[)EYG^_#X&@>1LEDBL/8>+,'IG1&7.R?N?7QE,S] M^UE('D(_GDTATB@QCYNINL[^^3B9!'](,O6CV`\2##TSSYI1NKU^QK.;./P[ M@_>1L&&^<]2,S^UU\FO'S#;!]_PAW^W5TO",)/19P#S\",TS4W-[7?R:A-E% M#\9NEX';:Z-)(DYSEBT%(VH!G_P;C$6#D+LCIE?'S\,D8Z8I%SO"+DP^_3[V M0OT$P]W1U"MC+]Q/(`;FW'';;MKM%P/C,*4BA3G=7)I!UQ;/WOY+C?X!``#_ M_P,`4$L#!!0`!@`(````(0"7.K*!,0,``&X*```8````>&PO=V]R:W-H965T M&ULG%9=CZ(P%'W?9/]#P[MB542-.AG%V9UD-]EL]N.Y0I%F M@)*VCC/_?F^I(,49F.R+0N^YIST]M]RN[EZR%#U3(1G/UPX>CAQ$\Y!'+#^N MG=^_'@9S!TE%\HBD/*=KYY5*YV[S^=/JS,633"A5"!ARN782I8JEZ\HPH1F1 M0U[0'"(Q%QE1\"J.KBP$)5&9E*7N>#2:N1EAN6,8EN(C'#R.64@#'IXRFBM# M(FA*%*Q?)JR0%5L6?H0N(^+I5`Q"GA5`<6`I4Z\EJ8.R:%NW"!:;.*&"C0VXX$C=?./5[NYXZ[697[ M\X?1LVP\(YGP\Q?!HF\LI[#98),VX,#YDX8^1GH(DMV;[(?2@!\"130FIU3] MY.>OE!T3!6Y[($CK6D:O`94A;"C0#,>>9@IY"@N`7Y0Q71FP(>2E_#^S2"5K M9S(;>OYH@@&.#E2J!Z8I'12>I.+97P/"%RI#,KZ00,:%!,-0=[)K%E+J"H@B MFY7@9P2U`E/)@NC*PTL@K`29Z6N)[RD$:9KD7K.47+!X":X\;WQOY3[#3H87 MR-9`?`?5$&]F0W851.^;I@VJ@6L.ME/V%4*;!HIJ6;`A;5D3;`UDVH"T M#-WU(H)>Q+X+8GD@\F]C173/JXX4=#9I1;]$^>,TH]N;79$O/S-:C MOR[]QU`GM71=ZQ[T)8,O4EIM$KNJM3@ULNMJO30$QU#L8W[:`9GN)6\0;-Z`!/[>*%.X"> MW5`O\*B.&CVFOYL^F%%QI#N:IA*%_*1[]QB.2SUJKA5;O(3N!$VF-1[`=:,< M=^L`M/N"'.EW(HXLERBE,5".ACX<&&$N#.9%\:+L-0>NH-&7CPGKK.X?:DK M],RDXJ)),'$\C%B3BHPW18)__WJXB3%2FC89K43#$OS*%+Y=?OZTV`GYI$K& M-`*'1B6XU+J=NZY*2U93Y8B6-?!++F1--9S*PE6M9#3K;JHKU_>\R*TI;[!U MF,MK/$2>\Y3=BW1;LT9;$\DJJH%?E;Q5![?>,-@["A3*8`&R&>C/0Q,Y?@ M9O?L[H>N`#\DREA.MY7^*79?&2]*#=4.84%F7?/L]9ZI%`(%&\Z3+!0>2$4R\@($<;IO0#-Y88I5NE1?W7BLC>RIKX>Q,X M[DU(Z$S\NID_LK<`@*6-R9UP2/,4(LE!0Y.>E3R8+]QDJD^XU*ZN!SUY#QHKU M06$*"G@](^0V9+Q))Z'G>"=M0 MX0<3&&U'Q8@-WI7KV8QXS.:3DU165A-9MB`8/MC&-A3,W@:+/@)FQ&,P$DW' MD:RLQH+!JSD])QLI0G_$/@H-7J?K0S/B4[;39K,:RS8EP86"CA2S,?V(S6R/ M@['Q_BMIQ&,VGT0GN5G-OMDB2&W02K:B5@$MU[?LL2DLF]T%['BKF2S8FE65 M0JG8F@E/H%GZJ_WF<^=W^T?_`PS_EA;L.Y4%;Q2J6`ZW>LX4^DG:[<.>:-%V MPW,C-(S][FL)NSR#B>,Y(,Z%T(<3,\_Z_PW+?P```/__`P!02P,$%``&``@` M```A`''>+<-5`@``-@4``!D```!X;"]W;W)K&UL ME%3+;MLP$+P7Z#\0O$>T_(ABP7(0UW`;H`&*HH\S3:TDPJ(HD+2=_'V7I*.X M21&X%XD49V=W=H=:W#ZJEAS`6*F[@J;)B!+HA"YE5Q?TYX_-U0TEUO&NY*WN MH*!/8.GM\N.'Q5&;G6T`'$&&SA:T<:[/&;.B`<5MHGOH\*321G&'6U,SVQO@ M90A2+1N/1M=,<=G1R)";2SAT54D!:RWV"CH720RTW&']MI&]?693XA(ZQI^3*=<[F#)F6BU*B`M]V8J`JZ%V:KZ:4+1>A/[\D'.W9FMA&'S\;67Z5'6"S<4Q^ M`%NM=QYZ7_I/&,S>1&_"`+X94D+%]ZW[KH]?0-:-PVG/4)#7E9=/:[`"&XHT MR7CFF81NL0!\$B6],[`A_#&\C[)T34$GU\DL&TU2A),M6+>1GI(2L;=.J]\1 ME)ZH(LGX1(+O$TF*R_>#62PDZ%ISQY<+HX\$O8*I;,^]\](<6;R@";;EWX)0 MB8^Y\T$A%-$6AW!8CM-LP0[8.7'"K"(FH^0%,R`8)A\JP*SG%;R?V8-?9[X9 M>$-UJXC)PB#/$TW^)Y$'8RO.RD^S]%6BB)F>868#XB^)"+E-TWT8R%8[-&Q8-OA_`O3)*$%PI;5[WOBK M-?SQEG\```#__P,`4$L#!!0`!@`(````(0!HW%'$_0(``.D(```9````>&PO M=V]R:W-H965TCA%>Q3$251?3GC\>;6TJT857""EGQB+YQ3>_6'S^L#E(]ZYQS0\"ATA'- MC:F7KJOCG)=,.[+F%?-W)*)BEJ'I;K&0Z:I MB/F#C/;BP+T6LI):I<<#.M:"7,2_B] MO]PNJ+M>-?GY)?A!=WX3G,KVA?DN#Y^YR'(#U9Y"0!C7,GE[X#J&A(*-$TS1*98%`,`G*06>#$@( M>VV^#R(Q>43#F3.=>Z$/"OW!5(9'S6;2XW?5VQ/"JP`X+6,$%V7\?UDGU!0C"B8?&3;V`'P/K,- M]KU43.>MI$<"&;J>!,50X.[&P2#DC=5,.IIINW.#OQU3]-C`Y'HV%$<4`C\G M)0CZ.V^LYK8I9^A[WJ"@V]X\3)_G>UQPL*_G0O&0*QQP60WLWK(/FSP-G7SAF]F"!?6^.G'1?W\+89'SDIF35FGTW`V*/O6 MSK\?0@\0>UKGZA@'0W$?++@X<%9C#]PD[!XH^RK8^2O(%GVRZU*'BX:$D\'1 MLYIC[F;^,`)H/>@Q1FA;B[V"2ZXRON5%H4DL]]@V`JA*.]IVM/L`;[/!^`8Z M7=,7W'8".DW-,OZ5J4Q4FA0\!4O/FDSS,X>_%!QN M2\\!<2JE.3W@7=S^25G_`0``__\#`%!+`P04``8`"````"$`O_!2%Q`#``"3 M"0``&0```'AL+W=O(LLYOJRH^"8.;73#34 M,:S4&`Z9YR+E=S+=U;PQCD3QBAFP7Y>BU2]L=3J&KF;J8==>I;)N@6(K*F&> M+2DE=;KZ7#12L6T%?C^%$Y:^<-N',_I:I$IJF1L/Z'QGZ+G/2W_I`]-FG0GP M`,-.%,\3>A.N;L.8^INU#=`OP??ZY)[H4NX_*I%]$0V':$.>,`-;*1\0^CG# M)=CLG^V^MQGXIDC&<[:KS'>Y_\1%41I(]Q0\0L=6V?,=URE$%&B\:(I,J:S` M`+B26F!I0$38D_W?B\R4"8UGWG0>Q"'`R99K*!R)-&! M!/X/).'4FT33^6($B^\LL@[>,<,V:R7W!*H&-'7+L`;#%3"_[A&X@M@;!"=T M3@D8JR$-CYLHFJ[]1PA=>L#<.@Q<3S"S#N.#;*<->N.U$8S:&%TTYM8M](7F MKPO%EP@AN"?D%OI"B]>%)I<((3BAX,9)I)8=KW/28>#:88[Q[L42ZFA\+!$, M-7C"&L7!0-EA1BC/+E%&\,#G.!PH.\RI*\1/-2..UX7;X>9 MV=H.IP'\.D!/&#O[Z&.#X*'PI.-UP@ZSM,*Q%[]1R,M+9!$\E#U6CY-UF'ZL MWSBM(;3-4Y^Q"<:P]H^6@;N&5AR]+X/H%X")F_4'$RX__'>M:]>FYD,CYRE3NC" M]?1E?%[W;C:ZT5%S5?`/O*HT2>4.YUX(&[O5;B;?V)'L=R]@)+:LX%^9*D2C M2<5SV!IX'G!L=Y]3FS\` M``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O M=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF998 M4Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5 MAT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX M3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV< M%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA M7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'# M'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LO MG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH- M<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W M%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)? M7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#. MM!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH; M!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK M-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'M MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5 MBF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U! M!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH M@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMS MX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[ MUQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[ MA28&80-1?F#R`Y+<&ULU%QM;^/&$?Y>H/^!X+5%`M26 M1%&6Y%@.3K+9'G!U@YR+%FB*@J(HFS%?5)*ZLQ/TOW=F^38K4N12HK37"#E+ ME';FF6=F9W=GE[SY_M5SE<]V&#F!/U,'EWU5L7TK6#G^TTS]VZ-Q,5&5*#;] ME>D&OCU3W^Q(_?[VM[^YB>(WU_[T;-NQ`B+\:*8^Q_'FNM>+K&?;,Z/+8&/[ M\,TZ"#TSAH_A4R_:A+:YBK"1Y_:T?O^JYYF.KR82KCU+1(AGAB_;S845>!LS M=I:.Z\1O3):J>-;UAR<_",VE"U!?![II9;+9AY)XS['"(`K6\26(ZP7KM6/9 M9933WK0'DFYO_*UG>'&D6,'6CV>JEE]2DF\^K&;JE:HD)B^"%8#XPW^V0?S= M[Y(_[_[X[EW_W]]^]\\?[=6_?OJF_-U/WZJ]3`V1"3ZHEWG9KQ4+7R>2>ZD% MMS?KP">&C(`F9.OZQ0^^^`9^!\$`YN'/;F^B7Y3/I@M7!@C/"MP@5&+P,MC' MKOBF9R>_6)BNLPP=_-G:]!SW+;FLX046&.GO/`?+'>)O/G"ILX7:-F76<;%8]ALJ'!I=4MF@ MT'@_OCL;G=TKVV==FH;/U0.PPW7+H@-=MZ9_CPU\G2-.SCR@=>HQF,#%[UWG MR4^&VVB[@1F=%3J;&)FKHO>DUC+;N*&')8`B0S\ZGATI#_87Y+6OJHB,Q^MR^FCA7P6$A'$BN.Z M^2Q\J.,\%:[V-QS_029*(H]@@UC,7X!$+OY]-%]T@7TVG70C4# M7AT+?3_"5\="#?AOT1FG:;[6NP*9RU-B!]>R_Y4@D.15@D"25\<=9^"Q M=*\2!)*\2A!(\BHK`G;85Z%B*[FO$@22O$H02/)J9Y//-`-/I7N5()#D58+@ MW%[-EE6+^WN#E83*,[/]\V.VDH.UXS((5U`L:_<;"!?Y=!',/FT.W-RC&?`M]TX6TO:Y']K6D)VV>P4S93XV?'>@%E7%TD MP9NH.)6&/!/I.,/7QWI_K(^TJV01U9%JSUXY6Z]L7:Z[,E:`1N2VV7#"H9\K M2<.AJ!#VT`NI^P1;,%NH%$N`5$5,-@K0I\]G8I(+1QC9M;87\ M4NH;9=SGA>3D!TW,%DAV^N9\?!@,4 M)0TS/#M),,U/6/%,MDR$TQUO;DG/CBGM]*1#%XR$ENVZGW!L^LS>I6:B+FAS"(;2MFIUA827L?GN$>/(-4D`B>8_3K M>_0#3\)\'*,?ZB*53@1>I.J'X!+6WV4\X'F=-*C!!32HZ_!TB0!6OQD"<((, M!'B^*.4`PE,&`EA59`@@0`L$`*Q3-)-]"H!IW)=B9:48XG;H:04%\*&&`@-&W6Z& MO,&^G"^-$))T`4/!"*2!.D:ZBTJ2D7F'\Q`2%)B*9$,`.%(@$$=` M*48^!DDC,(T&24,PA<"-P6?L$S0:N!%2$@;`(Z57%/.$`3=BG)$&`D%6AB31 MH,E*D12#K!Q9N$*3E2()!%D9DGI"5HJD&&3E2.(*62F20`!&I&1(Z@E9*9)B MD)4C"U<,9:5(`D%6AB2>&)XX1?9HV30IHM+ZZ=5!]5/E==U82!WL6S2!W[/F MR>HI63F"+]A:BBRE\8XN$X^)8^U4>0Y"YQ=89.*=719^1*: MFT?[%9:BR1;,ZWI_K1>09/6-W6#D$>[%5.B'$KZJM%'>.3]'8#F>B$;+V:*^ ML3"_$QE\<;LQ0AI!8'%'-@;D.L70>0ATU$6PY\JF"09)Z1BHJQ!/6G.&R]P< M@L\5!C"'R:0?&5 M8QWRL'!\GP+=U\U4G@C8B;-26)'5`LT##3Q5KUGXVE\U4M3 MQR&SEKV`RGV$'T<.\MLA".E(Q\<;?*K+,_(1-@#<6\2A3BU/]?)E3?,D6:LY M<59'W8F084QE/0'?"I6ZJI/(7H15$U&V-0*;(>1H.7^P/-\Z4?!1,/``O?[O ME0OEO87QFN=<#,3EUG'A_DG<$\%M+6L;P6U"\^1BNA%1)PM*/0GM&BX0B"SP M4UM9("&5A5N=1!84,-O*`O6)K"%82V3!J?O6LF#[.96%&]$%+AV*S6UQ09-4 M%L_]2)![OH+(@W-K*ROVH@^.(K)$@]U>5?N1C%?=717!1684?^5@="L8J ME57XD8]5-+DMKL*/()7PI<,7;645?N3SA"Z8)ZB-A1]Y[D>"W.]F5#[B-<&( M3Z04OH-WA"-75V0W;FYRK(N'S":("7P=#!KZ\(C<`-\@"X[/X`+%V(0GA83,6CQ;%LO MR@)N!\L%\?T!AU$10?>O&]?TS3@(WQ0\,Y"+XYT^$A3WIR#(.>(E:/!1!-"? MX7'#\"1C!7A)&.)C&/>+VXC)^P)/ST#08QD::)V@X>,/CWJV00.M$S%\4L7Y MDXB8#_YFFWN(SZ4X=(N(^.CX+_:*CQR>89P9BTAZL+=Q:.;QQWL$W,B$):0B`#.\>0B=C**H(R_FZ&/O87KNCLQNL>BXE04S/Y7K\4-I8SW M&!_(S6XUS=<#0-3*7IM;-W[,OYRIQ?N_L`<*0#"EO_K!^1S$3,1,+=Y_Q"@"DFX\1W/T/?Y5MZ,S47^_GX^G=O:%=3/KSR84^M$<7T]'\[F*D+^9W M=\:TK_47_P7*\.GEU_#XZR.>#LZ>8@[GH@;Z=>3",\3#U-@4_*?BVDPE'Q+X MK`@-L&%K(3.B%^5/5[_]'P```/__`P!02P,$%``&``@````A``+L(``` M' ML-_$3Y+?_U1UL]E-2MJ-`QAK#;NZZM3Y^)^/.M5?_^;S9.P^Q5F>3--OGNWO M[CUS<3JI:-H/$WC;Y[=Q_FSWWS[C__P=9[/'>^F M^3?/;N?SV5V]>3J(D?>:&TT4Z_^;9FU>'S]PB37Y1S?UI\^OHW'>F*AX8IN>-==8QK5PFO!Y66S_![P[J3J^FX_O3Y^B==ZY''3;_6W7/6OO;IBT MC9YE\*"+[GQVOXWOZ^.>[^WM[:/`!U_NUQ^U%UDF-:VR<1//G^_L[!_L'#;F M"'L[3L9QYMH(ZV::-6EH#8_C;(X M=[W%W"P:IM=?:_?.CCIG_MD]99N^/Z'SJ=0=]M7?:/ MW!XG2YRK#3?QIK'<9Z[Z?PVSNZ2/';Y+!XFUTG3(H_B(1;IC>ZP M/FG[\N*B:<]<+UCUSD]/^E]U^FXB^[[#W#W\KRGYX/N1>>4G==WC%:?=RX&W[G6V9'K M_.ZR>ZY1V^ZLTQAZU#GNP#V$^:%U\;[3KT_E*5Y/:2=3N?-]4[""O!Q=33$T_81C M\W_5-_7\+W_^RY_K/RXGQE.Y>#(;3^_CV&7)S2UJN)@Q81;/DRP6JM=?]J+! MY=ZX>9Q-W`-\"$,W,ZK=.SWM#J0E#0UHM\Z[8*1#4[KM;N>L_=T&0I:SNS2> MN^FU&T:S1`H_BJ^384+,T$"I#6#2'X`I1HVT7\K<&G1!FZ?!2OQY&,_F'LK< M*)I'/P=I#I\<&1S6^?!S-[,Y&+CH?.R<73:M$3&=M\Z^>]X'9EL7':%$NW=R MTGK7\PQRK?<7G;60T.[U#4DVS?S^HM?O.X#CN-O`"("HT[IH?S`X.8*TDYX! MBNO\X5R>H*$R)T+U'7$2H&#%9IV"`5JJS;H^KF6LG5.5$*\#A82?+[8!`,7<4Y8.O3>_@CG M,9[.+![N?";?(+[XXVD\N8JS1O#=*9"W'V>?DF'LL6/G*LKQ0@1(>MOP?=NU MQN/I,&#]M;N(A].;-/F)82&D;4]S=/Z/)TD:N^X\GN2-Q2S$"G,/*W/79?,^ M3O$E8[.?UFB2I!;)SI-/L7ML/X_QUZ3ZH76&PS=9-B!^$X??$4^GJ4+Q=]$X M2H>-P&C3YO!C8PM%YU-R14)-/*4<9@,+GC(!$>H\2X:*;/UK\ZWR. MLZ&B2CQ16,Q#$J]!1>%M&Q2<@U'TNIAXMV0LJZ[+)G';C2] M8Z%K=YU\9M'U2=MQDH+;">:64,.;Q-M&ZI9*;>-[1^B,9=PP57)-$D;('N<- M)&K;D%R[LFR/M8KIX`P5W%RK*:7HTC8J`Y1(_<\[6 M9$I&]U/IJ$?QU=PE>;Z0TR)GDY,6X^SW$34M84-=Y)6-5L1G2;^]7.R:S+,A M2BH6U#/Q/FR#_&@E,5K7R'HANI+-E8IRQ:U1V(B]42Z^+N6O[FJ9EC8V(P-[U#0:HE@:NYER M]^QCIV_AYP.F?+X@&)0,L(E9)A%2%1:O9+X6&=:74>W&&WE0OR+.&,6S:9XT M-`0U0V]^FYD)T\C'-KW'Q]WI(8F/ M8>`>0!XDJ'-\7%2N_D!AB3C3D9!U5&2RF).$130WUB,).NJT+SJMOL]M)735 ML&R#=\_.E+0P7AK8OOB+!)ZDZM@N'8>45UF6.=K-Q9;Z!AO9./HG4IW@;*]+OOS[K495HJ M?[;;O=V]K[TEF%Z^N,J341*IWKIM M\?K?_O3O!!JS*+W_VY_^X\6V6;Q&WMTRP?T.3A)-+E^[WW;EPB?ST2[CL]A= M)=,9C"J))H"%P9.E'FPE:7_490PN9+I MS/52L3?!TCQ.TCPX_3!E(/]Y;K#%SN91=B\RV_%XW/GL>0?/]+]S_J/R96N< MW*0*N[YYEB^`NGR8);/YLY<<>?WD?][?T[_@HL]K)AS5[>N7[)BS,#]DD$S8 MX%E\YRZFDRC5T^MHDL!OF]B&O[0EY]_^Y7\:=/S_K*0SQ*_R&:+XYAEQ3TZ. M'C_[MF`=,8M^U.&DR^]S4FZWA0:4S)(.[*)!KD]1T-)_CO7V?EV3NN*6"3*- M4N]'-^@*1Q8C"O\2^SBZX^CBVOX&*)$I";%.-4IM>K?[$6W"S]9+QGJ]LY!# M(@LYC4=D,"EL;]VH1&K4=TY;HMM%L]F8DH>5EE$5HC$+NU8FN$S9^B[G*K&5 M*E![]&9^1YY=L0Q3ZJR(0PA05XP)XE%"@@?;#=SK5U[=A9)2TI4SU!ZT1_?. M'\H<>-.[W.WOCP;HSA6 M!9*,HAD,YFSDA2T@/BI2V;$"^IS(R`)\B34:+<9S4E*.%>3@K=0?29*L+44! M<6Y20@*O`QS1@H[OHP7GVQG/J$/E,3)I[HL7HJI5;T/B$AJDA5I=S$#:67R5 ML<9(7-EZWSYZ@7PB`Y!"U`7Z0-$B5Y2`]GF06+OZG9@SSJ=+WN'1Q85NGD7Q M.'&GOLQT+R(^Q-&8`XXM/4=JY9#>!]--%*9J4ONH0)CL71;]Q(F,E'OS=)5! MRPDY>8]UZGYH^A.F"T:@XYDLOE'BSWFGBWSVJ&,?$0NSYI9'2,K(B;#,>P0B MWA!IMV_)TK8I+Z31*+(%6F1TE-B2:"VS$)6V[I4--0(D.5(=A])=56Q:,WBK M$I9*[0R[0.D=P(MYAE!]$GW/O]?LZ+[A,]?KT14V>^,F4?9#K%(8\A"YP('^ MU9]3;N,,J<2K*ZKQ(Y=R"NXZ)YV3[_J]O_WK?TIBY]>DX%GPL4).^[=$7#<[ M]+3FVADC!8D!D+()RM$@KT^U4\ MOXOC=(F>\L7V)-!7J&'X9ZN80(0B/G8>\$%49]/%S>WJ7-N!4_1\^.V+85ZG M0XB0.J^3ZYEV>1YXUI`.)N?C%B/93CT00*!34%0P8MO=3;/QZ`XNE3P!BD,` M89NMLCA>AXM+@=89@?DMYNB3S(#UJ:V`&N$HL=RJ%MEV(,70[.R5^:>P[:V< ML\8,P*=!3']$.@I"R&/RH_%)TBK3166JK,GNIO4IS5I89CD%&--)5=[A0U9K MX2O*,I3O*RQH#TAX0,ZC`8)Q-CNW'LLYB0.%\JC/\"YK["A0#<$@XR>CD<-W.RESOS] M_I?63'=8"9T-20F\8)8BY\"B%IPBP M5CZPJ,4D?`R*1G_][[_^U]3U\KMH/)JZ=K;XR0>GR90.EI^\_Y,%^XA,FN`G MM+BF]\'JX6OLPYO"U=+;KL#-?;I=PQ6^7EW*U MQ[A[CCP]ST5B*764R&07?Y['5DX5&:N`=(WN[^AUZQ\Q'Y[&,<)&8Y0@<"A* M8&'*NH8"3^R:!Y19T9B<;!39,1$*A$T0R)LH@?!%IG;1FZ`IC$;`GD9&EQOD M[V,O"J.`7I*(@QX?+.0_@-B5,KRQ>$5`-^056>K#?NTE)=!#AYUI.E5RDMO% M-14UCZ#\I0XB2@&@E8:@KU#M%=I'!Y`#$&`'\)@@A@V0S!.2;KM;NG7$ M/EJ51;YXM71G!!N$[VN7=<%U:-F@;R2,7I6"TI6:9.BC7)*J*2;I1RU)1'[5 MXY"_%X%4,&RE71+(XH1P7*_52-5(V%<(6-%;%2O'7ML*Y[U.8TD6DG')]&(+ M6-4&)A]\^20N>Q.IPQ`&,504[HU""M(0!MJ4*8!`%.JF;2#GD5=;22^G7D;_ MIGJ9O0T9I!;-RZL!$8'#-,.^X9=OK-,"YNV7^G.X^[J,APSN;1'`7F.]!6`? M2^-LT#:8NF!.:*37ZPS0NO'1OH=?;]?@O4\]X(9!E"QOZ04?S!ILGO.5P'L@ M^--,9O60JFPDA(P\*H$EZ+?,:K5,)[_EJS\A:F:7:P**)7!?1?0Q,&B5CI9, MEM`6L_9Q28%.3Z,@H(4GH>X2S2@]$`#O!?M`,P2XF!1'W$VI[A_4Q2I>5T.( M+9!&?7H";78HJ3\D@!?JB@@&&LBP+,%J"_+$GL@X8_.3,NPP#A3'_;GOM;&" M5K`1HI$57A*,7L6WU(-$TKK0_"%H?4A)5U81BJQ`&*RE`$4R!.(!'TCX]:\* M^`@\&[+#W%&PDY`]R\(>&"W>XM_`2HF^W&=02>,OA[.T\RB66R5E!;T:R`$R MZ01S+I+DRWW!L$1JF+4IB98\C22/28TW[W"H,$''P.*UQZ:UX7"#*`^>6D`Q M"X!KJ1+_SN+I=0,>NLN<2+LPNF;B#&4I'U_J)Q(1#UV5HI/%E7KH*2C#,%\` M$2O+Q$6J>*5J0I&,LY(/L;0Y7P!2_T&H_FR[T_AS,IQ2&_(EHDL*B@MI`8C0 M&E]1]J="5*%\%591G^%T>4#LH_Q`3OE8',]W7;A<(#=9F3]T67BQP**BH)R3(.-\C$_79)Q>+UVZ4(N< MU+U9(*Q/7N- MV'66/1#Q[),WX"2YK2/=:/N#'T:FE`"'@J$B`SU6.\,M2MXH(=[#B5&I*Q@6 MG2DTIOB6/Y*-">?R$?T>;O3\DD"A>+#5&EQ2(\/$PQ"JDD5/RQ+Y+W-BQ`VR MM9]E.-7*<[V*[&OOR[M++>@;7`JTM.'*=B:D":AJ/J$4S,:+NJ/?=BCF@C;* MY7S"T(^N8R+JEH<1E',2_:`6^'3'6Q*3J+3.X$]10I,[00"#2HFCW,=X=B)B MLEIEVQX3CE/-0)-H@N1)A#@UY9! M8,D/ZJ4+8^GUPA\#DQ97JH$!(&*\QX5U'4>Z3?.N&M&'RQ^]7P)>>,PKQ.R5CEUYGWR^CD/2D5 M.^(B(I&$&L%\R<<"'(Y_L:%[]`0%"C:U`JO#VX3<@5V1?7(.KY?*9()[4L1+ M"OIU]C@#-#$T=K[<)-5F$@YRUO$X9-7(L(!LI=M")MZF/+T@<*K0:+DX>2"V M9BJ[+AA+^9!&0M.?6T[G*XU*#2Y=-7YYIVJLWCV'Y:B^ M64/=\@K*E#/%ZD$=US"KQ1!"Q&_HZ_*-N8,*E4JM7"VAQ1\*+6]:=4:Y?9C`XR+RQYCT7(T%]JYF7X$7 MJRB^;[7.K?8H)31;3"85`I/E-64LTU9G,05Q3(?H!188DAUCP@:,6V#'2I47 M+3)B&)25F0S^7RL;"")`93+KN&+>2---9QQ)H%[,3G6,#$%,PTQ9,*KTOF[Q M/"KP"_7$3XDWP`NV^<*DH-07ABP54!LGHR*&4BW&BZ/8!6+GI'V9IQ<,"H8F M59->,-]27H$9'!#V/(!"P,/S6/5;?"R(4D]+@NVKN8(H.+"TF*1:_?:XQ/K: MA1B%&QC[U'>-GJ+_OTPY.3]:C'4.RDZ(1M%$%/I[8ECS-3[N8?&*WC^B[<'= MM;SH:807'B/?8V7DW!__;;DAJP'[$LP1H&'Q?W'9EMC53MK0HO\O8NZ1`5/0]O9*!DOI(6KX\W`3\[[ M9M]VP@)(V3@8-J+/VTX\532P]P(7[_#DMYJ,!"S#TBI)EYV/U:&*V$+\1'CA MFC9HI8ZL1>R^X`!S;]^J,?YHK3C]J+Y@U('3KO]BJ3K\,M#XPNG-U^^>K7]]NW;<'-%ME1=W!^GC^^%$E4:BCLY MBKBPNZ+3=LF`E4DT*CRR-FXE(Q8E824PT=J_@A'[7RKW>6E,IO,;=F,2*RTK MA\LVH`?KJ'ZG*L76SPU%UMOMP]=OME^]>57PX^W;+[?W7[\JZ*WSH\`1VA2H M,6TLWFY>](H",BF>@5%1J2G`0S'=CNDJ9M.0JWI/SP:]BS6]H95'C_6!'K@= MZV+=-%-H*\F_00`04)7M.H.;U#81H-KT5UNVZGQ:1_ M^3/`57^X96UI(UW4YJC,<#%\@Z#1G'X1W>']")<)C!NW7+ZH3_Q[TAS-1]1$ MS3-OO'"L]J=;]F6GH/6W!_8U@*()_[[^^/]:Y+=@;EG8W]]]LRSL8_YV962G MN#)24A&:7W1^*VD4P7U#DXY;W0OWL75RV7&G]&M?KO\2P?I1C^G7(>UF_^;6 MOUOGT@"7`%#,%#E/.!"S!,$B#8^/,E#=[P!^@;'*@S#81X8RR:5#\3=G3%DK M5SQH;%0`XZ3Q`;E5\<,#:9J\HUTK],5VS5YX)ULVT*95RT8=R4$\+, M?S5#3%^DE1^2%*>H#!^.L=5`5W5BPCY5@X6(]#P2`%E^F:MC(E%FHNI;K)[F M*Z:P)J4&-IQ81KK_E?O=@DB88H=DDKLMXC&+7^-1N,-B08AG&^FF]J'I%<@3 ML,BQ6!C19)\/I?W]'Q2FD!(=B#[&J6C7DD\WX+!6B>V@&,863+.4+=`,B(A! M#2OSCP^^.&LEWQX0Y6 MDN(6^(H<%YP_*>LEQ2/04`,;XC9P-0B[C4'(891E%NT95#Z1P&;0QAD.ZQ<. MWP["39-F>-NE6WN[MWM0^K72%(KR%(^6$-B@Q#Z:X/A6Q%E?M\CXP$C=NS1' M/.:[7IGO:KY7G_D7>O<0R$9PFWJG&/3Z]?;AFX--L2;!"9Q=^6"-)$I+8WDW MOCK7F^W]@P,J`7:@)&@H2K7%]F7Q_PF*1>>TG57ZL+JJS>5PT001U:LFZH92RIJ]QI@M9TSZ'FDI-M2;<]?&4S1 M:N+V7^]IVYO$R%"!0!K?00F?];)FJN$M\0BE&DTNFM908FDZ(PJNR_<0I_#" M%X>[AV^7::.78R%X73ETZJ""://)GFZ?+/Z3+>:[AE:I]J_Y@,@_I^Z$^\NL M"AFH]/Q0-&(!E@CWY\["[9#AV41HD*7)X10^],0(>W2'U0.8T:@I*OU)NOIB M;/;DJGI_I7LDXG>ASO(4R,DCL&\OPH=_9-N6I7I^%MRPLW'J,@H0BB^J09R5 M@2P%C4#(C/**]C10@UZ(T(!&'OD+U;S0IDTGFZKR+5>C[NQ`AL4VA)\8`\-6 MU4L?0O19/Z=&M-%;['+.900OL0*:1;GR%L(KN-'$_Z!R(5HU[B,/+PM_[J+W MWG%7YH>=_I"+- M+*R:BVX-=/#8O(6NJ[KZS%HC;WKDAJ+;.E+'[3C?^!F9KNZM6$M=ZE68KXS&.SGG``F4DD'(K$64Q-RN"[V(J@V&O,AK4&*=A>*H#3D^\/48D%7*4TIM&\L5"%JI M!=7'K"_"/+[T"H8^_3N?Q\L*2R,AJ)/6C+$?)ZL]UL$VGL_JZ`]"0%M?"RW# M66N%+:,H)@C!09VH=FAMZ!1?%-N$3E65)*TIRM/U8/T)2S8#WXIB"+Y"WW9' M_A+8"]]`V^93;NL^T;KWH,\B%-XM0^'ZYCF0G=1_VTS`$T8^\!6U@3YY6KKHV4!?)KX^SZ;!6!F>/VSF3-!]">'ZS?3:<,15?#4&\Q MQ3Y70M`E#2_Y9OBW_RL`````__\#`%!+`P04``8`"````"$`I"MG%70%``#I M%```&````'AL+W=O4ABZO3I.EV'[G*O MO[R7)^V--VU15QN=+4U=XU5>[XKJL-'_^?MI$>A:VV75+CO5%=_H/WBK?]G^ M^LOZ4C851/9U4V8=?&P.1GMN>+;K M!Y4GPS)-SRBSHM(EPZIYA*/>[XN<)W7^6O*JDR0-/V4=Y-\>BW,[LI7Y(W1E MUKR\GA=Y79Z!XKDX%=V/GE37RGSU[5#53?9\`MWOS,GRD;O_<$-?%GE3M_6^ M6P*=(1.]U1P:H0%,V_6N``5BV;6&[S?Z5[9*+5,WMNM^@?XM^*55_M?:8WWY MK2EVWXN*PVI#G40%GNOZ14"_[<0C&&SN.&]WVEJYO MV@S@VC-ONZ="4.I:_MIV=?F?!+&!2I)8`PF,&$@8/)H?;,A$>EU)UF7;=5-? M-#`+3-6>,V$]M@+"49"<_BKQ(X4@39!\%2P]%R3?0EG>MJZS-MY@)?,!$DF( MKVL3Q,.0>(2(=1.TR?A@&L/PD'1$B**!HJLL6!`JRX9J_[Q.HPHQB*AP\7S1 M+<3"B/@6X?H8DMQ""$EZBU!(D%#[5JCSH2%'H6(06$^M18!SC"3$42$8$=]% M)'<1Z1P"R81$U'K.UU&`-SJLX62U$"2:1)B".E>22W6(T&)AF;J-'0(9Y(9=3K MF1F)D2X/ZYHOE0`3/23C2$+DK`OFF;16.&XSDG6"XJ[GDWB*XI853%9! MLF#G4LLU+TN`B:S)!?W>%DG(L)AF0%3'*.P[9*M,U+!CAV1TBL*^8_^\4J(K M(7O_?0>*043:1"^E2*85T3.^U,T>=2@ M9.9HP`SB7,L21SMCVN2C8"JR2?S1N);$;A5:EIX_HTH M-:XTM[WD9!@]ELIUR)*EB)YYDT>Q+'&V/RY+=@)(%CE8(R8QLG%<>/!^X*,I M)H#`GE9\D(88F.W0[C+%%(PQ9:/%\L0Q_[@\V12`QZ]M,:U*Q"0&_'C%3$L[ MN/$N)+G/DLY"L$AQV#\N4K8&J(;3]M0KB)C$A'T?N_"7)O[QT\6-63\[(L%S MF,O;7111`F":$\L7;8$B7WQ-\.Y^DV6RF4"U)IME-&!F:RUI9B#)?99T%H+$ MPM4-$CM_(/9HW-3XM-8#1FXDH1589A"2-S(F&"OTH>7$KW5",+X+KRW9\L3% MD]CRQKDLA[G*EQ4I5-XLR1N8DC<''O/3J=7R^E7<&EE@R>M3>:,5L17P$U7_]RX!N"BZ9P=^!]95ZPZN MF/I_CW"ER.'&Q5P">%_7W?A!W*M<+RFW_P,``/__`P!02P,$%``&``@````A M`.#6,UL:!0``!Q0``!@```!X;"]W;W)KP,VOT*49+50]6ZE6^ETNMM]IL1)4`..@#;M?W]CQL78)%GH M0Q/PY_'GF?$WSJR_O)[HCIL[/_^?7I8VE;39M4N M._&*;>P/UMA?MK__MK[P^J4Y,M9:8*%J-O:Q;<\KQVGR(RNS9L'/K(*1/:_+ MK(7'^N`TYYIENVY2>7*HZX9.F165C196]10;?+\O252T:J=DI:X%_ MU,I]BKLSJE]?S0\[+,YAX+DY%^]$9M:TR7WT[5+S.GD^P[W?B9_FG M[>YA9+XL\IHW?-\NP)R#1,=[CIW8`4O;]:Z`'0BW6S7;;^RO9)72R':VZ\Y! M/PIV:0;?K>;(+W_4Q>ZOHF+@;8B3B,`SYR\"^FTG7L%D9S3[J8O`W[6U8_OL M]=3^PR]_LN)P;"'<`>Q(;&RU^WAD30X>!3,+&@A+.3\!`?AOE85(#?!(]MY] M7HI=>]S87K@((M>6=,^%<*D;>6O3SQ%\-)^CF&1P MC'KSW382A'1)U[U(!R\T`N"8(8'[SA%@<.)PY[&Q,$+\`230$>D]A$8-C$RG M)L`;&W;9!\5S]843A"R[H$:$^+X^G@['EZ$7WP@9G(GIM`38H$7T91.$A)AK M;FQ$,C6&U6S-5^$<4@)LD*(&*80@*1(OE2LPF[1A/U"<-5)P1*9[2H`-4IY! M"B%(*B*>F5C:<'R+E*AZ`U6XG_`";)`RLB9!")):4B\TQM/A>!S%KMJ4YJM8 MIS5-K,0D@Y[AE`0A,I`15>F#@=2&@TC%62-'0#:G.ZU#&[1&&BHL;FS)B_J> M6AF)22,2X,%Y[9-!IV:H_/UX$E1F3294\G8K)Q+C=P>2T!$Q-"&'_5NTA-Y. M3C-1*LU`&NLF$H,.B<,P4"M+CZ$1Z3'BP=\-EPD%GLX-]1K^*V4U19_L"3(WB,)'D MN$@,`B1)#FL`]6/C\*3=RI]E%RXKMP(LQ'IRA:`H[;!TG_:^<2@3B9%"YL8T M-`5%1\#M;JG(Z]DG%'\Z.8'60QN8]8$B1I*#*YPIU*F.\%TZ4!V=W*P:(7[< MFN14SLB0(N9^WMW%Z`1G50HZKA2!$;A$8M![#YZXX_9I+P\O6I$(&L:^.EPZ MN5G5`GHJ(^^IG)'>0PS^Z+MV:Y)&$$"NW9JP[X*=A9+5!Y:RTZFQBH4 MKHG]6^SW)&254-$<,=ZGH@_4=7+Z`6C#G+,#^Y[5AZ)JK!/;@TEW$4$\:VSD MX$/+S]T/_F?>0@.F^WJ$AAN#CH6[`/">\_;S0;2*^A;>]G\```#__P,`4$L# M!!0`!@`(````(0"@5SN\EP,``%P,```8````>&PO=V]R:W-H965T&ULE)?;CN(X$(;O5]IWB'(_"0YG1!@U:?7,2+O2:G<.UR8Q8'429VW3 M=+_]5,4AQ`ZTTC>0P^^_/I==IEA_?BUR[X5)Q449^R08^1XK4Y'Q\A#[/[X_ M?5KXGM*TS&@N2A;[;TSYGS=__K$^"_FLCHQI#QQ*%?M'K:M5&*KTR`JJ`E&Q M$M[LA2RHAEMY"%4E&1J/1+"PH+WWCL))#/,1^SU/V*-)3P4IM3"3+ MJ09^=>25NK@5Z1"[@LKG4_4I%44%%CN><_U6F_I>D:Z^'4HAZ2Z'>;^2"4TO MWO5-S[[@J11*['4`=J$![<]Y&2Y#<-JL,PXSP+1[DNUC_X&L$C+QP\VZ3M!/ MSLZJ<^VIHSA_D3S[BY<,L@WKI.GN/Y:S5+,,5L[W<$5V0CSCT&_P:`1!5"W` M(.K_2YB'"*.$;9CN]27D4[UL_T@O8WMZRO6_XOR5\<-10Z0II`&SL'IE* M81D@5A!-T345.5C`IU=PW$^01OIJZ'BFC[$_G@73^6A,0.[MF-)/'"U]+STI M+8I?1D0:*V,2-2;P?6Y,2+"83B>SQ7RXR[AQ@>_&A43!))K.%P-80C.O.F6/ M5-/-6HJS!QL6R%5%O&+<*"P2RT`7!'3.& MS?I^9G`0Z#KSGK3NAM`H)AW%U%8D[RDL0C#I$KY/AN+8A]FW*S*SXVZ-HDLV MMQ5)7W%EM\A@-P\G0[%-MK#C;HVB2[:T%4E?<8=L]A$R%-MDQ-WH1C*MBV!" M%I'S/C'ON^AWP*":AJ<,Q0Z84U];(^D&)FXI]"5WV/"G<_#A@&*'[5IAI@:, MQ&)SRB3I2^ZP+3_"AF*'[6IKV(S$8G,*)>E+KB96&1`X+X8GKE8[=$X%;AN- MA>=42W)#'Q[5P_G,P6[QN95!^H=_Y);&#/C@1[0+29U4?C6,+R7'FI.&$O1F!H M^[1M+INNKWT!;5I%#^QO*@^\5%[.]C!T%&!')4VC9VZTJ.HV9R`9MPR@`\5X(?;G!IJ3]7[#Y#0``__\#`%!+`P04``8`"````"$`(%LV_[P% M```<'0``&0```'AL+W=O(]QXQO%&0WF]JZT6NWQ3'#;1C'&`C*9?/NII@&[BX1*\N*C^'717?_J M^_[;S^RD_>!%F>;GM?#6O_W'^]NJ6ME%9]W\2D_\[7^RDO] MV\/OO]V_Y,53>>2\TL##N5SKQZJZ6(91)D>>Q>4HO_`S/-GG1197\+RM9; MEGS$71873\^7NR3/+N#B,3VEU6OM5->RQ`H/Y[R('T_0[I]L&B>M[_I/SWV6 M)D5>YOMJ!.X,6=%^FU?&R@!/#_>[%%H@PJX5?+_6OS-KRZ:Z\7!?!^B_E+^4 M-[^U\IB_^$6Z^R,],SS)X&&.V&"PD:OM%A[?@^?CY5?^E1=`_ANG)C+T8*-5Y/%QR.Y M:IS`=^N$?5H.!EDD117I]&5569<;\*.MS7(T-6>+Y0>RPY"95B>N$U?QPWV1 MOV@P&H"W\A*+L859XAUMRLH$ZY+XO1R&Y!5>O@LWM3-(SQ(ZWH\'MC+OC1_0 M69*&L24#LG;,;*XBFQ8174/X=;#!;0U7)TSUX;5$Z\/'A@`;0FF`SZYF;#55 MW49]!M=^VT>N=3,@WEW0H3_V@CZ!]'A[G&AC+$KA&$_46MJ2N8TQ4F'3)V8+ MU8G31]AJIC)NGT$O\OH$?I$OD=NX(RVM*PZ`P;;'"PP<4&#QM\:;@-*5NA7A:\Q:`<"-]B5BBL?0;6 M&RJS?8NYBJST"IASOA!640KFR9N^:XYQKY`,?';]&ZF_(0F')%R2\$C")XF` M)$*2B$AB.T0HHL%LJH@V/(0)>JU#5^N$,,=HH+4E`Q7H&"P623@DX;:$F*JN M^5A/.E[[[-T:^"01D$1($A%);(<(1298B2DRB6F>GG%$*2P7$L.6S)!<).%( M8EFO&^9H!'')XAY)^"01D$1($I$D9#-0F+9#I16E8.Y6E!KN4(+&"J'AWI;, MD$(DX9"$2Q(>2?@D$9!$2!(126Q;HAX(1&\@`]1GD9DOXCDM@.$8I-)1JKH_;INS/G=HA0!!/[YB\H5A?#DJ&% MJ]U`0YK1B$,C+HUX-.+32$`C88?4NW-S=!W7ZE5/U#U_7[Q!1%5/[(4_/SR* M$PCL+.K9=>=<)Y?=0`.";&C$H1&W05;UE#3!2>[1'GP:"6@DI)&( M1K:#B"J:V&A_0C2Y+U=%0_L@FTE(QI*Y=VA;O2&>.\WS`=%=PH5'//?I5P0T M$M)(1"/;0405"T*BB"6V8U/8S!$]311#'B&%F8; MA5E,9O/I'"%.@PQJI[YI.9TN%F@MZZEOFK+)9(DJ[--O"F@DI)&(1L3ED`C> MVZV6$LK+'WF&GO'BP#?\="JU)'\6%SMB\]=9Y:63S2PXQH93/V1WF05GU7V[ MSRPXH>[;;=."(\.^?6-:<'+8MSNF!0>(?;MK6G".V+=[I@7'B6`WNHK"W=0E M/O`_X^*0GDOMQ/?0Q/%(7*$4\G9+_JGR2WTP_9A7<"M5_SS"+22'$_SQ".!] MGE?M'_&"[E[SX1<```#__P,`4$L#!!0`!@`(````(0!7ZDDK'P@``(@E```9 M````>&PO=V]R:W-H965TMB MYX(D16RBNPOL`HO%7IX56XZ%VI8A*4W[]WM&I*@9DG4BHR]U;=I.A_TTGLT6TT-6',!? M[XI3W64[K-^3[I!5GU].'];EX8043\6^:+ZU2<>CP_KVM^=C665/>XS[:Y1F MZRYW^X>7_E"LJ[(NM\T$Z:::J#_FF^G-%)D>[C8%1D"RCZI\>S]^C&Y5>CV> M/MRU`OU;Y*\U^_^HWI6OOU3%YO?BF$-MS!/-P%-9?J;0WS8$H?/4Z_VIG8$_ MJ]$FWV8O^^:O\O77O'C>-9CN.49$`[O=?%-YO8:B2#.)YY1I7>Y!`/^.#@65 M!A3)OK:_K\6FV=V/D\5D?C5+(H2/GO*Z^510RO%H_5(WY>$_'1295#I);)+@ MUR2)T\GU?)XNKJ^0Y4S/Q/3$K^FYF$3I;$$7/],M-=WP&V#M=YSJ4;G-"1DCQ2EOOQU7@$I6K4P)>'Z/KF M;OH%\[8V,XNM^R`?A2QP["+Z+HH M!@B&F$Z788+2#A=EIR)U0OEQ%9-(,ECJF`C*6*GG,F1E0RQ+C@B:F'&7)MT[ M`V>?LJ!^H(7E%"6I9+4T0>>(VQ!+G".".$ARXN=UI>"67Y=W:9#4SOW*(/AA M8TCD&%0PJ!^H8+@8PI"")4.-Q-IFZ&98>8CBB+@V;D2N3GM3ST!^X+Q2&LE* M([&<:;?^;%`GM^*(($J+,'.?\]-(P9*.1KA('J(X(JY](Z_=BI2VB\10G2B3 M)*811Z>%K*:5#;(Z<41PC>`=[Q>JC9:$#`1&W<56/J0$)`F0%;.9(K46R:1? MW-Z_5&A3AUMT3);D9A#0D>O*D:N/ZCHJ`4F^9,R,[_G*(NMR9M!`O+9\2`E( M$B#/901(L'@&/QMX#T;&N[E<&G+DNG;ELE&]7!R2;,EH&=LWY#*VS#EI2-27 M!ZF(0Y(`62LC<+%[H&>[DX)-F2\S*V;\BE?1JUTJ5> M1MRZV[W.RH>4@"0!6EK5EPLV[-EL)TYI:7C>H&I2(.2;ID MPHSN&WIIRQ:Y/9MM'1[`W'S\B$E($G@A[D]*+C.:B!Y/Z;>3MNN"5:POB,@R7>0 MV].5';CE;TU4?U>OU7;N/ MR8<9W?/W8QOM%)@QYD:L@1K-^F:_\P M'1'5"V8[>@4VR/!CW_`-Q-19^9`2D!2,O-41[!(#B[5'B_JRMLT-S-W4FXY" M+MO1DXN,F+%]H[ZT;0M.W,G-?'F0BCDDY2)O900N7A]C;=*"F_5MKI>[N3<= MA5ZVHZL7O1K@=,_KU4;+^]%`[&HK'U("$GHE`<._I+S:/`XU:^1<+G=S;SJR M`2@!2;:#[#[Q[=Y`_&[T(24@22!@]W.,<^!N(O'-WD#0@:OE[NW[*.M=`I)D M!YE]HCV;%[R!L,)T5UOYD!*0)!`P^PO>,B76Z9DTF=C5@M][3!0X:A^P)+FH+4B]=<*`[%U?.5#2D"20&"M2*[I MY&[P1-OEHIN>9:HAY[9P5X<^JNNH!"3Y#EH=4G]U,)`03$(+AZ1+COQNW\6YL?MP9R!A(\;E^_T)'3A31QVE M">@#9'WV>H-32PN;D^LTOGU$)@S+:8$_X%"[?7+T M6E*TM.=*7LL<+>T)M->R0,LB>)TKM+0GE%Z?:[0$N25@@,V8S_HQF6,\K3>Y MV=!"6R"_SS(!`RSZH18PP)H;:KE!RTVH)9V!=7N>[S)(Z3.!(+<8U\&37N`Z M,:Z#YZQ`2X+KX&DGU(+KX,DBU((YQ98_U)*@I:TNEW6,/OH^]5K01Y>?UX+Y MPOL8O#V7Y!R!#DO,8W`:,8O! M2<0K3/M[#"67NJ5^DO:?0?37G"!A-? MPY0-OH!I_[O#%T\YCJ5G]))S6Y9-]P<4G=IOJ![^!P``__\#`%!+`P04``8` M"````"$`[7QAN_@'``#0)0``&````'AL+W=OV]0MDI%DL1*5MD`+%$4OSXHMQ\+:EB$IF]V_[_!. MCA1)WI?UFCISR#,SY$QD/GSZ=CXMOI9-6]67QR59;9:+\K*K]]7E]7'YS]_/ M=_%RT7;%95^MLM/3S__]/!>-U_:8UEV"V"XM(_+8]==M^MUNSN6 MYZ)=U=?R`D\.=7,N.OC:O*[;:U,6>VYT/JV]S29:GXOJLA0,VV8.1WTX5+N2 MUKNWJVNKV,Z[.73GHOGR=KW;U>X^9<>_;G:-75;'[H5T*W%0ON:DW6R!J:GAWT%"IC; M%TUY>%Q^)MMG/URNGQZX@_ZMRO?6^O^B/=;OOS35_O?J4H*W(4XL`B]U_85! M?]NS(3!>]ZR?>03^;!;[\E"\G;J_ZO=?R^KUV$&X0U#$A&WWWVG9[L"C0+/R M^#)V]0D6`/\NSA5+#?!(\8U_OE?[[OBX]*-5>+_Q"<`7+V7;/5>,`AK-.''![./B6+&;FRPM!=0-J'>"XBZR/">Q="!<3V#2+)%4+K'&5U ME$.NV\K'%3/PXQ+(=91BY/)40&`3:`CR23:)H`(1\TRY\Z(D0*F0*PJMU['P M?JCUJ@'N'I,-CEHX$FRUXWN7@9%* MDS5"I8`(']]%A"3:R?QYYCZ/?10TZCPG?A`A-^8"$/"BRX[P9]>"D##64SI* M69MGU:%QI0R,E*(#)!40J=1/[O%^RQP`>")&#-0!###D`F!I=2Q<2D=KV[+RG4`ZU%N=X#H;!P'F-22&:#:H:&M)DYN,@FA`Q!+"J?)-<8X MH$]L6;D.`"_]@`.8%=KO)L6D`P3&C@(J;1F9A-`!B"5%.D#1&`>($5E*2!29 MI''5LP;F]O"+ML<)/SJ)4O9G,GAH5/TDA`ZP]-4+&G;0Z<8/5\YG3<2.07,R MN\Y@WV,Q$P@4T'U36:%O528A%`B("*H8>A'Z,S))<"J[HZ)1P+K M+UQ7.FMY+.GCK0P1#9(M.49Z4HD9C;]JO#[T"AU@Z<=?T9CL5R.&V+)RA;/^ M9[YPT2TYPE$+EA+58@T5Z&ST*1U]FNNG1N@'<[D26<\S7Z+HD&R)"Z=U,3Q]'NH9[@JB8Q M8VD]#:'3D%Q#=+#UB,EJL^EU<]Y`.XH]INYDB\(9:-*QI2UD[S>:VR<5A=R:R)F2]9 MM#RV9/QR(/7Z;5%/\R2$3K/D&F)"/<;KRKZI(?,&&K)>[5)-DDFSGNQ)")4S MB6/ISB/$QRUO+B%VL`6O-"*Q'R9F:EYPA3%A5R/&]9:5XP#VBX>=[O,8YV:2HQ8PZ8AM`!B"5%.$!CM`/T MR`P'H*9MI@,&FC=$WQ)JAX3=M<2^"_423 M^KVAK#]$^T-Y?^C9&7*7B?HMMB?9FZ0;;QK`%16&\OX0NR3#/<@-A41QZ47NOO)K#R]U!S=I^'^/<'.JA&S9K`!\J.M. M?8%%K?5=K*?_`0``__\#`%!+`P04``8`"````"$`N)1!(,@"``!%!P``&``` M`'AL+W=O^)G<7]BZC0,U.: MRSK%H1=@Q&HJ,UX7*?[U\W$TPT@;4F>DDC5+\2O3^'[Y\\T2\&IDEKFQ@,[WX%>UISXB0].RT7&H0(;.U(L3_$J MG&]B["\7;3Z_.3OHWG^D2WGXK'CVE=<,PH8VV09LI=Q9Z5-F;\%D_V+V8]N` M[PIE+"?[ROR0AR^,%Z6!;D=0D*UKGKT^,$TA4+#QQI%UHK("`#@BP>V;`8&0 ME_9\X)DI4SR)O6@:3$*0HRW3YI%;2XSH7ALI_CA1>+1R)N.C"9R/)F'DW8VC MZ>P]+I.C"YQ/+F!X&\%WY;3I/!!#E@LE#PC>.`#6#;'O;S@'0QO+!,)U171! M7X0M-,AL"K)TD;GL;QO%9!1LW M#,?.X5\%`SY8+'V^VUQ6?,:5G'$Y2>*X/HTFP^'-U>$!5/P>*"L>0H5!,'SL MVFF.:46!^PTUL-E9GVL:Q^>V,[=@!5,%V["JTHC*O=VJ0JBZN]OMHJMQNQ%V M`["+-:1@WX@J>*U1Q7*8&GA3B$:Y?=!=&-FTV\%6&MB_VK\E?*X8+*+``W$N MI3E=V"7:?0"7?P$``/__`P!02P,$%``&``@````A``'VK]2D!0``9Q<``!@` M``!X;"]W;W)K?5V585:3TN#VH/*^NR*M(&/E8;KSY4*EVUFXJ= M)WU_XA5IOG M7PZCK"P.$.(IW^7-1QO4=8KL[L=F7U;ITP[._2["-#O&;C^N%^%W=)(%UO>=\*]&^NWNK.WTZ]+=]^ MJ_+5'_E>@=J0)YV!I[)\UM`?*_T5;/;.=C^V&?BS%!U!HI"F+&,=*2LW`$!^-RE;LKB/P0)$PJ#2!,D`/9F';X:WNPAD?9<#VF3+N^K M\LV!8H%'U8=4EYZX@X#'`^'C3T>\=$(XF@[R74=I8P'Y&M+RNA2^N/=>0B2.'%MCIF6&_BZC$",6*`QND47+TA!.$X MH1R'U=-@KAY[S_JE[8R9+7;#[.@- M^H5F)IFXB8EAQ`U$9`&4&7..V]Q-]%B(8$46&Y`9-3/62XE9/C+T0SNI*$-F M(U>TZ_$/8;-BM.LZQ$B$L^BL]"AB.IG;TU%V7[(1@29`^YC55FQ`4&&G)K(D M3/D=S:0/0GDR0[FB8H^3='S4J-@UBU$P97,H$;AN$@QO8!9`J$GF)\/46C1O M6Y:^V(!,VW:,#&4[+5O9+LUI^24S:7-69]6-BP\YDI]2^Y!T2;8'T!A]OL0$-]<8@A/+4 M0_QV"7'D4PFY;T@$H80!$SBAJW8P4E;,,_1DOOX:HW^J<^^0W#L,Z!*[KK,$ ME]CU^,8-['I\@[_EQ1)!R$X$K+<3NCRYX!J2N<:-ZO6XA^3NT89>N,?RCV3$ M]$T88C;W[2%HCGOV*62;+@6\%IKRT+70FX&TYALM,/FMF M]@%&/L3@-4S'*`P[7.V*>V;$>-^)]X*%JC8J4;M=[63EB[[+%'`'&PO=V]R:W-H965TX^TX0DJ$,<`3T]\_=3QC;8KFS4K9F7 MIG.H.G:=*MN%UY^_U1?C:]FT%;EN3'LR-8WR6I!#=3UMS'^^1)^6IM%V^?60 M7\BUW)C?R];\O/W]M_4;:5[: MP?S;NSIN7U]NG@M0WH'BN+E7WO2+^9GMY M(;C['XB^KHJ&M.3838#.8A/%,:^LE05,V_6A@@BH[$93'C?FD^UGMF=:VW4O MT+]5^=9*_QOMF;S%377XH[J6H#;DB6;@F9`7:IH>*`3.%O*.^@S\U1B'\IB_ M7KJ_R5M25J=S!^F>040T,/_P/2C;`A0%FHDSHTP%N<`$X*]15[0T0)'\6_]\ MJP[=>6,ZSL1S9HNE#?;&<]EV444Y3:-X;3M2_\>L;,[%6!S.`D_.8GL2RP-/ MCWO"DWNZ$]N;SNG@#]S@;3]M>'(W;[*J^=X3GX#B&^V#$%7>$ M)W=>;:3K,?C(1;@)`0(1%"8H0D"$D1DLF($OO\ M0[%3:S5VAD#L(JP]0@*$A`B)$!(C)$%(BI!,1I1`X1SX0)*IM1HH0WAC0`^" M/;<90P\8XL&1)16"MD["P4@H%B&BF"/C_IP,7C*UMD6G@Y&@SF0B10[:U.(S M=D);@NY<%2\[`B'`6KZS%EPX2]D)2TE4E1@BJ\1M))48XMG]D>Q,;4_=2,+A MO8@B0APQ1R2!!B]ZT`.KJ[*FPWO!FLDII!Q`W<_ANA+]]80*Q!IVLZ$30/!TN% M%1O,<3UM(6:"F7V0R/T;[2(^(B0UUX1DD*O6R%PM]WT_#CC*0G+'<2F&W,KU MF&JN5FF1>#^ZQ()X/NSX";9*!<2(5T@?>2IJH=%^[ZP5(1"Q]LI6/3'EKY&VH+#"#G'&5[>$> MA!:P!`48"C$482C&4(*A%$/T,F:P><^-'%WZP[]CO'AZ]9S+-S??B"P_B3YS^Q M@*UA!+B/NN6G\L^\.577UKB41Y!]VK=M#;O18C\Z7HO/I(.+J+XLSW#S6,+N M-9U`CWVWK8N>")$4LHKL+[`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`:^OX`TI2%2/>76_6`647B,.PC^BG"`AA#U-%E MF**GP]W8JTB3T'=,Q9@S6*F8&,H,4B]X2#Z$#"QMA-%$Q5V:M&E&5I^RH'^@ MQ<#)+[\..D=\"!F(VP@C#I(V\?.Z4K#DU^==*21!12S&;K&'H'Z:L!%&9SF& M#@5S.AK)I,/9C8X=]?YE4C#/JQ&95^ZH7"-8B+7PE#>0"`9E0Q!;.=T_+?\X M7P@*Y@P5DB@;I3V?>XBP$7;M&WYMZ5WQU=18[;O]BS)Q8@I)>$^[.VT(&CK$ M1AC7&+WV?J%D-">D(5LJ'Q(,X@3(3*U*2;4R>3<:D(-9B'B1B&^($R!\M`B18$B\O4DQ9 M+8K3UVY%-R94V%'LVE5LB.HG"C,1$"<\RK=CW[@U9-4G]R'!($Z`K/8'*:9= MVU9,08YB-ZYB0Y11S(8X83)CB_`;/::LFU71=G/M"AXD8AOB!,AA+0*RQQ93 M5'WDH2565LVX#>YMW1TSYQR;ZXE6S06#&%TZ8MATS^LEH[GM:\C>DSXD&,0) MA&P_SB[9D^#@6JR&>(=ESIDU-U%#AS&($QYE^W1EQ_8UA"OT5\M]2#"($_AA MMI_XMJ\ANKHY@&7NR=-$]4L0#.)\R8^M'?%&BRGWMML^L0U=;4D?$@SB!,AR M+0*T):_PY7GTEJ1OVFXQ%>3HY1Q84Z2>^Z6N(-9B*LB#! MHC@!-!E/6S3C9;JX) M>)!(;(@3"'A^/,<6&FGYB6_Y&G+ZRSWGFR@CUW"O_7RX9S2U?0U8S MY3XD&,3D2@.6GUQRBY2)'&[J'N#HY9[S]41[/S*(TQUE^*EO^!JRKI;[D&`0 M)Q`P_/BR6V3J.[Z&',7<@[Z)&CJ,09SP*,=/?>I!@$"<0LOD+]Z'O].E@V)9B"_>H:J),88>)@!CA;)33RVC>61JRGD:J(&O1C$Z8YR^LQW>@U9VR[W(<$@3L!Q M^O,[,?/-O(>LG=A#Z!*S$Q?."56$H\RQC-,^9[^\:8GVE_=UL3L&B.(&` MOZ?7].)LK,5GOL5KR&DL]\AEHDQC?=?BLU$6+Z.=C:C-VZB3ZRA+0\$@+IAC M\1=_!0HY=[Y#)11B^52ZV`TQUE]7AMZWXMTQ#;B-KJK5LBBU($U/M; M]0;R4#;/95[N]^UD7;_0NUD(_'`WP.K%\2I+\.98%L8;R3`B7VYX(PN,R->\ MWL@2(TNZ;7LC5QB1;P.]D6N,R"WOCJ2X#@XC@6PIKH-30F@$V7`3#(W<8.0F M-)+-P4"^`'<99/1>73[J<$<29,,7E]!UD`U?'T(CR(:3>F@$5<`1.C228D16 MW660HCXX1`;F))BCFL>=DV`.'C6$YD!K.%!H!%KCZW9H!#7%E^30"*J`;YR! MD1ASXN"<&'/P9#(T!UKC(6!@)('6>#H7&H'6Z@3N:0"MU:YU1V+,P1N30+88 M<]3MVYL#K?&V(30'6N-I?F@$6N.Q>6@$6N-YMC^"'W@\!ON#*`?B5[3($$[M M%,`?L]O'\"8D%PA,6&$-P26@BL$BHH;!$L8H(=ZK8&PO=V]R:W-H965T3:)`:M)'-FFM'^_,W9(DV!*>`$RC,^9,^,9AOG=:YYY+TPJ M+HJ%3P:A[[$B$2DOM@O_S^_'FUO?4YH6*U8TQ[ M@%"HA;_3NIP%@4IV+*=J($I6P#<;(7.JX5%N`U5*1E-S*,^"*`PG04YYX5N$ MF>R#(38;GK`'D>QS5F@+(EE&-<2O=KQ41[0\Z0.74_F\+V\2D9<`L>89UV\& MU/?R9/:T+82DZPQTOY(138[8YN$$/N>)%$IL]`#@`AOHJ>9I,`T`:3E/.2C` MM'N2;1;^BLSN(^('R[E)T%_.#JKQV5,[?J=%PRR#77""JR%>$;7IQ1- M<#@X.?UH*O!3>BG;T'VF?XG#-\:W.PWE'H,B%#9+WQZ82B"C`#.(QHB4B`P" M@%*IW"W\X'L0DG`YC0%DSI1\Y0OI>LE=:Y/^LDU%4@T05 M"+P?02:#<1P."7!>``EL0$;?`]5T.9?BX,&E`4I54KR"9`;`;D&@!'U7Z+SP M8]^#6!54X65)XG`>O$#FDLKGWOK`Z[M/[1$`:L!MZPIP70<&0\@M(_O*)YK4U@+ M4#13.W37#`=V[W9`YS:5M3C43-NXJ":.<59<4(/GVA36TE$S M;;+*Y!!$L,\;F>JMR!SLL-B9T=%TIJNP19K$']\&X]UALZ/#I0E;NZ-I3`8X MHB^PV)D`9'4+$6OJ:)J69<1;W1UFC/==&J";#41!BQ!NF M.%"/)TL>R49IN:_!]C,:4 MO7!WBPMZ*9A61A4V`#KB$[WT/"=S`DS+12[`@2L[TKS(\"I*'Z:8+!==?7X+ M?C"#W\A4ZO!9B_RK:#@4&X[)':/Z^Y85!0H`GBQ#$Q54,"\$12N,Z`@M!C]SZ(W%89CN?! M+$G&D]D4:+;(3"[Q/+*-)D$S#402B_R$A/J/. MX)I:NEQH=4#0-"!I6NI:,$J!^+HCL.*P*P?.\!0CR-7`*>R7T2Q9D#V4CITP M#QX#SQZ33'H(`=5>&N1NEW9@)^V*ZW)Y\(&A3GQ=9O0>&0?.,#S[[*/9:_I> MV6/&`\QK#1VFU^L[ M>8^4`Y]+^4@\[@9PV![09D,+;N9&X21P`_/O+G4;SS5\!#2&M9V]L>.GWP^' MY+KDGWA=&\34SDUV#.W>1_M+9Q6[M-_&Q^FJ:U32?X#+H*4E_T9U*1J#:EX` M9=AYT?XZ\0NK6L@*&4?5F`,.G_1Y9_`0``__\# M`%!+`P04``8`"````"$`'1W_9HL"``")!@``&0```'AL+W=O&;!GT_)5,N#MS]XHA> M26&TU:6+D(Z%1(\]7[$KADRK92'1@2\[,5#F=)UD-W/*5LN^/K\E[.SH-[&U MWGTVLO@J6\!B8YM\`S9:/WCH?>%#N)D=[;[K&_#=D`)*OFW<#[W[`K*J'79[ MAH:\KZQXO@4KL*!($Z4SSR1T@PG@DRCI)P,+PI_Z]TX6KL[I)([F27PUF2/+ M!JR[DYZ2$K&U3JL_`93LJ0))NB?!]X'D,IK-XTF"FO\A82&AWM\M=WRU-'I' M<&90TG;<3V"2(?%I0^C$8]<>G-,Y)9BKQ28\KI)%LF2/6#FQQ]P$##Y?,`." MH>B@C&KG*WNP5_:E]:G8V6EEA)QO MT(.Q!VCKI6Y'M0V@,Z1Q'LZ7]N!>>BCN/O*Z#I/3+B_?(^7!KZ5"))WVQV\\ M'CAE8PO]B4MF$:;V[QGU^UY+A`A*C$L[?>,F'/UP-!28"CY!TU@B]-8?ZQ2' M?8@.-\XZ]5F_C4^S=3^G;/B`-T''*_C&325;2QHHD1+//WHQX2X)"Z<[S!R/ MLG9X!_0_:[SR`><]]L9+K=UA@<)L^!-9_04``/__`P!02P,$%``&``@````A M`-#[;"9(!@``$!D``!@```!X;"]W;W)KM:_?*TOQI>R[:KFNC'MR=0TRFO1'*KK:6/^^3GZM#2-KL^O MA_S27,N-^:WLS%^V/_^T?FO:E^Y39I;>84[ MQZ:M\QY^MB>KN[5E?J!.]<5RIM.Y5>?5U601_/8],9KCL2K*H"E>Z_+:LR!M M>BOJGSKI/\;W;EYB]OJ\&MU+4%MF"NE_Z-Y2\KJ=.YANF>0$4G,/WP+RJX`12',Q)F12$5S@0'`OT9=D=(` M1?*O]/I6'?KSQG2?,%DL;[(WGLNNCBL0TC>*UZYOZ;V9E\U@LBL.CP%5$ MF3]T<+D#7+F#/9<>^^!1'O>$*_><36:+J4N'^\`/DJ&)PI7[+2<+>[IR%T`> M^$$>U&\Q^+UWI+#$J"=#ZX=&:D/QL+DD5<2GZ;&J%JL&6EQ!WN?; M==N\&;!B8;J[6T[6O^V3N**LF%!#H?U;G4&!D2A/),S&!.F@@CI8'%^V]FRQ MMKY`01?<9G?'1K78"PM2O21LH(-0!Y$.8ATD.DAUD$G``ED&;:#(?X0V)`S1 M1F2U$V`4R]&$$!;")=!!J(-(![$.$AVD.L@DH`@!B_='"$'";$SX5RJ2I9KY MCMG8,"6#T4PUV0\F@SJ(A(A$B,2()(BDB&0R442"?>I'B$3"P&*$J1@$P$N) M&SU2:3`95$(D1"1")$8D021%)).)HA+LP8I*]U]?8ELAUE0,D<2.$0=V*DF> ME58A@Y%P"Q`)$8D0B1%)$$D1R62BY`YOF`_D3JS5W!GQW&$GV2,2(!(B$B$2 M(Y(@DB*2R41)%-X#'TB46*N),@*)2I,\GVJ3/!@-DXQ(B$B$2(Q(@DB*2"83 M)7?2;\LOU,<%3JS5W!F1)QF1`)$0D0B1&)$$D1213"9*HM"U?"!18JTFR@CO M5T]G`Y&(G0F!U+D M(,V3H@?KI":DZ^S/5?&R:V#'@AW[3D&XT#'Q/HI$476B@:%;9TT]%8HC6U** M(\^FS9J#NG`9'7N M%`L4PE`MK& D&,X(ZUURU'JO4#BN6(^_ M]#2#B!NX]&.6UG0L$/N2)`6 MU<[7V]_0Y6HEQQW%QAMS*]9AJKE9OD;@_NL0B\'R8V@1;I0*Q MP"NDCSP4M=!(@R87VO,V%W(K=TYEFZ$V M.!(&HT\LD%QL*'(JK'CDF:/-2"8,[E06:>_^OW*L280"'EW+D MH^]IW!%:$JE2M849C?2_`F(D4E-9T!1B%&$48Q1@E&*4;D\'0< M!).!'8:R\ZJZ;$_EOKQ<.J-H7LE!)SALUP-FI[`[>R&.8?4[G@]?I;#:=#[S MX8OM#I_[$%SA\,#Z+:EQUGZT"O?L;F`?VU`^A ML$W$KA#VC!\!QH>N$,W0VV\<%[]1'_(.?:=2#O'A_,A_(2=Z\.9".9/ MGO\$,P0WK.$)CY$G]N>CB(IJO] M#']Y**%UF$Y@`SHV32]^D`<,?\O8_@,``/__`P!02P,$%``&``@````A`!76 MAN,R`0``0`(``!$`"`%D;V-0(9QMQ$()H-W^O:SKZHQ>>4G>EX?G'.KY3K?))SBO.M.@/",H M`2,ZJ6%(SII:A;V-,XVZYVPICN'4WGDU%?N^ MS_IRT(C^.7Y9WC\.HZ;*''8E`+'#?EKNPS*N_1H]TI>2YO[U8+Q`J25RF9I>1Z51!:5;2L7FM\:HWWV034H\"_ MB2<`&[Q__CG[`@``__\#`%!+`P04``8`"````"$`G\8ARU("``!K!@``$``( M`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````"<55%/VS`0?I^T_Q#E'=("F@9R@T(:(%I)N]KI'B.37%J+ MU(YL4\%^_2Z-"BF$2NO;^>Z[SY_O[#.Y?EE7S@:T$4J.W.'IP'5`YJH07($X64<*F\SBBO92W03S/%L$DC;*'**#I'&N9L%XH M9=/P5\;F04*#D,78MWY8>D.CWRFR9%&S]Q>H@T?I;TWG+!GCCWAC^P4:XM0JGBO(5(G7>(/CJ7>;_LIE8[!<5%\H^U3!P_"/E>Q#[[WJ#^]X(N23 M26NFQMS";E#M.PE=<0T%/N%=_-U![G%&Z:HA"5=<+J'883X'FK&Z:/\.?WAQ M.C@?X,3L^(CW_DOX_P```/__`P!02P$"+0`4``8`"````"$`8Y(2U*&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`%A8TUP#`P``?`@``!D`````````````````Y0\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+_P4A<0`P``DPD` M`!D`````````````````WQ@``'AL+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0`,%':^#PL``*-= M```-`````````````````.LB``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@` M```A``+L(```&UL4$L!`BT`%``&``@````A`*0K9Q5T!0``Z10``!@````````` M`````````T\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`"!;-O^\!0``'!T``!D`````````````````RET``'AL+W=O M&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``'VK]2D!0``9Q<``!@````````````` M````/W<``'AL+W=O&UL4$L!`BT`%``&``@````A`&.<6[+8!P``NR0``!@````` M````````````WX(``'AL+W=O&UL4$L!`BT`%``&``@````A`")=3B^3`@``C`8` M`!D`````````````````EHX``'AL+W=O&PO=V]R:W-H965T XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

INVENTORIES
6 Months Ended

Jun. 30, 2014

INVENTORIES [Abstract]

INVENTORIES

NOTE 2 - INVENTORIES

Inventory at June 30, 2014 and December 31, 2013 consisted of the following:

June 30, December 31,

2014 2013

(U.S. dollars in thousands)

Raw materials $ 1,845 $ 2,342

Work in progress 133 92

Finished goods 5,157 5,523

Total inventory $ 7,135 $ 7,957

During the six months ended June 30, 2014, the Company recorded approximately $1.6 million for write-down of inventory under cost of revenues.

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V8C5B.69D,5\W8CDS7S0V,S5?869F,%\R83`U M.3=C83)D9#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-43T-+7U1204Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-50E-%455%3E1?159%3E13/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DE.5D5.5$]224537U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-) M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-50E-%455%3E1?159%3E137T1E=&%I;',\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V8C5B.69D,5\W8CDS7S0V,S5?869F,%\R M83`U.3=C83)D9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F(U M8CEF9#%?-V(Y,U\T-C,U7V%F9C!?,F$P-3DW8V$R9&0Y+U=O'0O:'1M;#L@8VAA2!);F9O'0^)SQS<&%N/CPO'0^)S$P+5$\'0^ M)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(P,30\'0^)U!,6#QS<&%N M/CPO2!296=I"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)RTM,3(M,S$\ M2!#;VUM;VX@ M4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS M<&%N/CPO2!F;W(@96UP;&]Y964@'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\V8C5B.69D,5\W8CDS7S0V,S5?869F,%\R83`U.3=C83)D9#D-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F(U8CEF9#%?-V(Y,U\T-C,U M7V%F9C!?,F$P-3DW8V$R9&0Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8C5B.69D,5\W8CDS M7S0V,S5?869F,%\R83`U.3=C83)D9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-F(U8CEF9#%?-V(Y,U\T-C,U7V%F9C!?,F$P-3DW8V$R9&0Y M+U=O'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA&-E<'0@4VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&5R8VES92!O9B!O<'1I M;VYS(&=R86YT960@=&\@96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO65E'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO&5D(&%S2!F;W(@96UP;&]Y964@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(')I9VAT'0^)SQS M<&%N/CPO2!F:6YA;F-I;F<@ M86-T:79I=&EE2!A M;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-S`\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V8C5B.69D,5\W8CDS7S0V,S5?869F,%\R83`U.3=C83)D9#D-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F(U8CEF9#%?-V(Y,U\T-C,U7V%F M9C!?,F$P-3DW8V$R9&0Y+U=O'0O:'1M;#L@8VAA6QE/3-$)R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX-"CQT9#XF(S$V,#L\+W1D/@T*/"]T6QE/3-$)R`[(&UA6QE/3-$)R!V97)T:6-A;"UA;&EG;CH@=&]P M.R!F;VYT+7-I>F4Z(#$P<'0[)SX-"CQT9"!S='EL93TS1"<@=VED=&@Z(#`N M,VEN.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B M;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!W:61T:#H@ M,"XR-6EN.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE M.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\2UO=VYE9"!S=6)S:61I87)Y M+"!0"!,=&0N+"!A2=S('!R;W!R:65T87)Y(%!R;T-E;&Q%>#QS M=7`^)B,Q-S0[/"]S=7`^('!R;W1E:6X@97AP7-T96T@*"8C M,30W.U!R;T-E;&Q%>"8C,30X.RDN($EN(%-E<'1E;6)E"!,=&0N(&9O2UO=VYE9"!S=6)S:61I M87)Y('5N9&5R('1H92!L87=S(&]F('1H92!.971H97)L86YD2=S(#QF M;VYT/G1W;SPO9F]N=#X@2`H15)4*2!F;W(@=&AE(&QO;F2!T:&4@27-R865L M:2!-:6YI2!O9B!(96%L=&@@*'1H92`F(S$T-SM)FEL:6%N($U/2"8C,30X M.RD@:6X@2G5N92`R,#$S(&%N9"!B>2!T:&4@87!P;&EC86)L92!R96=U;&%T M;W)Y(&%U=&AO2!T:&4@ M1D1!(&]R(&%N>2!O=&AE2X\ M+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!09FEZ97(@26YC+B`H)B,Q-#<[4&9I>F5R)B,Q-#@[*2P@ M=&AE($-O;7!A;GDG2!A M9W)E96UE;G0@8GD@86YD(&)E='=E96X@4')O=&%L:7@@3'1D+B!A;F0@4&9I M>F5R("AT:&4@)B,Q-#<[4&9I>F5R($%GF5R($%GFEL("AS964@8F5L;W2!H87,@86=R965D('1O M(&$@2!H87,@6UE;G0N(%1H92!# M;VUP86YY(')E8V5I=F5D(&1UF%T:6]N(&]F M('1A;&EG;'5C97)A2P@97AC97!T M('=I=&@@FEL+"!W:&5R92!T:&4@0V]M<&%N>2!R971A:6YE9"!E>&-L=7-I=F4@ M;6%R:V5T:6YG(')I9VATFEL($%G65A2!T2`D/&9O;G0^-#`\+V9O;G0^(&UI;&QI;VX@=V]R=&@@;V8@ M=&%L:6=L=6-E&EM871E;'D@)#QF;VYT/C0P/"]F;VYT/B!M:6QL:6]N('=O M65A"!,=&0N(&ES(&YO="!R97%U:7)E9"!T;R!C;VUP;&5T M92!T:&4@9FEN86P@B!P=7)C:&%S97,@870@;&5A2`D/&9O;G0^,C@P/"]F;VYT/B!M:6QL:6]N('=O&EM871E;'D@)#QF;VYT/C,N-3PO9F]N=#X@;6EL;&EO;B!F2!A9W)E96UE;G0@=VET M:"!0"!,=&0N(%1H92!A;65N9&UE;G0@<')O=FED97,@9F]R('1H M92!TFEL(&)A8VL@ M=&\@4')O=&%L:7@@3'1D+B!!F%T:6]N(&%N9"!S=7!P;'D@"!,=&0N(&%GF5R(&$@;6%X M:6UU;2!A;6]U;G0@;V8@87!P2`D/&9O;G0^,3(N-3PO9F]N M=#X@;6EL;&EO;B!F2!O9B!T M86QI9VQU8V5R87-E(&%L9F$@=&\@1FEO8W)U>BX\+W`^#0H-"CQP('-T>6QE M/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M"!,=&0N M(&ES(')E<75I2!A(&9E92!E<75A;"!T;R`\9F]N=#XU/"]F M;VYT/B4@;V8@=&AE(&YE="!PFEL M('1O(&ETFEL($%G6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EFEL:6%N($U/2"P@;6%R M:V5T:6YG(&%P<')O=F%L(&AAF%T:6]N(&%P<&QI8V%T:6]N2P@<&%T:65N=',@87)E(&)E:6YG('1R96%T960@=VET:"!T86QI9VQU M8V5R87-E(&%L9F$@;VX@82!C;VUM97)C:6%L(&)A2!A=71H;W)I='D@:&%D(&=R86YT960@86X@075T;W)I M6UE;G0@9F]R('1A;&EG;'5C97)A'!E;F1I M='5R97,@:6X@8V]N;F5C=&EO;B!W:71H('1H92!R96=U;&%T;W)Y(&%P<')O M=F%L('!R;V-E2!C;W5N=')Y(&ES M(&1I2=S(&%B:6QI='D@ M=&\@:6UP;&5M96YT('1H92!N96-E2!S=&5P2!S='EL M93TS1"<@;6%R9VEN.B`P<'@[(&-L96%R.B!L969T.R!F;VYT+69A;6EL>2`Z M(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]P M/@T*#0H\+V1I=CX-"@T*/&1I=CX-"@T*/&1I=B!C;&%S6QE M/3-$)R!W:61T:#H@,"XS:6X[(&)O6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T M=&]M.B!N;VYE.R!F;VYT+7-I>F4Z(#$P<'0[)SX\2!F;W(@82!F86ER('-T871E;65N="!O M9B!T:&4@2!B92!E>'!E8W1E9"!F;W(@ M=&AE(&9U;&P@>65A6QE/3-$)R!F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T:&4@0V]M<&%N>2!W:71H('1H92!396-U&-H86YG92!#;VUM:7-S:6]N+B!4:&4@8V]M<&%R871I=F4@ M8F%L86YC92!S:&5E="!A="!$96-E;6)E6QE M/3-$)R!M87)G:6XZ(#!P>#L@8VQE87(Z(&QE9G0[(&9O;G0M9F%M:6QY(#H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W`^ M#0H-"CPO9&EV/@T*#0H\9&EV/@T*#0H\9&EV(&-L87-S/3-$0W5R2P@8F5C875S92!T M:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N/"]P/@T*#0H\<"!A M;&EG;CTS1&IU'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQD:78@:60],T1%9&=A2`Z("=4:6UE6QE/3-$)R!F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A="!*=6YE(#,P+"`R M,#$T(&%N9"!$96-E;6)E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!T97AT+6%L:6=N.B!C96YT M97([(&)OF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D M97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I M;F#L@9F]N="US:7IE.B`Q,'!T.R<^/'-TF4Z(#$P<'0[)SX\6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS M1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)OF4Z(#$P<'0[)SXF(S$V M,#L\+W1D/@T*/"]T6QE/3-$)R!V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[)SX-"CQT9"!S='EL93TS1"<@ M8F]R9&5R+6QE9G0Z(&YO;F4[(&)O'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[ M)SX\6QE/3-$)R!B M;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z M(",P,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^/'-T M'0M86QI9VXZ(&-E;G1E MF4Z(#$P<'0[)SX\6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQTF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D(&-O;'-P86X],T0V('-T>6QE M/3-$)R!T97AT+6%L:6=N.B!C96YT97([(&)O#L@9F]N="US:7IE.B`Q,'!T.R<^*%4N4RX@9&]L M;&%R6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D M97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P M.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P M,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^4F%W(&UA M=&5R:6%LF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@ M8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@ M,3!P>#L@=VAI=&4M'0M86QI9VXZ(')I9VAT.R!B;W)D M97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P M.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P M,#`P,#`[('!A9&1I;F#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@ M=VAI=&4M#L@<&%D9&EN9RUL969T.B`U<'@[ M(&9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!T97AT M+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE M.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@,3!P>#L@=VAI=&4M M'0M86QI9VXZ(')I9VAT.R!B;W)D97(M;&5F=#H@;F]N M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D M97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I M;F#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D M97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I M;F#L@9F]N="US:7IE.B`Q,'!T.R<^5V]R:R!I;B!P'0M86QI9VXZ(&QE9G0[(&)OF4Z(#$P M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!T97AT+6%L:6=N.B!R M:6=H=#L@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O6QE/3-$)R!T97AT M+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE M.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=VAI=&4M M#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"<@=VAI=&4M#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@=&5X="UA;&EG;CH@;&5F=#L@8F]R M9&5R+6QE9G0Z(&YO;F4[(&)O#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M'0M86QI M9VXZ(')I9VAT.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3L@=VAI=&4M#L@<&%D9&EN M9RUL969T.B`U<'@[(&9O;G0M6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F M=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE M.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[ M('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^1FEN:7-H960@9V]O M9',\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T M=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"<@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@'0M86QI M9VXZ(&QE9G0[(&)OF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T=&]M.B`C M,#`P,#`P(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@F4Z(#$P<'0[)SX\9F]N=#XU+#$U-SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@ M8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9#L@8F]R9&5R+6-O;&]R.B`C,#`P M,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I M;F#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0MF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T=&]M.B`C M,#`P,#`P(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6QE M9G0Z(&YO;F4[(&)O#L@<&%D9&EN9RUL M969T.B`U<'@[(&9O;G0M'0M86QI9VXZ M(&QE9G0[(&)OF4Z(#$P<'0[)SXF M(S$V,#L\+W1D/@T*/"]T6QE/3-$)R!V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[)SX-"CQT9"!S='EL93TS M1"<@=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O3PO=&0^#0H\=&0@ MF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T M=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[ M(&)OF4Z(#$P<'0[)SXD M/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R M+C@P<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6QE9G0Z M(&YO;F4[(&)O'0M86QI9VXZ(&QE9G0[(&)O#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0MF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T=&]M.B`C M,#`P,#`P(#(N.#!P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)OF4Z(#$P<'0[)SXD/"]T9#X- M"CQT9"!S='EL93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@ M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6QE9G0Z(&YO;F4[ M(&)O'0M86QI9VXZ(&QE9G0[(&)OF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)R!M87)G:6XZ(#!P>#L@ M8VQE87(Z(&QE9G0[(&9O;G0M9F%M:6QY(#H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W`^#0H\+V1I=CX-"@T*/'`@&EM871E;'D@)#QF;VYT/C$N-CPO9F]N=#X@;6EL;&EO;B!F M;W(@=W)I=&4M9&]W;B!O9B!I;G9E;G1O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@:60],T1%9&=A2!M96%S=7)E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E2!T:&%T('!R:6]R:71I>F5S(&]B6QE/3-$ M)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!M87)K970@9&%T82X\+W`^#0H-"CQP('-T>6QE/3-$)R!F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!G:79E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF5S('9A;'5A=&EO;B!T96-H;FEQ=65S('1H870@;6%X:6UI>F4@=&AE M('5S92!O9B!O8G-EF4@=&AE('5S M92!O9B!U;F]B'1E;G0@<&]S6QE M/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!I6EN9R!V86QU M92X\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)R!C;VQO2`Z(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9&ES<&QA>3H@:6YL:6YE("%I;7!O2`D/&9O;G0^-S`N,CPO M9F]N=#X@;6EL;&EO;B!B87-E9"!O;B!A(&QE=F5L(#(@;65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^ M)SQS<&%N/CPO6QE M/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-"CQP('-T M>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M:6YD96YT.B`P:6X[)SY$=7)I;F<@=&AE('-I>"!M;VYT:',@96YD M960@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@:7-S=65D(&$@=&]T86P@ M;V8@/&9O;G0^-34L,S8R/"]F;VYT/B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE2`D/&9O;G0^-#,L,#`P/"]F;VYT/BX\+W`^#0H\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@:60],T1%9&=A M2`Z("=4:6UE M6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E2`R-"P@ M,C`Q-"P@=&AE($-O;7!A;GDG65A2=S(#QF M;VYT/C(P,#8\+V9O;G0^(%-T;V-K($EN8V5N=&EV92!0;&%N+B!4:&4@0V]M M<&%N>2!E7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA6QE/3-$)V9O;G0M9F%M M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-"CQD:78@8VQA6QE/3-$)R`[(&UA6QE/3-$)R!V97)T:6-A;"UA;&EG M;CH@=&]P.R!F;VYT+7-I>F4Z(#$P<'0[)SX-"CQT9"!S='EL93TS1"<@=VED M=&@Z(#`N,VEN.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!W M:61T:#H@,"XR-6EN.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\2UO=VYE9"!S=6)S M:61I87)Y+"!0"!,=&0N+"!A2=S('!R;W!R:65T87)Y(%!R;T-E M;&Q%>#QS=7`^)B,Q-S0[/"]S=7`^('!R;W1E:6X@97AP7-T M96T@*"8C,30W.U!R;T-E;&Q%>"8C,30X.RDN($EN(%-E<'1E;6)E"!,=&0N(&9O2UO=VYE9"!S M=6)S:61I87)Y('5N9&5R('1H92!L87=S(&]F('1H92!.971H97)L86YD2=S(#QF;VYT/G1W;SPO9F]N=#X@2`H15)4*2!F;W(@=&AE(&QO;F2!T:&4@ M27-R865L:2!-:6YI2!O9B!(96%L=&@@*'1H92`F(S$T-SM)FEL:6%N($U/ M2"8C,30X.RD@:6X@2G5N92`R,#$S(&%N9"!B>2!T:&4@87!P;&EC86)L92!R M96=U;&%T;W)Y(&%U=&AO2!T:&4@1D1!(&]R(&%N>2!O=&AE2X\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!09FEZ97(@26YC+B`H)B,Q-#<[4&9I>F5R)B,Q M-#@[*2P@=&AE($-O;7!A;GDG2!A9W)E96UE;G0@8GD@86YD(&)E='=E96X@4')O=&%L:7@@3'1D+B!A M;F0@4&9I>F5R("AT:&4@)B,Q-#<[4&9I>F5R($%GF5R($%GFEL("AS964@8F5L;W2!H87,@86=R M965D('1O(&$@2!H87,@ M6UE;G0N M(%1H92!#;VUP86YY(')E8V5I=F5D(&1UF%T M:6]N(&]F('1A;&EG;'5C97)A2P@ M97AC97!T('=I=&@@FEL+"!W:&5R92!T:&4@0V]M<&%N>2!R971A:6YE9"!E>&-L M=7-I=F4@;6%R:V5T:6YG(')I9VATFEL($%G65A2!T2`D/&9O;G0^-#`\+V9O;G0^(&UI;&QI;VX@=V]R M=&@@;V8@=&%L:6=L=6-E&EM871E;'D@)#QF;VYT/C0P/"]F;VYT/B!M:6QL M:6]N('=O65A"!,=&0N(&ES(&YO="!R97%U:7)E9"!T;R!C M;VUP;&5T92!T:&4@9FEN86P@B!P=7)C:&%S97,@870@;&5A2`D/&9O;G0^,C@P/"]F;VYT/B!M:6QL:6]N('=O&EM871E;'D@)#QF;VYT/C,N-3PO9F]N=#X@;6EL;&EO;B!F2!A9W)E96UE M;G0@=VET:"!0"!,=&0N(%1H92!A;65N9&UE;G0@<')O=FED97,@ M9F]R('1H92!TFEL M(&)A8VL@=&\@4')O=&%L:7@@3'1D+B!!"!,=&0N(&%GF5R M(&$@;6%X:6UU;2!A;6]U;G0@;V8@87!P2`D/&9O;G0^,3(N M-3PO9F]N=#X@;6EL;&EO;B!F2!O9B!T86QI9VQU8V5R87-E(&%L9F$@=&\@1FEO8W)U>BX\+W`^#0H-"CQP M('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E"!,=&0N(&ES(')E<75I2!A(&9E92!E<75A;"!T;R`\9F]N M=#XU/"]F;VYT/B4@;V8@=&AE(&YE="!PFEL('1O(&ETFEL($%G6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EFEL:6%N($U/ M2"P@;6%R:V5T:6YG(&%P<')O=F%L(&AAF%T:6]N(&%P<&QI8V%T:6]N M2P@<&%T:65N=',@87)E(&)E:6YG('1R96%T960@=VET:"!T M86QI9VQU8V5R87-E(&%L9F$@;VX@82!C;VUM97)C:6%L(&)A2!A=71H;W)I='D@:&%D(&=R86YT960@86X@ M075T;W)I6UE;G0@9F]R('1A;&EG;'5C97)A'!E;F1I='5R97,@:6X@8V]N;F5C=&EO;B!W:71H('1H92!R96=U;&%T;W)Y M(&%P<')O=F%L('!R;V-E2!C;W5N M=')Y(&ES(&1I2=S(&%B M:6QI='D@=&\@:6UP;&5M96YT('1H92!N96-E2!S M=&5P2!S='EL93TS1"<@;6%R9VEN.B`P<'@[(&-L96%R.B!L969T.R!F;VYT+69A M;6EL>2`Z(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)R!W:61T:#H@ M,"XS:6X[(&)O6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\2!F;W(@82!F86ER('-T871E;65N="!O9B!T:&4@2!B92!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A M6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!T:&4@0V]M<&%N>2!W:71H('1H92!396-U&-H M86YG92!#;VUM:7-S:6]N+B!4:&4@8V]M<&%R871I=F4@8F%L86YC92!S:&5E M="!A="!$96-E;6)E6QE/3-$)R!M87)G:6XZ M(#!P>#L@8VQE87(Z(&QE9G0[(&9O;G0M9F%M:6QY(#H@5&EM97,@3F5W(%)O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W`^#0H\+V1I=CX\'0^)SQD:78@:60],T1%9&=A2`Z("=4:6UE2P@8F5C875S92!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N M/"]P/@T*#0H\<"!A;&EG;CTS1&IU7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQD:78@:60],T1%9&=A6QE/3-$)R!B;W)D97(M M8V]L;&%P6QE/3-$)R!V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[)SX-"CQT9"!S='EL93TS1"<@ M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R M+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@ M8F]R9&5R+6QE9G0Z(&YO;F4[(&)OF4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)R!B;W)D97(M;&5F M=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE M.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[ M('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^/'-TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE M.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SX\6QE/3-$)R!T97AT+6%L:6=N.B!C M96YT97([(&)O#L@ M9F]N="US:7IE.B`Q,'!T.R<^/'-TF4Z(#$P M<'0[)SXF(S$V,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)R!T M97AT+6%L:6=N.B!C96YT97([(&)O#L@9F]N="US:7IE.B`Q,'!T.R<^/'-T6QE/3-$)R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D M97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I M;F#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!C M;VQS<&%N/3-$-B!S='EL93TS1"<@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D M97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z(&YO M;F4[(&)OF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[(&)A8VMG M6QE/3-$)R!B M;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z M(",P,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@=&5X="UA;&EG;CH@;&5F=#L@8F]R M9&5R+6QE9G0Z(&YO;F4[(&)O6QE/3-$)R!T97AT+6%L M:6=N.B!R:6=H=#L@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O'0M86QI9VXZ(&QE9G0[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I M9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N M;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=VAI M=&4M#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`P,#`[('!A9&1I;F#L@=VAI=&4M#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"<@=&5X="UA;&EG;CH@F4Z(#$P<'0[)SX\9F]N=#XQ,S,\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"<@=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6QE9G0Z(&YO M;F4[(&)O#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M M'0M M86QI9VXZ(&QE9G0[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)R!T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6QE9G0Z(&YO;F4[ M(&)O'0M86QI9VXZ(&QE9G0[(&)OF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)R!V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[(&)A8VMG#L@=VAI=&4M#L@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@ M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@'0M86QI9VXZ M(')I9VAT.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE M.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A M9&1I;F#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B M;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=VAI=&4M#L@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@ M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@'0M86QI9VXZ M(&QE9G0[(&)OF4Z(#$P<'0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T=&]M.B`C,#`P M,#`P(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@F4Z(#$P<'0[)SX\9F]N=#XU+#4R,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L M;W(Z(",P,#`P,#`[('!A9&1I;F#L@=VAI=&4M#L@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT'0M86QI9VXZ(&QE9G0[(&)OF4Z(#$P<'0[)SY4;W1A;"!I;G9E M;G1O6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@ M8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE.R!T M97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I M9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P M,#`P,#`[('!A9&1I;F#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@ M<&%D9&EN9RUR:6=H=#H@,3!P>#L@=VAI=&4MF4Z(#$P<'0[)SX\9F]N=#XW+#$S-3PO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N M;VYE.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4[(&)O MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B M;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=VAI=&4M#L@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@ M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE.R!T97AT+6%L M:6=N.B!L969T.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[ M('!A9&1I;F#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN M9RUR:6=H=#H@,3!P>#L@=VAI=&4MF4Z(#$P<'0[)SX\9F]N=#XW+#DU-SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M;&5F=#H@ M;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F#L@=VAI=&4M#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\ M+W1A8FQE/@T*/"]D:78^#0H-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS M1"<@;6%R9VEN.B`P<'@[(&-L96%R.B!L969T.R!F;VYT+69A;6EL>2`Z(%1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]P/@T* M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V8C5B.69D,5\W8CDS7S0V,S5?869F,%\R83`U.3=C83)D9#D-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F(U8CEF9#%?-V(Y,U\T-C,U7V%F M9C!?,F$P-3DW8V$R9&0Y+U=O'0O:'1M;#L@8VAA"!":6\@5&AE'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE M;G0@=')I9V=E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5R($%G'!E;G-E('-H87)I;F<@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!C;VUM:71M96YT(&9O'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A9W)E96UE;G0@;6%X:6UU;2!C;VYS:61E M6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Q+#`P,#QS<&%N/CPO65E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S("AI M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-2PS M-C(\&5R8VES92!O M9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-BPQ M,C(\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V M8C5B.69D,5\W8CDS7S0V,S5?869F,%\R83`U.3=C83)D9#D-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F(U8CEF9#%?-V(Y,U\T-C,U7V%F9C!? M,F$P-3DW8V$R9&0Y+U=O'0O:'1M;#L@8VAA'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)S,@>65A'1087)T7S9B-6(Y9F0Q7S=B.3-?-#8S 7-5]A9F8P7S)A,#4Y-V-A,F1D.2TM#0H` ` end XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2014

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

a. General

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx^® protein expression system (“ProCellEx”). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (“EMA”) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the “Subsidiaries.”

On May 1, 2012, the U.S. Food and Drug Administration (“FDA”) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the “Israeli MOH”) in September 2012, by the Brazilian Ministry of Health (the “Brazilian MOH”) in June 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.

Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO™ by Pfizer Inc. (“Pfizer”), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the “Pfizer Agreement”). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO™.

Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.

On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the “Brazil Agreement”) with Fundação Oswaldo Cruz (“Fiocruz”), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of 2014.

During the six months ended June 30, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.

To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.

Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.

In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.

An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.

In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.

In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.

Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.

b. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.

c. Net loss per share

Basic and diluted loss per share (“LPS”) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $0.001 per share (the “Common Stock”) outstanding for each period.

Diluted LPS does not include 7,413,383 and 18,844,777 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the six months ended June 30, 2013 and 2014, respectively, and 7,356,464 and 18,778,154 shares of Common Stock for the three months ended June 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 17 0001144204-14-047741-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-047741-xbrl.zip M4$L#!!0````(`-:#!T5)-!;0F$````<0`@`0`!P`<&QX+3(P,30P-C,P+GAM M;%54"0`#\^'C4_/AXU-U>`L``00E#@``!#D!``#L75ESVT:V?I^J^0\]O'<2 MITJD"("K9'M*EF2/[MB2(LFIR5.J"33)CD$`Z08DT;_^GM-8"(`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`OHQ6['U`\3%"/!3XW M)X)E2_9!_9^('T?0B7E^7 M8HUF1^LE??JS;[U>A>9Y?*K15*VWA?16,_[0ONST^)AKKCI5UES-E+_1)7J_ MZK_?G+RXZ@9%LFY^L\5UL:$4=XNHG^\BZN=G++MUL<]Z7>SS,YC=8/(3#R8_ M?Q/932+M3"')17:S$8\\&_&,C:+U0M/\UOI2W.)^IM8NS7_.:?ZS-)9=FO]\ MT_QG:3"[-/\YI?G/TD1V:?[.%%J[-/\YI/G/TBA.)Y[M3E_Z*HL+#T/!F6.Q M>V;=N&=2!DS(T#+"?V=3.UF.?W!+"*?=>\T7MZ62]9R.U3=8UN73?6[!KP2FL372-P>&@'7Z_S(R`3 M1F4@V/OH@,<#>")N*+Z5;AQ;6M3R)1/78RI8CH+%;T']>4;QQ?-@`F61[XJ\ M]DO#2HNBN,44N1/FN%!]+2<8Z0?YD&4HSC<:WTWQO5)Z2FYR@6I605K9^F4P MIY1LVQ[\6:GE,\A5%K2,,8G#[7+MQCWVG/EA1?W9E5*1N*$CK48BH[["LRI3 MHWD$6U`7T;*)Q4P^H;9\5ZL;M?=US6AU6N",WNX7-E^"LCY/V2A%6=/:O;*4 ME?(_4,DLS/;`R:D1A!B"48WY=K>;H5],9!T@K6JRT%O]?FDD:#0GS!/00CB, M,G&%S[^'?SO6D90@QHE'N4#7'"-K5Q.1!A%*(5N/ZD.0=JK)4.MIU9'&$$!U_#&`(LDZH8KS26AME*!G+3'FGB^%'R)(@2P(>F7$:/1709RG^0"4!:&NC"A; MS<[&49XY6*VZ@K-9-RD(:J5LL:?K*_"EJ%4!5A"YRLC-T-H;!!;+^)).4<"8 M"IFF")CUF=,!M[F?0JP7Q*U2L;;7+*GI92@VRDE!_"K5_8UFJ[=Q7J#".:9R M?"E\M]2H5B\=ZNU/*IY2$LPW6C(HU)D0#3=\:;VE%JRGY<)Y.GMXS87(Y&XDP M*A:81L[&5M$K)?JD)BHI^HJ!.(?]86"RC)T.AV$%>F^.<6_;%?79A8/-@]O% M_Z'KO:4V]L>$C8KUI69DDXEU:&\`=<7!5JW3VQ#JXFM:K]_L;Q7X$70?(:;0*WZC]JSR-W*1-_P(U5*PO8[1 M[Y7`FJ/X$)"]`I#JI-WE4Q=ZTV@_+M#^/-#P$VTU2R0Z&J@ MAJ'IG:I`<50PMMPS)U7^A2G/\K2[53$":MUF,B2Y-O%-X*XXD@J5]29PHUYL M)I,(?S%,Q_T$9-78IB<8EQ-:?SBW53IPW4M^X'#[7V"/7D$0,#\F$BA%W#@@^V@P;PZ9`=JXSPE_G%S>GQ"`_T8EW^#]:NWE( M/AZ=79'?CCY_/25?3H^NOUZ=?CD]O\&W]F>OJ9]>B&U#Z-2_1KO1:GM^A#0$ MU6D^#KF;,2.XRH`Z4Q(M0)%D")9`;E58I8Y%K-`>LC>BAU5I#W`$&8:]B=J$ MXB2[5*_:,[_>(!]G;W-)\/.W%G$=X@,$#\R:P5_4)W=N8%MDP(A0TP'PS!!< MCGI*0A`F[A!:#FGL$:#K46X1WR4^3C\/F2`TH3K=(]S!IUUA,0'&YL^FJ(&" M?\>8@P+ZQGQH!ERWR4$0"-U7]%(\$@L*@\9KM0`:CF6#VXN^H"PL`KZ&#FPN MQ]`V36M^S,$S"G,\#?4%JG,%:/@[/.<.)!/AK!%J/W!2%[CC!2#:`+4.ZHID MFVZ8.W`=N43>$)J/!Z0I(<17R$"X%,P*MY0!AW=C;HX)A68L)DW!!_@A9V:[ M=P>O45.?D>N,@+2,<`[(KX&+7[E6O4F2-X%#K3\#"9=^41T!PQR+#%Z&VD/9 M@?8AJ'&EM6+#5QT\ZM;P5Z97H_T46L<(B$G5W)B/P(H24YFB_ES/I-I,Q$6XG?C#J4X_KDKU#O;E['>V00^!"OA7`'>,Q8^)WSR..! M8ND/(EXC)]ZO!8X)9:N@6X MJ=6=POAA.L69`T[<9P*W?T(T`PLKUC`9O'/%-S0!,]S9&;\<6P#')"*@-N1SX:X)$Y\11.6HD:J`L!D- MU+QB(<>.(FG9=&U7'!`Q&KQI[A'\[Y=#DJVVYP^KCW,.N\,:0DA\0&OCN M(<&RLDYM/@*>U0Z0Z!)W4-$HA_OH2ICM0RO8EL,.,17TF:*:@GW'+?,D?1_>A]/%L.CT`TT3\Y!]\XKD"=QP!][9+ M_8C\$IL'!W'+H+9`AP&Q&K-IB??^+X#V#-`15M`J>GB><,%S09@&3?UO.@IT MFPT]%WFX;:LJ)LX&:)@4$SV=O#4R+Z5M4OT-Q3K^2JWH738$D!N5G;%UP@9^ MT9O)ZO.",=E5@\?MVONN6KJ;&9-=33,$:3%^<".H!8J^GDX&KIU`63S:^O[R M\W_?[L^]F1^3"5=<3<_9;'&]7G%L/#>&GVZ[!%5C[?F-;K^=7S"XB*):)R_# ME=TSDJU*C/9T([?))--Z&<+MM7GM=_M-HRS1$S;$K<+16FH<=0X?QJ%H^!%= ME^>N8^:`=2I)1.OJV3G@M0%L"O_ZDV1:N]O;)/:%8_UI6R^8)BLC9KUE]/*# MV`N)58!5,"FV2GI&5YM;NE`24KS>.#.=T*G@6Y5HYI0X:[L,66U]UEMS-K^( M9&A`":UJ_K7?Z;2U`@^PE-3Z3E73#,,H\C0Y.MG5HAAB6,[+=:JY5Z/=SR[D M64)J?4SK>]ZYE0I5\:@58GD\%1TN/-%>!BI-:WU0%;RHWNP:U0#EMAWDL51S ME5V]IQ?VSBR5M9"L[QW[^6TA95"DIHYS"+K5?*/>U;I9&/,D2D-8WT_JG4Z_ MLQ;Y7%H\'^:[U3QHIZNWV\L2\$4Q?36@]?ULIYM?DE\23,Z&"L!4]+O]MM9: M9JW5`:WO=%M@LITJ8#Z[SNB&BH;!?`+'',9!]!:9P?F^O`>A_>BI66K5)=;'+E5OI>CK[;>3&OV]8Z^ MR'E60M(K6E"V,B5L]XP'H$AH%T2/,E*`>CN7;"_+XNJN7)^MZ/>;N0VURVA50%7!(S?[ M6D5$RF//'I,%>"KZV'XO&R464UH74;^"KVWEQC3+HL'S(KFO)J!PF:]:]S=B MCIERA/TRR?OR-75EJ)1-SI=36I[(]NGAM_GE@OV%V^#?&'+ M!5OIY8+7-Q?'_R$W5T?GUT?'-V<7Y]>/M%2PV6AS)S\I!E<>:?9Q*?F30.!T MJUJHQ^_)!.B,)6%X.$9VLFLO-YTK`WB"$M^-)GO3,U_M]I[1RQI>HZ(&RWJ'4R)"54FA=99 M=*Z'S,U(AZL]Z&@DV`@72WG14NDB1#(PQPDD&<)![A?/_;6,/>@,&7"-U3-Y MI7MJ00=7IVA:H3K#?3GAZ6M+EYGW%VYMRA\U.O,XT:%N*9=^=OZQ]K[=!I7G M6%D+TSH\+3W1J[]PJ_'Z3'7`Q,HR5>(HLM+K__L+MR`OYB$7:)NU]ZU<15QN M-P`NFC\/L/&+(1XUR2U.TV=C],LB&A-?%`NE<,J.##V$LAMM=$B/+\PB%A\EV'17NV M9Z`*ILT7?K!Y*2P]P55$,+75(D'(;UGJ2XW`Q9#[JH-`CP'J/AVE#MQ:E$NM M\UWAQ9:GU]XW&ZUX8]`Z"!_,V*+\;!Y]G367X+S_S.J)@A M+BJD%WP.=K'%=/#\H+3%+""[Q#="?+T8JJH@G)?39A"K[,9MXXS;DJXU3V^^ M(HC.J;^DXD*HX\PMM8PE/AYV!K#<;%=RK&P^YC0;33PI>0W2N:H6RA6+VP%: MQC6#DD(5Z:?WX7*]T)%,O,"/-KS%1ZW'C87GH\VX*;,O:CYZ@KOOMC3#Z!FI M,G@3P+;*:YG`5LBKUNNU6MUN=ZO,0F[!Y<7P$LACOXX.Q[SF(X?'Y M[/CL='7AAV(P;2I!O<>!D*ZX=#FN$TYQ%F7O\1N^6GIL,MOVJ(4KT=`PU.]H M\:+ZK98IOJM!PO#/6B*9P[1L?"4;!V0C0MGXH6QD6C9UW_64?)(+`]?WW4EX M+072%PD5->UF4CM>J@E-9->1YE^U"LK3\&)4O_@B_0/Y3PMD/Q%0]E>A]!Y9 MWEL46O)JO"*U86#U/5"[V>HV&\:K3^-+(EY&YJ9U]\Z!@CEI9+I'$AB0I3;VPHU7W/4@H$ZHJ1!1&Z(?MHSU[-`U@]1V M5FOVR;MHD\AD@H4QGH4<#C"X0]S?ZDX&N"-";;J+.<7A(Y]Q)[=#-N+B9XGW M/>#3!YP(\QC\U.F]LKW`2^FKVPKU%5V-FR7LWA.XW0_:E5.3 M5@,D#[KS_/`S$UB/YN2#VP,G.(KEN,C((JD2/"A7A'N?Z%TRBG;.\"4;Y"13 M[7YH_-;86S2F=QK@JDGJD"_,@NS$`0TC%!TI^G6%Z`K.B6:&@'6PR[ZM7'=(!]=UU)]Y$0$(Y+^^A_H*:7-CR=Y M;0H7-X>CM8SLP(3^(QFA]I"JS:K<^3,TFKU<[QER(?W9ZQ92A;^MP/3W4#E@ M!6):"?:&".U===)!X"`<8YSS!N'DF[ MA;V,;\'.B93P)3![P08"B%OX]IM/QR>_A)OFTD/RD?L"J('$(?W$*Q12OT.I MV=*="74P5O/AW6LD\ZW?0;J*F/PCZ MG=L>0I,"@4;!3:.DDUQ#]'8#6LOI!5/"H0> M3U5+8?`)=[.AV(['W&9[Y)@ZU***P%&`I@U8%JDQW"2'%NKA>G"5A-;#.+`B M7,Q)'SH,[HI#?888)_1/^%W`T71KF^/:G4;W\?;&I?U-L7@'#/42[MJ=[3<$ MKX^_U'"(3`6I@4"=.11\P>GGT\^_7U_$4X#&(4HY''J+\I)4#%67,^E&U@7- M9P.X9Q2R1>6`O.B4FA@=PT)?XJ9N,$KU>0%$)=4X&*$CP4(/!7B4"4>G6F3C M,]Z)T.8Z1W3U*&XG$_=3<1!Y$&XP&N\_:W+:M[%_AY-Y.TQG9D:BGV]/,*(G=>DX2N[;3<\^G,S0)26PH M4H>/..ZOO[L+@"1`4*(EV584?>FDE@0L=A?[7NPSJ3V5#%,X.'*:0#JJ&DG< M%G8G!AZX5`6=P8(0DKAB1#*3WBLPK%.5OP,0BY&(\!7LE"6_)RD(AINT+!#X MKJJ0,*RCZ*16B:HO$\;XDQLJOU@SU`JX/UE"CH6S$3"X!*`&8@3P:F;%A&KL MR:PRF*T+[+;."]:D'G:IK@*SR&7#FTW@<_$X315;`&U$;UNHV6@$.W]X!@B4 M+28Q=M@N1$8$)+^2G1VTC]7<;-Z969^.=C/I`IAHQ:\W".8T($$.EL4DY=SB MY*-O52#Z=3"X`6A']%1*>#F*64`O03B5@C@6/Y_4UEM#2Y4N@LVO! MJT!0AS3093^*!MDOHB'<(-\-TERFYB5NA7!-JC8/%17P'05%\-.0T6^P@8T> M/L')5Q)_XE&`1KZ>`5SJV542_2J6?J#55%[3OG"+8=P6W0OI9K10I(#-Q$\B M/I&@:B=AREFJ<,L+I$@(EN)3("SWX-)U$T!/[WM!^!D\%OAT%GJ:E'D]]/+F/1O9P9T1>6E?W M\AF&4_A)9%\F=$WB1]3;._E:\0S]RX4]:C`<892[%K.(%M.J5@FJ?F+]6TG]@ M5'(;1CSY0K8[N81BW[1`3?Y"F:\&%1)LT5`EY#US8LY^R@60;$P/D:"-2.\R M*:*WO/`$KJ"R[A&N2^"1J1G"S6&@\_GM7P1@%-?!S(]7'C;V$V<=R4JSCXEW@VSN%?@MH-Q*Z MGY^\E?O(W13&C7@437C-J**6 MV06WCOL9OZ3",4[R]\+XN@^#0!R5@Z`+KL+9!F:GD@@6\,WRV'$!/8LI8BV-<4*-M&[P839Z#K'` M=*3%#W[$,-\,R%'G3"[3PWM\^2IJ3E&^P#*.-6&@*M"$L;2'6%6F^$%RJ>`% M7NP^I7RW,/L$;6`9>OENRG@>HJ!?.<"C\LL[X'G`SARYSP^%\C0ZU!6@N-KG1D%,4\]][HW& M+)KL&T>=%XZ'1(@,T22%?CM[-VZIZ:"+WW,R:%Y9$2[(8STH(6Z1CC)X"CMQ MCPMIPW,KK2*QTK(^L*^^&[5D]N53G$TSA_L+X^#6"3'Y4H)<;T8!KHODB#@E M'"1><91!$0`CNB4!90"ZWFTL>6IYSHA@^POLD<3S258EQY;H64/[M+0^3]A( MC5`DM!-`TQ?&\33Q`W&MK)#JXRE;)??:-QXLX2E/N%*Q!F5Z*"V+3[J2[*^) MP16ZE@?4C('$5A[W(KXBDG&&/K8H;@(:!2,F8#&V599RPA"0[U+87<0 M]LR8B@-">CFKP[489SC?4W2EW#!\?=#Q\;WK'S_A0ZCB@Y?CFT\_T6OHXBNP MY%AA%N3(3^C$UK!F88B4$MEZ[GG/>&<,Z+WY)-.N)6K,&0Z#\I,Y?Q!8)E0Y MU422^5*:Z\@)U\Z$`>U$#0J^;NY\QM<>PR.ET*#T0C!7NH)A@>'.@.0NXV\/ M.ZA+,WQN`$0RZDN+:`#>"C_F4NR2GE6%1V$H$\TODK;L2 MMPQ8@=4*' MADUT06[,^;I20@B9D%L>L%(%:3SH3+DJ'&1`#Z,7E@&%IS$NZ,E?\-42/OZC M4@RP;Q=&5_@5?%>4J7S*UU`75ZFAR!U@O>AD/Z/M2ZRG&M\$;U!Q+\U:2N;> MA65:^*VE"I4D([Z>9($TL4OIR*),H4PL@`NN^3S)"R<+KPR!Y^_M6E%I@`_^ M?L&HGI0G9[BUE`>?0,CXTU#1@;GM6/9,$N`!VC%G#ZKFYI8U!O#`JZ8@(S[* M2Y0-'*+5JY-D:-133'QVY\!48**0/M^2NY9C?5@)F\;A$Y@0'T M"'`)-Y8+4/@>E;$4@3X_+F4(RU3%!:GK=.\$U47.:P;C7'?DD%H5!/+!,??B MVI`L\X`E7=0C!6-7:G/%W!FB.MXL63P(NAL)AW99B:Y)RA8JMPN7@KK$\_N@ MYN5=-"@Q0.TD$:8>$'BL@N7[1%D*=UJ&IE%RY+.MC$2F9H1?7^"4$']R7S0V M%/C]^HOE!LR)?[:P=OY!SXG7]1,H,.Q2.\=N-L\<^D"6=UK<[G0?"/7:X7TL M=]M]`UTASUB[*292D;Q#T9V%3N:1F0.*TL/X,I^[$04DJ[W27(D$[2!AJZMC M(XH("U&==C$):P$*U/476!S"8YLX<0)=@D5M[6BI(N&W M\?BR7-G`B])!&('"A2&PL_%$8@D,N9BOPS;LA'2'&4OJ0W5(2U M%Z/#1D8&&&-@R?R4YS8`@$+?$0A\+D*^L3P%W(@L2(M$C$20,$N04GAE8+V" M>G):R+%UD%?&J2XL87"2/^1()U MZP0D+Y(98RG:_Y5=BZ`&7`9UA*%$@/',%!YTELP:/%AK!VOM6[?6W)VVUG"\ M`U7Y8JJ::H*_`5/M^8)8:-RZ8DALD*%@4Y%7MHC>7UXK'7PQ%ZN9F$H(F/&I MU#^4)!!"FP^8PG0(7$8LNRK26L5+<*H;7GX7#A-#=T):50:'5RUTOQ6*'>F-@M>D*7%I-U*R@P-->HY?SZ#X:M;G_0Z@UZ MEO(S`VJ'PU&KT]>^5X.5//V'[WBM@I]7Q:E@8J$A#E"D%A=1,"$M0@QZ'LD7 M;';>KBG_7_$(SR8OYAC?WM&^?\__6WUEIU-]#^Y17]DY6'`'"^X0;SO$VP[Q MMD.\[1!O.\3;#O&V9[)+E]JA*ZQ'U>+47X2L-367#,<]F)H'4_,0+#P$"P_! MPD.P\!`L/`0+O]-@H=DH6V%@J=;8.?!)B.5__P)#F+W#5PAR`\Q>[T'ZSD![ MD+ZZAS82Q9TQ+\.'ZO-OBD::&QK17#4-N]_86]^E<46BVEJ<$XU^I;^;/SY9 M<2G(MTY0-H@+/HFPT0+(_//C2<]&HKJ!V$%S:`2XU MG%8*B6=S0)Z2;#MW@J779'^83.J=XKR@@/:+7KG+NV4IOP-'7T;P8?N'[U?B M+]'`$E`!E-4!:X)"TYOKZ(V/F_M7W]CE^P[%_;?+8=W]HL]CB?=]L)Z;CEL+U]>WIZ=M;`7^4! MJUW!TY5S9^$[8;'O!,DW3MA=0W@=.XEOR8T[].6[F9^R(XS7,-SD+G;J,HO_ MV_3@M/Y.G;SY(97@=6O44]\GVWG2&P^JT;V/7Y1_X\#UO[VHTC.==">H?+C@ MV[G@=JO;LP\7_*D-\)U`I!'4?T7Q9[0YZ5$:EBPU3+YU(;(#`G1?Y$BGVSU( MD28U7\_/@MH63_K_2LKE[W4I-FW]JVI;>^8D;1$D6F]J$ M>M]8FY"I1N_CQFVKVGK4#:(LX.+1*'5JE#JU2 M&T,;'%JE&AQZAP[ZW=;.[P#DAU:I0ZO4H57JFRKY5X][:)7:/?&Q=QQV:)4Z MM$H=6J5VEC*'*J9#J]23P'_HI#BT2AWR>'M<=GVXX(=6J4-)TB,H^4.KU*%W MX]`J=6B5VA^4[^-U.[1*'8(,AU:I0W_$=]$?<6B5.L0C#J+@(`H.K5+?<5SB MT"IU:(O8C[:(0ZO4P:0YR(2#3#BT2NU-J]2CM:J\RVA\[\K)7[V6,CTU9CBG M&&?:+19Q]-7',A,XL#*?KG,\4%C.`IP$.)X,AW7=X12H(P]'3463PNKB,](L M-TIH0'#,X.\92X[K\&*8+V5H!N-M8XO@Z\\?:4SQQ43,#8["I';R:'^/)X\> M!H@^XP!19Z<'B/[&YYRO`G$'IH9B`QK753X.J89UC@1-5S;A;7^TY&6,[B-( MT#=^=#,##"Y8!O<&?GX>NL?62^S#D],&^>QI'T=F9[>)[_E.[.-&E9&=*&I+ MTSKY,$7\W=T,EKL_`NF)@R+E(OH=MVA&Z:T?+69./`?MFM%-YI.L M0QQX/8G<#(=[1WS2M@?B-H@6-)X=MX(OSEF,(ZK]O_F<>9+)\.=;G%V-HZKS MDV(^/V5^F%BW3FG)8J8I?+Z`K[/HLBC_<> MQ]G4&GMS3(.EW*8H4_/LG4[-.,)I\,@MTR!SX?XDV.L[<<@L\L._.-.TM-LS M\6,PB?*?>[@K_-O+W+2%Q`$N8.'?]W.DY"*`NTZ7F-]/8*_3JYMBQ&L`0OT( M3(NYE<;,2>F;P-2.EP4IV-BI3Y/HB6L=Y&/8&Z\)$'L:1HG/;\#]0AV9JTTB M_LW)7+Q3GI\P."$P9_7`L))3%@LM1;;@Y<2=\$?`]C&[C6%S#W_]\K>W[WZ" MHSBI8I0*\06@9@D:M;E4,.Y^AU@+DJA`JIC7?)[$#@M\ZP,GZ3T"\3MS`D"' M-E4Y_^;%[V4BZ]-U@6_$TF]BYV\_\%$"K%R\]-W*\F29Y_-LQ>)"4J!1&+-I M%CB\83Y+9Q$8VSZ?F@L82!U8@4L\-\K"E"L?/@89T?9VY@>L9;UU0L=S:(-Q MAJP-L-21D3KLB4.!]X!V:(0><3VP0EU4L`\7Q@(^17IR&.?.7_#_AA/=/]J$ MZO[@>+C<-WLL>6-&[RU#NL`O/[.43V\F.13Z^'_7J8.CG0LE=1LCS4('9,'I M^]/W_[Z^$&?H=W]!+%].P`",A5U2TJ'T9\7<4$50U1I8.'$*UB()(*2B[Q70 ML:_`3PGH$`N8DH5X&IQ,2"N`A%F;I'6.AII_Q$P&M=CG$7\=R M'47OE_0@GB&.LNE,MXPX,A.)(82:WV9A9(7BKIKQ^NE21>NC<>(SJ3V5#%,X M.'*:0#JJ&DGY*"8+A)RP*![[)5D\D+JKY,&!`48+Q3^<6:H5;`_Y/0%XY M01`),VPELX*P&1+8PFUK&T9='8M>!4(ZI`&N@SD)M=PL#QBSB#?#=*< M'ZF0DD*X)E6;)\'A[GQ'01'\-&3TFPGZBL!&090@>W#\`5LW]O4,X,('CH+4 MGHJE'V@UE=>T+X!AX".KCR7TTLH<[(_[XD^[E4RX7^UNQV!!-L>_A)9%\F=$WB1]3;._E:\ M0S]RX4]:C`<892[%K.(%M.J5@FJ?F+]6TG]@5'(;AO^4V^[D$HI]TP(UJ42- MKP85$@S.JQ+RGF%#,8*A7`#)QNQKRC,+DTA7#.6%)W`%E76/<%T"CTS-$&X. M`YW/;_\B`*.X#F9^O)K#@$#UIR$7(PC=9,)<85\KX$19K$5/4F@H>41QR%SZBQ\S2&`0` MQ?XP90)W))LX;LI5'/P+30L0H@[_"EQV)J4!MV=A%1XM8&C3@#L'\@(]Q98U M`P%G_3=SQ`)"<@ADH"P4)KM1&QR#VC*(.WERM$I0/ONI$-:++'9G]./4"I@C M(QKF_%&O1OV"Q0FWS:R=O"*=Q7EZ:12,LZO@^!Q^$O88(`/Z(`7H6\6A_!+E MGN)("\`O@G!LC?/K$NBA7H0JC%(%,N5N3'R\9<2XRZXX:!Z0#O*H\FQ)H\/9 MHX>?CM]/7;3";711C!5,6*$K<&R,YB6LNM3HWS?/;--\KON$"75#C&"7]0 MTQ-)\P="(([*0=`%5^%L@S.5HP\H`HR9S84UO();._92=D4BE(WUEP[J_@G9 M_,+[6D:9GTHB6,`WRV/'!?0LIHBU-,8)-=*Z25C\!79(2IB.M/C!CQCFFP$Y MZIS)97IXCR]?1@DL%+[A`N<2:4KY;F'V" M-K`,\@GH2IZ'*.A7CG(Z"3XQ*Q(-)1@5O5M1;:!3D\SAAAV:P#S_5PJ(U@:7 MN)&2!SPJO[P#G@?LS)'[_%`H3Z-#70&*JWUN%,1S,!6(],A M$2)#-$FAW\[>C5MJ.NCB]YP,FE=6A`OR6`]*B%NDHPR>PD[K>QY*GE.2."[2^P1Q+/)UF5'%OBU6ZT3TOK\X2-U`A%0CL! M-'UA'$\3.#:_5E:84>8,LU5RKWWCP1*>\H0K%6M0IH?2LH`-+OMK8G"%KN4! M-6,@L97'O8BOB&2`$0RZDN+:`#>"C_F4NR2GE6%1V$H$\TODK;L2 MMPQ8@=4*'L5$$:#SI3K@K$@>-2E5!N&5!X&N."GOP%7RTA MR*K%`/MV872%7\%W19G>1?%G1+JA+JY20Y$[P'K1R7Y&VY=83S6^"=Z@XEZ: MM93,O0O+M/!;2Q4J249\/7*&6TMY\`F$C#\-%1V8VXYESR0!'J`=<_:@:FYN66,`#[QJ M"C*F((7HTN:.+@YCH(CY`CP,*=@4U>S.?#@D5D\%>-ARI3P0!UVAE,0GNHQ@ M]?&P<7[(EN5/,*`'4+1RBU:NC5%C$D#@L0J6[Q-E*=QI&9I&R8%DIW()(Y%WI2_G M'Z\:=944#2B7(J0^INM^$[UAU_"+9.(S[R:ZXN;.*=RV%+RA*U'I(CM2!FI' MRCDF.]N#SN@_,E;P/O4^4-7A"[`(?/ZM3]?O7@#I71\D7?+KBZ/!B]?VB/=A MM3GT#P=)'<,TAL\\/\CPGEZC-41D.\6H)]@K9^!0(P]D*6'F8G+JQ,CBR26+ MK[%X@6];G')8[;OI_J?[H70D^EE2/E7[Q>MAMS_H#7I%0]!6P'K4DXX,'48- M3MH9#8>C3O]QCHH,\9X'0\>AQW/E>9SH,DH9:8*S#!E>F,AOL,[S(OS(TDL1 M8,U/>&*B9>?#@QBV#R>V^R5^W12\FB%B5\[=!_E8,GSY8G+%,.S'BN/8[>H% M[+4'W?82Z+M(KUZ?@&^^Y?H@=@PR8CEX=K=G;P<\?-GQ/+SDRKX&/GL]%':[ M9A#KM]P`QNZ#<7A2@\$'@R=?T_H-BW9JP.NMA<)^IS\T`UF_YP9`]A^,PW[? MKB'R*@!1*)`@HZN.H@[D`\FZ<9&G>W-??$5(AO&=$WL7"U+8OV$T(`%:D65) M__<.>/_,\>,_G2!CQ?WER?_O'I]..-=8IC%.M' M*&[3O.]7VA3;R[R+[2!D]=XR^FOW#/4"X!*\B8"YT!Y_1_Y#%">EYB7X)H7/ M*"^KM@&I-2"\F^;IW#N` MG06\8`N6],&3SX,!!MAY-Q/62&+,/,%(()@1E;KH[G%7?2>!:RJ0E".`;A:4?@B,%=EY,7IDX,"<&.8#2 MH>>)0/0@RPMII6T,S7EU6YY(%>4U@&,_=&,91?PB2KU*Q5$KZZO$R3%\<_N7 M<%WS'#F+Y[):->0Q)?`:_V0\JRK.)C%.ZD*M"C`W4X*NUQXVX*QY M'N+0%PQ67`:.VHYIX9'FO&09Z0CL:GTAM:(<,H\WXA&P=)?(RN.*Q->!XWX^ MNG9G$9;^\M\<(2-3R"#R6"!*&9=5:9UT*[QVK(D?PX#>.H6AZ96M:K%"&1D] MI08ZM^H_G7\\`W.RWU8LC>V"_4"4)"L6/Q42*U__7W1KF3>&Z^A,F?S\D@1: MCC*#Z]743)%^81EO]HO7*!L?@+.MGLN`T]O5]+JMV1HE#/,^4IKY8L*9),=< MM[U=9C/QVI9AW](EI/\(Z'S6)TF M:[KV`P_::>LGW08\FF>S-88Y1?7^A]3NYX5RS\_?79/]SU,VKS#_J.3=//H9 MMHTS3HGZ_0J,H)TD\6>:-[^,?^Q_;Q-'#X%9NTIHQ(!EX8%I";_&=$!^)I,W M_T?G/U>BP>N-#$EW3/>>CK+(HG M3*9@Y:E-B-=FCT(KD;G(MY=<2R#_=3@6":*5>7S M0R#:VH$,!M'FE\L^V9'3&IV]XF_'#)P$2)YNP]=C;GL!F>8!287\_R MZ'3Z(P5L95^#9Y%<9"E6O]!;#CE8YCQ\M[W.O3WI]MLG`]O67(CRQHUMH=YP M'MLRSWJ@.I(T4DST8=K<&XDD=B.LQV4EOV-\:<'U#RKF[.MD'K'XR M&CP,B%I^[QMRRCTPL=?C]GZG?3+:!K?W3:GD%6`]*J_W#7EC!&@C3N]U>UOS ME?JFS/&Z;IS=`6/[8:`]F1?0KWV[=R-BG+2_!Q>J;TIP-S&PGP4]VW(K^J9\ M]\8LTQT-=\^#ZINR*4U,OFT>9@L.5-^4XEC;@>KWNP-[%QRH@2G_L#$G]@PF MR7/X&P-3'J$!\VT7?K._,3"%_C?Q-[J]06]S?V-@LBO6]S<&[4%OH">DUK+` M!G65:,]G@PT,D>K>YOY&[V2P-2ML8'`?>^O[&[;=`_`>#MQZM[=>2ZXD^=?$ M_SGT@U]?I''&7EBO&K._R8567[+@MN3JL=UB;*87E.'LRWW%8 MZSM^8^?8NI[;VL6J==ZV@N'2Z2Z=^"*F_ES.P;(JK`"E+G"ZNIJ,KEK[N-WN M&*]9W=9-C/A1;7[PF4BGJ;91K0/42+4]+G>--DC>[D]'68-R>5`Z<(4'LK;V'M57[&P#L!J^JU<$SZRB1O75 M*(^'CI,M1];:\JNB.J,\7JPOWF3;-2L3.G:I5]B\;R'C$FHF)%04&]=/ M?ER.X\%PI(G0TO*-=JZ5<"N*2>S12=.=?\/'XWDG=+%OK;F[*BA[HG)Q:?$& MNZY9J]<;:L'@VEVQ3=2)W=DX]-X5[X><\H>Q"SAJ\P@K&*UOVR/M4BW9;PW0 M@)/7O`/]8:_W4-#POO!.%OC2%?/GMUF<\*IA\0J$=Q'S?]%38#F0ZX;T`?/Y M17W`QAM"NZ8$[9X,NIM!*TE0PC^L#=4W5 MT+/U(HTU8+V0+XM6#2^[O:;NP!*EC@J:89L'P+&F-@$XNMK#`ZOA0*OB8Q3F M+ZY6J+6N2AEJBKQNIQ7P<,!S<#JUQO$*NZ+77@X-WT>SSRN?Z]CIK*DPCCI] M+=-5N]>#05I3*W2TO&!#@/07>,#C\EU4S?B(3^%9VIV&XK^F8_.H?=SI%\"M MV'5-$!N*_"4@VFN"J#6,*CV1I91>+>1-Q+_Q!:83>]C'U'X!]WJ@;/^D#Z8UXE`FWA0,1P&Q[(&".P]1>^#*_&&?54N[]1 M;,+67^XRO,MG?+BKTS@F8H@1V/I;7`U/VQZM'Y>P]0>V&IYTV!ML,2IAZR]H M-3OYL#TO(HA/EEC=4L,!@\=0S"]#3&:J2" M*60_:@3"_&+%*K".^KW><'OA!].S#ZMQ],<:FJ%C-.P]0N!! M?YVAH2ANVX\1=C`]K-"`3P9#^W%B#L:W"E;"HSU;T10:4]+4-KT;T`0CG8X6 MAJDO:S=O;&SB;W);NL.F&S>-7YC:\*LXJ(]>M(>/'&`Q-M0_!8`;QB-,??-- MGK<^L4%?C$Z&.Q5<,;;)-SJ,?3+LE]N[GR&T8NJC1TIL(1(QZ#ZUWZYWWTM* M;'Z88>?)HRIZQWY.F6W$5.S^X,G/4Z/2MG&>7F=S7M/K:6R]^;^A@=*S^YHW MVZ1ZQ]:[^1L:T/9`S^4WK=VQ]=[]AN<;%,G8AU?NV'IG?K-CCAJ7[:RR.O5& M_.9/!`T?;G>NM,?UKOOF13V/8)";.N,;^,6#Q\#+6H&DAZ1'/>;_3(-+[J_8 ME$1.F'YTRMBHSUV_OKRZN!F_/_\_Z\WYQWQ_]X M5;>XOO5;4$(@^`7L*"I5&"XF5ZQN4T77K]([:@Z-N6UU?6:G8 M:"R'6Y\%SK38H#X__'H"G,#XVLJ/BS7%:,TS/W&=X-]@$E3@KVWS!:5YU+&/ MN@+M=2OI)#[S`Q:_A0^F.!TIWZ8^=_MZ7'K#FGY=IK.R7)4H!3AG\)="ZNK= MN#I95()HJ]1MP^FF;52?-WW]AVW:IK1*Y7KH9>:&%E#;W#([:G>6FM^RWWF` M39_*15JR)X%T41:[X!=^G0>P:#@%^,.C3]?:/O+' M)P\YE/S1B]=7;`$[T4.R8I!=@`/?TIF#+YI'60+8_<$#^/L_7N%B_L_X M7_C?_P=02P,$%`````@`UH,'120S`L``00E#@``!#D!``#E74MSXS82 MOF_5_@>M$)L/KB>7-\/S@(RQ>F_ M!W?X"0A_,UUEST/ST]'3Q/27R` MR'A\7A#/%6=&P@_OV&*[*EE)5^ M.LY(C]Z_?S_.WKZ0TDA%R&4>C7__]>8^G$,2;(E1/?&HH#=%'VCV\`:'`A>&4]`N&LA0:"N9T*B&(41@U5V#`750B#.%S&&>I$VR@) MAF<&:00OQ0DM;&&2%;$I),9A27`L<(Y)6>5B+)@%=)HAF@>OAR!8C(4M8X@9 MW3S)K!L='N7`_B%__,4!H'4XBS$*AXR1`3]L@OQ_VJ?K8D!%)FM$"B M41KR0E.VIU#?IZ1L6D#"C43^9Z6RRU$FIQC399)DTD:(0;+AGQ&<:-V.[`D:[#GQ2GBSY/4%8W(DPNV\8()77E01999%^!7A M3L,0+[F:$PB!JSR-X3.PFD[,@D7NTXPL>P`?!YL=46.6G(/EG1]@N2-X`82M M1-!D'.H"YHN$*\I5UH#%AD4"BYG%%["H4.)@K&W791:9P^-'/^#!NUG@N(W. M,-7F\$J::I93I/&YQDWF.&0G11E^-?E;-@>RC4VTMG>H9Y!JV\3@2]4;>@9K M>QW[!9-Q"49/O5@9[A M)$$LR6;3T^@,IPRE#Y"&>C18<,@K'2:._42+O1/:H\=8EE\)?,&LVG5;(ZT^ MONC77_M+.VW6J,WTYN33KS5G<\7I4U#'I69E,89$5+'"[$NKP.G#%R#).4Q9 M?;,P$LOM0D.\1R"QLK8,@(,$1`AGS\5#R!9 MQ'@E'A0V6E"7<+NC4N3UQ:Y+V2,D[];##9M`YTI93*'W7$LUV7US#VM2>L>. MQV_O-)PGTKC&TUE#GD,_`F%H&H-5GUQ+7QGP:.F]PH(YGME:W3`R&<0;T/)Q M+#ONAO^_ZUW;8H=\7V"](IC2.X)Y7-;`4T$A`;)$T5NSRQ-UW<2"_%JR8?NZ M_S:D\CBNM43=4`JRBLUC*Z.KP8SJX,-Z*\15@'A_S]6HU(V))+=*3>)M'5E8 M9%5/:CF^]7.4W4\% M`GV:ZE722-4KT?2W'VX!)!"3F[56&2CE'7`JROX!K*X6[&*A&L@EP:4];RJ! M?LV3\100E[6\>%[P\:LN=-72RSC7T^\!(FRM=<2%0:Q?G5G6V1:U-8.CCERU M4U9)[@$T:FM>WC-;;[<&);J2*KMGE254PTFU?^S#@:9@BFW&46IO*<06_502 MM],D?@(4N#_FYSQ1B?$BG]J[2!]0"D"V-53=1-R0NY#Z.W%[#X5V_G""B7-1 MGF6?&]VYP@7US4'9BJIIEC!S?Q1!I=CX>69!6.A.XU45R18;V.8 M`$JF2T*S=8C\@!Y$MX53&8I(U8"[$*F(]H]Q%SF MPQ6D/&#'W(;3*$$IHDR$[\>:P8@;L[RETI+9^_ZSE3<:95FV)7F&M4H2O;;. M=C!3IJX;RVRH^X=/NZ&,TNHN1S*;`CQ<@`IGO:U`J2]?N.,]`(ZXQP@$%,YA M_5LWR]Q`A-5]&3H1O37LB]D,0G8[NW@.YT'Z`).`P6VJ5E[CK"8B)&>YB>@_ M+C3"!^[$9>KXX:)0,:2X*>+9_"LPH>$=P8^(!ZE/JZ\4N+&7*`W2D$?'TY#W MJ.M]'=DFY"5_EO?..#4L0'0@M+IBT4KH_@.^4[=VVP3:JN;7M+/&FI>LM,M& MX2C4KE%8"WW;ZY@]K>ET4W' M>"8O/X)G7FQL(,'EH*8LX2V"N[D+=XUM)\UR:/_D1^0N]C.WLY<9/].EM38L M\A5N1I:W"%8')^T:G695KNW8- M40M]<5F^NMX:JGK46K2K6[P.PM4Y[?\&CNTO*)N5W"R-'OJ17G!/A``1O>1UFETU>+O(3+UX!A(BJIU$L^:K?F2F MCL];2+MNH,'-W>6$7DN]I,_;U.GCUQH^;U3988$O^#3\K8SJTW\=1LOQ#]V_W>W9]&#,) MGGX-&!`4Q.);@N+&,`KDT3"K9,NH,]S`V'^S5]:@ZNM^MN:KFW&Q&.4G_PSB M_1KXOFC\&R;?KM,L[Z-N2*KGU$')Q+E'6+)V0$,PF>3[M3/]1>5+<0Y^#M$5 MQI$;FNHY=6@R<>X1FJP=T!!-)OF&S9C:C"%_(7Y,>1["G_P-4$L#!!0````( M`-:#!T7ME\'VKPX``/7.```4`!P`<&QX+3(P,30P-C,P7V1E9BYX;6Q55`D` M`_/AXU/SX>-3=7@+``$$)0X```0Y`0``[5U;<]LV%G[?F?T/6O=U9=G.I4TF MV8Z2.!W/.)'7=KO=IPQ-0C:V%*$`8&SWUQ?@Q:)(``1($`0S^Z*QI8-S`;YS M<'!_\_/#)IY]`YA`E+P].#X\.IB!)$013&[?'J1D'I`0PH,9H4$2!3%*P-N# M1T`.?O[7W__VYA_S^7L,`@JBV3VD=[.SR[.KV?L`WZ#DG[,+=`\P^^7F,?M^ M/NK&XO[\_?+C!\2'"MXN3HZ-GBY+Z MH"#GOT;TJ4"5^,4B_[%*"A6L8<+-"G>L8P7Q[^=,D1UE7>G[9QGI\:M7KQ;9 MKT^D)!(1,I['B]\_G5^%=V`3[(AA._&\HC>!KTGVY3D*`YJU86M-SJ04_+]Y M23;G7\V/3^;/C@^9$0>L_6:SO`4#'&(4@TNPGA5__GIYUFP2F-!%!#>+@F81 MQ#%3.>-`'[<,201NMC$HO[O#8"U5OVQ;KM4+KL\/&;=%?ZTBM`E@,M^`S0W` M%O6K\;6A*=R`A#OJ/`+K((VI36V;O.UJG-7&,`H7K"WH>\?TPF%Z`^9/["VJ M+.1>U;I4N:XO9[W%B`8Q?#@,T6:1*;N-'^9A2!#:MNO(:4^.CI\?O7QVE.E2 M+=Q?A1`2$$8]U"@9]%.%!-OHN*,61=F>"M"NE9"5["D<=!8.:L)9#(`)Y/T) M[_7VF(('"I)H)XJ+UP=J)J.4$J-PCW7,^S"$A=Z5>=8Z(#>9>['$Y#8(M@MN MR0+$E)3?9+;-CXZ+3NN'XNLOIZPFT",`5P!_@R&XN@LP>,@]VFR9*V9] MYS*.BUYTM;X$(;I-X)\@N@`8(D9'*&&5`*RQ8I^S"@56V.T M&1["R&U+?'BJG-GKV4"VS2B:N;$I\T/6=`;P\H M3L'N2Y10%J=/8\#2##96(N"6_S&BIQ<&@TA<'Z=V:=!D3=;!;ZHT)>U;?TY&CT M+9ZZ5'=@?3GV"5I[9@R'K(;1(V#+OW!]"0A@&MXMD^@#^`9BM.7V%/W.I[T> MO(8P@Y(UE&F5=)N/Z+4GZF.]"=QRN57`F[UJFC%W/5^=0\[5FWOC@2)K;!Q!M%3 MHQ/;TZ\92PY?>!=-N'FK]540`Z*,'%*Z6I00T'D>$=HLZ^?]#Q3@^/- M0C"_/OC$>[&Z,MKD^]<4TD?NJRAA]:S,VY6T]8EP,>V(;KC9H.2*HO"/%C>4 MT#7)9*V1A(WR+QM)*(^[[;R;A.(,-;1E%F9TP8&4Y23R)P;B,T)2$'U(,5,^GSC\+8A3\!G<9[_(NP^# MLJ+`T5[62PAU,+MK>-$6TX#:\ZE`+7>?CEB3%-8#6Z/PA-"F-MP>W&1R&GCS M;W5`Y4#9;ZLMKR%R^L`&)["RB]P@S"GY&(0\"9\)`5*[.BR'0K7(!DQ_F@I, M<\>S@%,-1B;A67.Z^N69_D2#,QNWJC6S=N-3'(*9<;(6:BZ)AWD%T?0=PL`4IA2'A M`U>\13B#G]#^;H4KP<.DL-LHT;5)4<]:$<8*0V7*0-)!B4$3)#'XUO!/@#6Q MUD9;A9:<=EI(TK39*G!:94Y@I\,RH3""<S)3W6!]\BJL6O1M9(+D.0<'_*KZ5<1YBJ+W19)>*; M3)0T@C:MT'C>IC)K^K5IDZO[::DG?#&:]E854(E\M4KE>KIKP*^@_8\ MRM;]B%+C&S*F7_PN`V[A,8:EM+/Z6#:^T$U.DVC<[0,=RB81$\_BU'7#,! MJW5EU*8(-$K:&F0DM.[AHE8:]1\M*R`DE+TW"])1Y@2BTBA;&.33@_TV,3CH M$8?"J5ZP]\#9AP3@,F!%AB-*$\G,O*(8A!,*W*IND;!GL[A0U+,8<"ZYA\:\H&XL.'=S M3TT'`U#'\&>&NO/&7E)]>6/>4=W"K]55Z0QCR62@3;FI6D55P(R9S M,U73'2\:QO5$B%+"!-:$+C`*`8A('D%C!@R^8PUAV=BJE;Z6T"KH?0:/J;D] M4*0O:M#Y0&$,^01C0"A*P$7PF$>G1OR0D51B1Y/$YZ;7,*IGS)!R'_1Z$&$# M[X#&TJ+*V(F!<0UIECJQ%(IEPC2X%8U'.I6O0,.PO.^XZ5,=/4'5370S:_%O MAJ9RL?-%@%OEDF4Z[R\Q2!/3Q%EGS"(/Z;\"'8Q(LJ.;Z^2SZ!( M7T435[985D8C_5GZ#.8!*JWGF,6:-LV3^D,#^B+%X1W3)W>Q:_0.7+$^G/#- M%=?H$H2`/_>69-447<+;.R&$NS.I;M_OP,1WF/:NF)[`["%_`GMIJC.-_)FR MU7I%[P!>$@(H.9;D#'J%%+._HD(^X["3X9;G@17R!KVC5;Q86^2&CK>[';D6K]JV.P)G$QR`$WI.:1QP:DZ)SN0/1+A]J@MPU-3M+C'6)3@M>LN18C;HD\A18$69.$\`+ZK5.05I M"U+7R"B!2&2?MY_?#1F2]48:4ZN*G%R[L.JM?#QP/ M.Y)B&V#V=L_IPQ;F3RODD[6R&K+-OUZE]OB/VO^KY^4'JD0=_Q9/V%M7J"TJ M/!LU*@B7()KFOJN;6RRV_<((*3G3\!3K0D3N8E&(YSXS5'7VT&%VN53_9_1_`M_R":/D-X.`6E+]?8!A*L[E1E##U/LM*3-@[AVR.X;QW M&*W;O/N%U]XMJY+LXS=`Z--ZOVSG^Q`B;/6+0A$3]KON5>F^3U3IU.8S+T?W MF2[IKKY2/1^]*P5>M^@*:C6YMO_=C-M\1G7JP: M)_IP&F`,>/9TF(\VY;L([J5G#]06H'@OUSK-&JW=C-1M"TS>E^\L[I M\BY9;MJN@N/'P1RPBQ+6G=%,B>_9,7LTQXA.VDGK-H=]9=MAK4TK9?]]""CX M&$"<71HE-3=7@+``$$)0X```0Y`0``[7UM;]M(EN[W M"]S_4#?[81+`[G0[BP5FL*.%(LMI81U)(\F9:02+`2V5;6Y+I)JDG'A^_:TJ MDA)?ZI4\19;M`(V.1=8YIZ1ZGG-.O?_G?WW?;=$CCF(_#/[ZYI>??GZ#<+`. M-WYP_]^_P;%B1=LO&T8X+^^><+QF_\:_-__\Y__[_Q\%&$OP1OT MS4\>T&0Q6:*1%]V&P1F:A]]P1-[PGY! MY?=`PA+TTWE>[)P^.O_EXOS#+S]]CS=OR*^'4/K[1>$6+_`=HO_>+"9"FW]^ M3TN\#_`];:)K[Q9O29V9BN1I3QHR]G?[+NJKL+$V]JO;]%,L=);^NB:_%4RCK\G.-C@36Z>&I`T-[//P,4T M'W6'ZY+6+05.&'&_$U-XY\6W3"OAXKWG[8GV7_[]/=XF7#;Q$_I3 M&,J^+_\NU'[IEXEP'!ZB=;6&[)]_-JJG3HLEQ!/B,O32;]?,[FY+ZDT]*0[. M;Y9OD+]IIFE`WR/B@M&:_H%/)?_S_>G7J?^BPZ@,-R]:Y]^+_*GX0;(2[]3 MZ2=:3&:7KPC?%WWB^Z)3?'\PQ_Q(\DBJ$T1.IC\!1\XI47'.Y"`A5>%8!J5%1 MKZ9"26"0?_*Q(\CG-E(-ZY*FK&*[6+2.9LL-#IW@UG2;M3=U=L?/+*(^UT97 MNC3]9@<;#RXI-1KV3>KSO,K6UQO7K8@,V%0O\O.GS[;Y50.L!LU?'R[M<%B) MY1R*<21>F>K`4;D,3,>=9Q>HGUY1K=$M+TD,TH^.=0?X#57O9$O:L]:G+I;E M=*)M-[MA-J_GQNH6#-N?AK'4D:VS7\:EW+T)#-2#*P9`Z#4/O\1W?H`W'W%` M_DCFI%G3NEV%$?V0/8^GY'>4>KW&>BJ>L8$>$!HUKC]@WZ!)'=14--?Q=.4&EYNC ML,;WMH"N>@1C?76O\6RX`=V-:E8!"]2@D2P30ME;1$N>H500W841>Y"_I>.@ M1^D?'%'&S3Y8TFO\G4?A'D?)$ZU:,@PV=#Y]OR.U$H^+Z8A4HJI?QLOG"P&=7%@;!+TZMC2_E@Z'2\?! M04=";8Q\&PQYYF/=;N"R\N,+!C6UQC)%@YB@C6=Q_-IHX/HT8NW>2+6J-37' MID7MV:LGN0Z#^Q6.=I?X-E$...4U@?%$0AMJ3`M$!_3Y.0G> M.T3?G*'Q]_7V0#?0Y_-TZ+.7'"(_<6:UB:+):XS0@DB5'WRA.E]Z@)25O$QB MJBFVJ/^\]KU;?^LG3\@/$&G;`*_I20/IB0OK<$OTA!$[?`#1#AO[ZR6A3.F' MV^&L5S\]"G<[/Z&=ZICN`PJ#A'@-'*R)HQ`X:PV)ZG9\F03,ACEUG2"WWDNM M:6R*D\@/1K//GR[PX$MWZ[[=F6GKGW1%>&LUUX>ELD)1*"'9)<"=#]:I(Z M6=@?R;>FOUV-)S]P MGZ7;;5U;BPF,-^W=CVT1YY('9UM]C#PX3T+NP_":J5:0XGMP5L)M#]X:;Z8>O#'BG%@3 ML,"/.#@HTF]Y8<$J@6IAT,EB?DTLS!G7#.E/'5=$3\L)HO2%(WU81>,*YY*E M8*ARAB\DGEON$#P6U@R+K#3%3K;Z-T5/]LHQ+PR#(NVE"K4(J<@S!R0L`9`4XH\_1I3/G6Q0>&98XR0-&-](D?5Y+4IG)H`9_JF M.WA863XA,-,$)_6-@-M3F9<`%_6<7R/`]#S7%SSB*/%)VJRU+$-9OC;/)RP/ M-!>CJ`_4/(S8C,X-,N/>'*RB(- MN;46`$NG^$X0"\+$%5\,B2N-*;WVR')I*$%GQ[:\O'Q`P<8N4WE][`TKF.^H M%D@_D\$%S;V=6O!0=`T5.S7[093EL88F^Y"%\IP1!]?B/R2Z3(<>&N&KWQV_ M.*!W5@V##1N%GH=Q$N'$CS!=(4*>T@=XM]^&3_1!81MS7.@8*+V[)2O5?<70 M5F!VAMKY[D!;2<$KI['W%-CF(%/(UH.EIW&6=;(79:VH>%Y"?(9*(T:N>31; M[*GOB[5*TZKO!+;&V7O[&OR!E?Z=C3IV[AC*R_[I62BI,,8H\N\?DA@=]L1K MG$S\8#L,$%\(WUV9&%)O/3/(D6QZM@[RE>99AR!W<#KP&Q*Z21#6I%;GL+$] M>62^M4P48M(II&T8W".V>]'E2:3&*#*92C+&D2N.5NU>U4X5GA/6'*@I[$O. MTCEH:P%:'\12Z,(WLFUW9^[D"J[MN;>ZB?.2MGNOCFJ9A.O?'\+MAG3AZ"E2 MR9/`7XD+5MP6KR`(L,4U`.RC(TNQU>3T60\'?WF!M`E M+5G#N[+5JZ"O"]2QWR%"H&=!!!::`(2ZPN+3/Z'L]QHF2>3?'A)V:> M.WV'=MA1NLQFZ`&[+8.CVMY5R0)CC:!$+T'&]WX0T(--/GI$P=J1398M`:.Z M4Z,A8*"N(^:HMG7WL,!4([A\>#,@-E\:5E07`3?$2I]7_!:RQ&&PT<[5=,7$ M'4Z!&'0'15H[\*ZIR)I1#X:OI-B)/1YKFSAREY$V'&3='1T@27I`7'%IMZA/ M"-KN.(N-MLU5!7%>K`Y6 M2RT*W;$NZ=5O4.KL%DXM0]5O4J5G4C=JSYMFXF1VEU5%X&ZX96J;8TIE@#8N M<.Q";8(IJ];9EU"4&-"/-!9G#]R`+;^A.'L/Q.U9A6^I+&^'@:S9NX/QIRB, MXWD4WOFBE1"<$A4(ETJ``)AC$S`5+6M7([A8?O!I,5LNT7PQNYHXEM1NN-GY@1\G]"SO M1RPGH)EP=1I=4QAF'L.HID!3J;HV-:8X]%0-LG)G*"O)6%LNZQ9Q#1%4GR5I M@L#:O(F6$LY<2C,$=T?N67HD?W`_"=;A#E^34"]@LJ1DA;;0&QXTN?OW*"5K#EK'%*W?94P'(DZ.SH%BI7Y#)&=1HBAG0UZ M'>EP-9E^0M>DA_DRH*+L?C0%2Z_=$;839AH&85XO>2*D*E[UH<+B,/Q0U`;( MFXJM:!!$))R>OHN*K]S*6)1-72>-'CAJO!&(<^9/R6I<^Y=(J]N2E M[9"G7!=+W#D::4"=3);'G/25H\2I-+*:-UQ4*&F3I6=JUG0!(RO;CF6V&N.) MYBM7D^EP.IH,K]%D.II]'K\L(*DSEY90ZC6#J5='GL(HRU>\L*0\"(&4]8'Q MQ#(S:NZ(I0<9F\=Z26JF[Q&)5V45*DDE*N3J3=@6>E#RJVU0!C//Q.` M_6,^GB['RW?H'$W'CLQ>0N),Z;0AD-:OX\:)%!M'3/"`]2&L;)6H[UBNAE5S8(I&CX0-(Q7;`P>749SW&T?"`1^Z,7^VNZ;,+?'A*\$61$FE*5'$DI M!<()S;K!Y%%J8VJZJ'0,\@*(E$"LR!EBA=)E0FDQ-\BD"XP:O@:&5X4L=F:TS2'._C<#D9H>'T$EU.KF]68T?'G:W.)K=L7K.#DF<>&S#MUZT:*>L$D2:*@,A=+MO`LCRQA51 M4[^A:E?]04OPU=P$")BKOJ.9TKI+>8;D@-ZCT*(6MKA!HV4NB3)1E,K2C5M, M.D8%>6?3.S?(I`S%_=*IW_O-MTPYWN0I!=Z,PAT=9_<2/PSDLY)FPM5;SS6% M82ZK-JHIC&?1MJEQ?;6>JL&Q7.HDSF]I250LZM9R+4,`U2^W;@+`*OOUE'`N MO'8/P%9ZB`:FH9#,#JC)PAQ. M85)/H$,K-$UJ'&:AI6F@W@WL&)7-P%,_':,!]JITUM+!.4^C$72[/`X_RP_2 MD_QH2AX&Y&,LR7JU9&J'Y$ME@`XGUJ@7U+'H_40 MP#G#6!\X5?Y)97GG&IO@K3R8CL:ZVD M-[J4@V-)(WFI2=6OXT!O_0#%K*`C^]O$K5K/5!0`J&4GU?*(::(*3BVQ2+CXK+CYY M`0!17O/3!"#U/1L=KNK8_.\A3FB'*UZ%P\W&IW,-WG;N^9M),$HO86`UOJW. M_"TPZ:'%?H*7.'KTUWC.'-("K\/[@&GYXFV%QVUW9;:ZDL2Z69@I_(Y^':#5 M*_9KJ[%:P'8E!@4+E-0G&X@:020.9F;.A$MJSM#1&,JLH=0<*MASPTUVQM#Z M@H=N?4-MH81E\YPE%C^\$JVF6?ZKO>NTDVKW[Z!D"Z%0A--A-`*]F-X"A,(] M?>[(+NJ7ZVK4J[)>G+/I_Y+H21P?\.;R$)'<.JUCFG*SE[,4^./O.%K[L7!C M47-%O$NF#17!W?C9Z!L`S@HTJH3F3:%F:@?YGW1?1.;]T'WD!9E;Q+O]-GS" M.'9P1*,Y%OFWD;;!=7UZSU2AX"[3Y\$1*]=TF]?`!D6J"41I+\`P(E2Y3U=T MWCZ5.CAS[XD]'G[SHLT9RM2>H5QQ3+M&B73WI7BW?.*!?#-LLG`**V M6H]>T);IL>F/U/6W'[*E=6CLCB1:M0.VTTY%`WJZ/D4;Q9H.1:Q/VY^X1XB. MXK.B`A;XP*(SZ[JG4B@5RP+K&6*29R@MD@D?0[#;@;<3CC0-NU99TO.MJ+M= M&+!Z21>S"ME0.Z(55@'X;A//4Z-Z56I0;IHXR!;BTP$C6M7 M:5,KS[L_506,+J<[N0->4@)HR=0F&J4R0./Q&O6"W-VKL*W) M^_/3E)IC?-)#!&>T61](]8%BB2QOE+=G_$$G8FIC+>%'$ZS*G.[K`J#&7`4< M!%W)?.9>-(O8GH,T35S/KUK4+@]V+(W;CBFNEYZRG\Z*O!+&J MI;[6$-OG0@C_U_".1<-"7$J5)>`YJJH3K92'XX](V;6Y"NQ MY/3&.1H*FU]&/P5F)*2K2DK)UCW0+.8P7%.M4%;/6=(2+QYN)GE)*\#UOWVR M=G2;:!)=6IBWD9)3&&[#D[`F@'N>>#8TMSW5186+:-Q@D*)Y^7N@5'"H3:9Q MA01[H;J%CY6#+R6FFN+HN!P+N7JP)0R2]/9<-L92KW[W*HRP?Q^,#E&$@_73 M*O)(K=:T6I\\/Z`W]-P$$?:VDO2ZB8J*CS93`4*])K6&\>>&EM7L-%(XR$JC MO#@JE$=4(+O3\`R=I-Q@`JY5WINHJGN#5J#OSD/,B9\B=1H&&W;W M]#R,DP@G?L16VG[$`;[SD\H)P14'T4!#Q3\8:0!Q#PWJ#.,=S`RKG8.)OD%6 MF)W>QXJC.;K>%%$;\2(T6'/]BOF&E\G"91)<5D>JT6&"3[OMF#=-)B?(G3?R?! M);[#I$NW6>!''`B/%]*6J]_RH9*#NNM#KWZ`'-6QJ77YAT++(']%<[Y-]I)D M=.PMVUZ]WA[8T5A!&)RO60<]07N*P#!P9,NU/GYXMX080:_*7*4\]\80-U`+ M/>>I9Q``M#3`Y(70V[S8.XK@O"3*BKY\@"J#BPV(.A9FAFN6/\0+O,;^HW>[ MU8\T8E%EL.&)6F*NN):VJ,NUV(2['$4B\N9%T:FLJ_R5P$:#PDK0J3E<5Z%# M8PW(]LGC24"\"['F8\E5<&H9)7-+,I8HRZF7+:Z6334A:5&#B)V%,JZRDH<% M#3J*(:3F84%6AX`RY+D00>?>$_4*]"*==/SW.AO^-:&DB3+M*"M79CGNZGP3 MJYT_S8JT"=!2U06GL"DZ!2\/V?M4F@WJL*D#;UOJ/6Y#>KHRCG;(V4ZC$6P- MHKP!#?3CODRI22;@+*WL]TZU:V&+59)^[#$5GA=XE6E`!14_N,1#C)-LZK7/ M/,7)R(L?YE'XZ&_PYN/338PWDV"VQ_2BO.!^N$[\1U;-41B0!P?R+'L9!J+( M#Z.TD@&T50KBLF"^&8SC:ET7M?MJ:6)`Y!%5@'(-]-3!MU0)\67OT%$/.BDZ M0R=5Z*3+#7\&!.R:7P,E3-6[M5->]W(O@(B&LZ=AXFW5R3E`E6PSDB86E)-K MRLE#2D,4'EGH'85_T$T'/,^"<+VF%]FILO2,\O4?!S_"Y$N0FB5/$/]F_8P(E], M.6!8%;,TAL&OG:VQBIJU)F,2%26BL8=3,9;4N\%A;7AH#"9(@:4>-"B+ZPP/ M*"#9?9R^"B/B.M88;^(K\C.SA<5T:B(NYQF*8&VH11"QM;6`AFW#NL/&;GWC M^@%<5^0YIN"-?O2&(A M^S&Y3$A;KMH+4!E/'='5XGL[OQ]S4[U&OA)7@6T&\S#-@T M-%TK\NAMZ:R3(*%HHJ*2/IBI`/%136H-V(,P-*_V/48*!^.KJ_%HA697:/R/ MT:_#Z:TS&V M#8MU&E73\K2SG$L@*H+"($V`Z6)$]D=![K5"7QD\NP-_O_<)Y:<1ONX-?_F-J&13L[RE<4 M_\Y0*H0XRW]?*_;5%PMUAOY>8^-'+_;CV=V<$(S4D/5B2;V7_GW@W_EKNL<@ MW>A,NKGS<.NO2<=WA;\G'TF5?A?$2@B5E=C93B6(1J,AI.5V@X&LUNIJO)]!.:SZXGH\G8D8@+`M2:%P*$?]4GM5%=]U'/ MG%30$;QU7>QRBD9X)D_[OD4-+.07=*"3$I1K05^I'L04_<\/\JD`Y3S]7$@9 M*M5[2O^OF1QH"O/3`*4PI&_2K"FH#U+;U/8U*E4GGW(J>9;ZC2?T-?O75>>A MBR*1FS!#H<`=*)0(B>\2BJU<.F!@&@K.PB#YFF"K&\E42<',]^C5#7(^4VE18UI'H8.MCMB&<8SV.$(Q+>(&176A4)^8 M,<)0;29&+LV9?'$!?.#SBQKF6F./S2)F1>C`*&*%W,]Y;"%3/4L(C$UG=AN- MPBVI>!A16\*3#U3E);N+*N7!%\ESZV-I:7S5EMF"^++T8'[G_XL0;W@?87:G MW1DZ[`G8Z34SZ:YX%+'CZEW0+WCN%FLVM0G5#+9!6 MWQI4>OWRP&6T`:@IO)SQWTMOBV=W[,2,81SC)/Y%PXF+A63[1#E"\'N>A#6S ML"./9\MPDU-=174?'BE!.^+I$3-I(?( M+74.!-&KIV^T.279U9[9D,=W0D2Q`U0'57+S6&T0US&RWD]X0)55!5 MTKC6%L32H*@&G?2@7%&>?1Y5L17,G%&(5*$;[@F6`/4+="WPJ^KJ0&QP+N1] M:?2U<^LT6,TZXC%-&_)C(TB;[\EO_T"7]ZW#W8Y0-F;G2@1A@M);CM*SD9A5 M>D?+?(EN\=H[T/6`#QCA=*?"M_"PW9`7R",U/,^K^(/@YLA\AA3O-3=:DKJQ MX;7E&@=>Y(?#[[YHF%-:MI*[",J".#-I/6!R"Y$)M8_A2P[R3^@K_>S(;(&\ M06M4U6G_*O&X,G4BZ<&E.UJLB('9W3"*Z)XE6B\)+:1E*[00E`6AA;0>,+00 MF5#3@B\YH(_9NJ+3"[94<1H&YU[AV8K\&=/=\#3JND0A>>/7**2#E2J%N#)U M"NE!J\L#_],[39\N_7B]#>-#A%5++'1$:@?]RT2`#OE7UPKJ@'^I)9W#_24* M!L>WZ/3:P46_6BC@G.>OC9TJP62BO'/\>T6'*")_K>@UERHO;RI>[5EHB\-T-@QK M"]3_T+>JT27153;(2]*4[%CV#&6E2:Q@E\XZ%S&,$57OVC3#9*VWHZF&TP%R M$]56HHV1<3AXI_&W"5LJ+;QOGST"5-_;QE.$*+T9G9K*#K$44#,F+^ M:N--2%^Q!@E_70"KW;"BL`N"6AI8O`YOZP048G6Z$ERL_\&/2L_H4 MAANS\**6%(47F20L8]5U!`XO4H,&1)7H*8:7O!ABY5R/+AJ($3-8&VY"_HHU M2/CK`E;M1A>%71#0TNARQ.H]??TZH*D?7(#!Z49P^7OD)_@R_!8HNRK5@L*> MR:D@<&Y7K8$.U;2OPN.:,#3!+SR7%,MF8H/ M5N84!?(_:^L)#)Q>,+]+B\68P_CZ>KEPL\I8>'A%[/>R)(#1["[8:@ MC1[,G3Q-PP1+EHE58H"Q?&WOA+8\T'X*P_I"K@4QL*VS^4)7VV"YFHW^&ZT6 MP^ER.%I-9E-'EB6:@X>S3Z,9_JJ$UM;#V\_A*(2ANP=FA@$13$-0L?"?4%H< MT?)N+_#N$N+J=4\=@+S_:#:)XP/>7!XB>B`GNV"";4",V?\_>C'>T(V*.(C9 M3D597&NFB1?A3#7!.8IFWP$ZZAG70M-[&.H=C(H;EWTF3.<:"9$#S'91M8,EW+*TPSG4P9AH%KN:Y$,9*C&U0!2M\.<9=E,JA5#"[/>DL/:(C MSOX]OZ7BJ"A_G`J\"J,[[">TV_.#1V78.,:D7L-W>M3$)-@0_[M9A:SF>;J1 M_E^R-=E,N!*D=85!W(Q936'\BK9-M2/15)4='(*R@A2=:=$_Q7GZ[M+F9D/X MU)Q`(_A56:^GI$[TAO`U97:,US_=AX_O-]A/24W^J'*9//KG<(>##=V6?;7U M[BM4$+[/?A+.^U:D$]IKQRN>6C%UZJ4'QX^(?NZ7`^(V"94_8P7)M7(GL*I; MUA8>LRTZ5Z2WZFU_PUXT#C:77E(%C$[1`DK%15L#5E6+]MB56)##6"@XR'=. MIJ\0?8?(2T3?]H]O9<.&)@W`0;U(I$P`;=#8XL)EN#Y0`J:IH)@(TG(%%@C* MM::`U'Y[_(O4R\'/EQKDC_-K9=U!O;P50^T?G(-W;ODRV/6PT>'AJ*<#8^)A ML)F&0>'*Q.Y_Q[A9'%6RVU%(]\-14"\S9B,WJ#G2(J;%QC6,.#74.B@(: MQR]=ACO/#QSIHS1%7OT@PE80KO9:#+5QCA9LR05;L9*8WOC!_?)I=QMN.3&2 M^[X0&ROO6\=$KKWVL;"J5AX#RZ4'V4>4?NX_XO';)%3^C)P(5RI7CFSREK6% MQW%`:OETY6]Q-"*1]#Z,GCBHE)0J8)-;JC5");;;XY2O7(Y6GLP@?8C84Y0_ M[A^ZLH8+-7]E#HPYITZ^"Z(I0#^_08T>>N(%O0?!QH2QNZCNUR<1ZX%9"PB^X1R6(B;\N&9_\; MBUVVH%P-W[5R0``7V(=">%V]#L2K4CG&L^?I]`(B;UQ!N:@5.3"7-W@=YY7R M/*"KL&$9Z6QY!9MV3"<99XE1169 MBB-OTA4PK%0^@X\*!9VAD0XJ>)S21Q.'8!)A+MM,4&A[1/+$QOL7?]<4;4H=X17WOR\,=Z*!'^4 M5X65;O"?CC7K,8!35LB!4EE@%G#J`HJ]Y M45 MKFP=BA[YFFCBL]),$R1=FWP'P%TPS6JAS7(CO8-<".U3*38/[E$Y;QO_Q2G* M-X*>R!>TP+'`29AH%'J/YT$*Z)TN3:M@A1-TI\N1%?,"*S))5!`MW!'A9ICL MC3/JJRE[8DV_5W)O_O<0)VQQRRI<8-J._A9/<3()UN$.7X3[RXH=Y%#[Z M&[SY^'03X\TDF.UQY-'<8KA._$?VO53QVJ*I:D"W8@K&N5G\%2!3`CO5U/"/ M-@P/"EI1A/\X^%&ZZ2?*#:``)VA+E-.G].\U,4%<0[H%-\QU(^^HW)54Q":K MZG[7/H=K;MF"28[??ET>`SQ?LE7'?AP&R[@*+H/`Y:B9;1M.=:.W5/L[^IH: M0+D%=/N$WMZDON,=.MI!)T/N96?/WHVH\[MGZTC-O"7F[Z?X_`;13&B6@W-(1*6<9GK!+>3S?\5A:\L7E-#'VNJ8&J9SW) M(ZJ`YEN9BC-4/.#A#.5Z$%/DH.-LBF6Y@VS'$*D;-%2M<'?/CW=63KUL72&[ M!*3)#>^HH;LP8KV>,_:`\6S]@V:?TF$$'B;_SM@60U>(G7AXCE-N/O MZ^V!I#]7I)7I&2^'A!WQ,KL;>U%`LJ!XCJ/T%)@GO@+):2L=6*RF'S8MPGA) M^[\)4/)BM:(:KM6B_4'Q'3J]=.JPF2[84W?$G5&VYJ7M6>8X\0[]1-\>GFYF M27K)Z`/%-8$*#9%S)0?K8X>EW:=O6 M*:0!A1IO>#(#I2D*-)V<+@YZ=6NCK1?'LSLVH'CM!WB2X)UHN$U:MN+D!&5!$"^M M!PSL12;4V.=+#MAC>@IY.M/UE;Y"[)TC5)`W;HT1.EBHTH(K4V>''G0ZI$@8 M)Z0ZWA;+C^03EJM2HUX.AA8B^X!9`,^&!B=J4@/Z*+V?^Q$'!XR^IB]<(8.P M*>M$4+1ZC035\AP"=`40Z&2!;Z`!/M*IRQ0A[/$+PHVB"D%YSB$M\F["= M9T^JB_HD)2M.DEL2A`62.@`Z2KX5-15X.! MNNFK/.!(U)G0*4Z@_:7(1".84)])'Y^A]`7ZFOWKW'5T;7&C]*!-D=.K%ZW- M`7JQOQX&FTLZWX`WL^0!1X6;6Q4C42VU5;QQ8VT@3&SY76"XVKP2:C8WU3W( M!>D1*.DQ6F>(";-M@YGX&6(*RE=W.S80TQ:N-;Y\GB6AK,RO MM*F+-6;16/KW\>33KZOQ)1I^&2^&G\9H>O/YXWB!9E=H^>MP,5[2OT:SSY]G M4Y3>;7RS)*4G4_IP?L/.LKB>+9=H3H28!#I''X?+R0@-IY?HU\=Z`(!%XY#>\";'.0*T291LGM MRB>UZ7Q.KC@_EC/=YN+>A*-SQ]:?RYNV3F<-)-1(R9/A M4$L+.-T1Y,KSHR_>]H#UQYUU1"ITD8N`L$:G5C#D45A2Q@-)M>CJ=TX);\M9Q=3RZ'=,QWN2+_4&JQ M4=X9Z9P/5Q-2P#FFJ5!0(YD>;*K\$DC5J:6+L]Y8=9WEI=)L3TM&SK"JC`V> M\>MEA6TU4\:%E0\DT)(P;:RK))S"N1URKP(DY[A M)4[_+9Q]E9UCH0YQA@KJG-16`$50PQH##E$;&=?BKZZZP>B!WI0<5\[03#=] MT*4(V].IN(Z,9S?`%H_CS?#)(;RF(B[[7<4X]'HY0\N0$*?S-'EI]#8O_XX" M_G3N8R;C8I+8(=:5\SO=H+W7.:!)\$@B<1@]G7J8REBGE*@%-XD$$-.5=8(B MMLR0#H_%\H/)]`OIR,T6+MXIH]/J'"KJ0J7./*$DCVKZ^.J.6<;7QQC?$F/] MWHM.[WQI>;6+[`:7_!2#Z\GPX^1ZLB($@16]#)6.L; M4N07H3R+NTY@<:9,G&"0UFMB5*C6E/R^IAY<+"-VXCP9:*Z)ZP5.-JXI([9Q M-)3I=BK@,N,D6)"13@DA">OJLE+B]8,\*\L?U19;0C!="#G]A%;CQ6>W4PHP MX)DX_-;0<\7M#X,-.]KA(=QN"/;2-0_Z$4!+7!P,%.+0[-2J+7B(4%DUHJI< M63%PL)'>;+&/PW%##T$R)IM@4$)IJ1HINUU"L>UPHS8.!V<6A$ZA!TW'*[8< M?SB?K(;7Z')\1:\FGHY^>VV@-HE4EF#=:_R:XH1WE\^5'WC!VN1RQ.:**C&M MB2(0O]#\&P#ZAT:54/N)!FH'H^'R5W1U/?O[$ETM9I_1U60ZG([H[L_A:#7Y MXE(.VP)\-<_1&LA5#V*NL.Y+GA$IH(?C&M;`!B=H%*67YTGNRCM*NWQ77K]T M48;1^,;V`_#\DHT=CDRM;4P3&=]EZOG M%(9UP*?K5_2!K.E5)`JUO8J+I.@H#*MJ8(,3&F'X*/T,PW!'=&D:ABT3QL4P MK'%%L%X8UK]$O(TBFQY'XQO8#\/R2C1V.3*UM3"<;9UY1F&XT477K8&LZ56, MKJA^1J3H*`RWOX6^D6)5&'X6-\?W2Y>F8=@R87H-P[,]W>8S"3;X.]ZL0G8? M;#YJOB+&I5O<(8QJGJ`1#*O4K M/):4!Z&NLCXP;)6941-4+#W(7YVAPDO'&*AN\QKI=&%2Y9E0KDXM?61UR:8' MO#EL\>P.Y@RCE7>[K>*_$ULU%ENQ!>0!+/X.4-[#3A5U/(\-RX-<+3V/#?X@ M-V;$&=]GDV4L"/5KURX`D#2D&/.B1A?B_EI\ MDKX&0'K`?];#--F>:R0K8HE<%I8X.O4$YI+"I`&]I)J4!QJS_8R_#J>?QDMZ M5QV[/&G)1K_[6:R^@V]K6]X?.?<>A0ST(D9;8!9(YVH;?5`LY=43$Q.>(0/-=6"MPFO,L&;&[KD#OE/+"TDN'N2J&AXRB M*E!)F%D3E1)2#<5>>)AMR/*V\S#VV02,-A^5HF)>2D2A^:FL)3A/91:-^"I6 M).+MQ^'U<#H:D^`['J^<9JL:/#+6ZD)/PEZA"BF+]8';)9M)J&=+S#:7A\@/ M[M/94C:_&D_Q-_9*W.DT$:XQ6D\8B-,F-84<@=4UK$-N+54#.A@7!BAFQ[YYU:1W:;5,(CQ9?5B6%76)LWY];0?P6IV&[.\HJE1_'*:Z`(HZ?)'GA`O M,DF$X)BLK!D@@66V-'DK5C%8KF:C_T:KQ7"ZI-O"7;Q841,+?%[J8HA+1Z&P M@(?ZV.N0?G0Q"QN,\;;YD.HD(+G%SM,9O323KA)25QJ&F69UA4P7M2UK$%93 MUV!Y,Y]?LSF'X>(W-)E>S1:?V=6HB/Q7.'-I>LD]"!%-9RM:;';]A;XX35DX MC[^3\^_,P"'WGP3VIFB^-X_!U':S_.]VJDN\RK@R+Z`MDOHR/0BM7Z M-6I'8RT[8MYJB`_R]R@O@&;YUJ.L3+\T,VC\T+QY*E12"Y[8XP#(S*+%)EP? M&,FI;$.X*0*%E@(&.;0Y8$1;&-U&X>\XHC?@^C%=^(TSN9B.J.%\3VXZ\!:F M2GYZB9`4^G=84'*\.#@L+P!3>$USK3!Y\69P]'X$=!G*T'WD!=E6A!R'+](9 MGMK++O(N`/.'<$O,AO2LJ4<\C")ZI3;U;?,HO/,3-@LT)W6@WNZ^"N/&\L7L MPDR^/>&:U!<@]S`TJV"AD;9!J3@JE$>I0#JUBDXB#G"S$:S"UBW-XZV)G@J- M70:WE9S'N`*`0&<940GJ7@'J^Q3J=!4,G:C9'\5SVGA_1JG"R-W/A0NIF M(MR:Z.8U;9^T&=F4,]M`U:!8%A4+(U(:L>+H5+Y_"C<`4=BN:3G4U5=2YJVC M(+:1G!E:AP(T.PKB@21C]R1*W7L)/L:CZ'3<&SW.D93);X#>IZ>_)0]>@KST MV"^Z).0A71!&AQ824C6?[N[VJ+4TSOE!]2EIZE15G.JZQ0&F62`;+SND@Q14 M:UK\)S3-KD]XKGO:>4]/R"6L1?1XQ%B4O?XL&7'9S-=M.BWR"=? M;A-^8V?9937(W_ITA5L4/5&)1[IDA=8M?7Y'?JCTF0.I:'=DEB:A]ND,DGX: MF(/./0U-@['YHA*@*/'*R+_SZ5G2*?Y?%:!EJ64'@(9,*K.`0JR,`_)MGM3K M:$S%BHFDEEA[LAK4#B!YU+.FX*6.DD%>BN6':3E4*.C,1+\Q1,*FS<'>+(P[5=(H7*"8OWII:.K5I3RF%%3F5I,*# MXY'%E$*%]^AK6L(!YFBU>&C:*ARFR,3*#.D1538Z2$I[S1%&.T%*C#F0_L." M3)KBP\`,)(V7&H!.W)7&6J",).-=NU8I%&TP/&FT_DQ[T.XW@6I.?ZQE>'8$,O M&UQ@>F%2;HF.=XC.OF3*:_ZCE'L'RKWH MJ,Z!C,H]\DDS-G?H![F%[!-=G1^3SNX"^[O;`\GTJ(5X@=?8?\2;693^Q3EU MOZ%T,>";2+?W..9U!0CE1D85_L-`UR`MS$8;R\517A[-(G22<,`=-,!2V+*! M>337UU+AM*MHMA(L#" M\9W&.@H97@,=K?GLQI`$X+N&B0_U(.7[G[("5!&_BL&OBP' M[!SX@/G@M;^F/56B/KWT\[AG=!XFY/^^M[UB6T?GWA-]^I'4-;_ZP2ME*H\ZMR M,%\M6L9P!RUN(\?BVC!K?9H#G=H_\ZH.#.`U`X`TUS"#`$@N4%,*'=NY!@P1 M<,%!`$HB__X>1WCS;*$@BX"&4`",4%./QL+9W6R/TP43\3S<^NNG%?Z>?"1J M?N>$+&V90@S3D&F-;NUZM8]R.J;DL%=K&*1%Z.KK4R'T-2V&:#G$"CJPK4(? M$6&C!N-01BE;YI`3^+,1<_6,ML3B\>RG]9JN<66'#Z8PC/#6RXZ$IF0L!+117;,X4'C=@80$H3CPAL7PG`K MA,B#;2.,P(14GF+P*"HRT@`B%T6(O"0?(@^0S1`"&`9G)">.Z.ZQF&X?XX9` M49%"^*L7:8U@D=7V88^C60[8FL"`/4'L$4J?]0]383.%.C\K!YS5HF5@=M#D M-L(:UX99\^?=T%&XVWO!TY]B=A0^6Q!:WO1SG*AS(,PU0X?IPMTMLVAY\68W8-Y[-% MABRL&2(#,)RE5UA,@G48[3,:"L_#4I8M!#A)V=:@5M:C?N?0(3OJY@V-6H&#D)A21I/VZ()),** MM4.'6KFEIF"Z>#5^21J!6V,),B9'8>)M_>\?_9"DS9&WQX?$7\>:0=I8N!BU M#83;,\>XI@!QW<2F@E+ZJ@9Y640*HV)I=TEG#J.P7>/R2*FMI,)2-V%L)<,P MLPX%:9:#&(+:A;2D,U3+$Q?KN(9);?3-@>NQYR1QH@AYYB`/ZLW%A;NH57F8/I;E0]=J MX]M,&\I&#(%02@)>!A2TPK8N&$"#\$FK4:Q]Q-%MJ!MMRS9,T7!11L-/+P$. M.O%.&PZ0T2L[0R(]O'05?L1+0OCXSL>;59B=;34.6*4WZ0&FO/#66$DQ_C50 MTIX4C6L.$$&;V%9PR5SEZ1215`BM0O01HZ,<_9Q)HEPT.P3<`3HV!UX(`P,> MG8V55?C^/(A@)9MH5@MH4N3K#.ZV(3U;*B=(>DAW>@,QW9M$WNW"B-YV'"?A MCIXQ6EKICG;D.8J9K2>Z1B&,-JEOO\V*;-.%\^OLOHS\>.^`%2-Z2/]VQY1N M_'B]#>D>?^]T);T+:_CZ(Z`\P>J<@C`IFKE9\/&29E4`9R#)`;/C+];A;NGM2)SHV&ZW^'A:\*MFA#3'[)X1@%GJ(CNW^?)T9#.[S?7>#S"._.!^ MG)[?/,6\+?8-I`MYJ9%T:Q?0H*[M,U$SHW*NF^@:Y(51H71V^_&Q/,H$Z-DV M_=.["9;"E@W,H;.!EC*/G46SC732U#P8LFD"N5"=-7^&`NS"`M4N(2W-VKH` M->2%*\LU#KS(#Z\("81#_^)"A1C#*]2:?&++[2,&5[>Y)"DP88X+T M!-EE@U/BXM$*1SLT(@;]M;@*1:TPIPN&D"#W$FKK1A7MF`*ACS"88_T%J\NAZS'.#[0 MT^2]`'W&&W]-.C)H>(^#]1/R]OLH?"31[_F[#ZT@IPT9"R%N1SXC;F8;90FH]:ZV"P&?JJ9HR! M40I_+PD:6C'0!!R@<;"HUU8DK-HPQT8>#6D@'+H;ZQK!0R?>&<'#1LS[%JHC M7K4,+]Z=RL`AN&H7,-855&N"]BA1<&;?0A>Q6FLN/E(%K*!;V0IHD&V'!VU&HMF)4LF(+A&,C\+9W&#N_0G'3E MO"3RUV@2/.(X\>_3'4#TPC#ZRXT_#U^`]]"+D(4B3)'BS3,+U[\-O7K2)ISB9W5V%T1WVZ_6:71^K8LT9918@ M,FV4ZGK6#JJ":2@WQ:4*D*M*=8,Y+'<8Z%@Z7JB493:RPTI_(6>FD&A'#H51'E) M])661:RP"Y-*9G`)FS;?;*M#-A'0)F`G9)5^I9I:) ME]MJ0;I4A9IPK)SK7"NC0I]G/#1I;I66V+2-91T\.D"],A MUD`I[TB!PQ)T)S%-]69[=O/F,-@4(Z2$C1N11ST=^0K[7,*GE="@;1@`JRQ` M&*#5A2AA&:[R6&$)L#"#9UJ6P`?(M*U"X/7BS2!'JO?*_:I\0,H64"$'EM@I M;J/C(6YS'/V&/6XR(R]93%]$)=NS2UX'@!1%:$!!'(%Z0TBKQ!]YP`Y M%"T:&OST//CS)2J`[QHK5M(%B:E&N+%QPNF>X&[M;7&P(6WPE#4$G:0@\/SF M)P_/Y$A3"-#*TXL6L(5)(02ZP9,&B9UFJ#V="GJ\X1?MO._^[K`C2`MB?X.S M2U7VWA-]^T+@)$T"VL"I6:#/?A/V>]QY\2W[40[Q^;WG[=_3#.`]WB9Q_H3E M!.<__W+^X1>6%62/TU1D$L<'O+ED:WKG;#EOFHCP)\>R*3"\J6`;4F7V$\.H M;,55R&_5+G,!JHF8]"`&LDYN*HY2>90J.,MZ#MF_V0QZ4+"\^;@<_^UF/%VA\1?R_R7ZFK_L M>5Y(N['KJ:$>/&I)GT",D]#I`JH_!JWP]^0CL?>[)H5JY14<*I2W0J):?>RP MJ&C&G$8GZ<'I%4K?H:_T+6*O'652O%TKS$N&*,A`8++*;-7_%+;!U^)/:S=JX;XN"*M/B3?,WO"6 MO+S_A`,<>5MB;KC9^8%/^UL)O2S3HH\U,*V1U^DJ&RS'U]>3Z:)0\XFH9! MN&>K;(ZLL8)AJ3$U:B7B@ZO)=#@=30A`W4*CJ,YB_*E;1(`XD6`=8S(3(*BZ M"B/LWP>C0Q31^TU6D1?$WII.)7[R_.`ZC..;(,+>EAX+:`5IQA50H\]0Y>#* M#[Q@[7O;_')0>EK#.MSA=^R24/1V1\2V3^3M^H&NE40;_^X.4]V]G^;0Y"N+ M`=T,#`*0FRBK`]^T*JWSX%SM+$A/Q(RO#L$&;R;T2(@]7I/>WWBWWX9/&*<7 M;-/#I1ZG)>WKR9(")H$:\+D&%_B]-])D.WY MC=.;[9A@E3_2F"S;T M0IZR81@KJ#0TKX:HD<+!/-].1;*/?5:0^56)BTM0+*^JCJL MS:IAR=F>-M..O/BA(W_+,=K$Y=;4#-(K:MC/G2;4^9KM#=Z'L>\(AE7?Q,3M MBMI/V_.6%>@XW[I)4/]+^K"$"&N,-_$5^=G86$YV]5!P/R2=V4<_L94:-*F# MOB?6UYK=+]&L=\B&7]Q`NN$W5[ML8W`H_+:F/K'S-JB0A340>N,G?TXY$.![ MNIM%S8*Z#=-5$!^62=.3!;3-9!0=%@[L0.+@TK`#I= M=_%CND[5UOU.U]ESN)6YEZY\+LM_6$';0/UIT"L>N(36H! M/V5W\6/*#@P>KDS90?%$OAO1#BO4-MON6-79"^@&HJWL6%6A%73'*L00H,EV MPB;C?:LP\;;R03_3*L!M7/WP8^.JO*'[VKA:'V3K\!`?[EF0P]/)[A^?3D6R MX,&N-LVNHOA$"B;Q)$C/EU0>\VS76O4`(5O68-8NV/TM@`XOLE9)C241EFR7 MCKHM78Y>T(UNGTHG3F?ZT^O2S_+[F,Y0:H0FNOEYU:=36=]>XGV$U^ST7$*_ MBY1^CLPGVJ9B?15')]ROIB"6K')6B73D;#H.#;?J;W1;_48DM/GI;0[IEY$% M`TC]//,FK;B33M4X=W>3[MSL'QENAD.6'N-$^V MG1Z[[+%CQ3<9?\?1VH_Q\@F M(ECYY3J*&-!U!X@HL%72BCBQ;L@YVBY&G=P^RBIP+(58%9Y)"++#?_,09=,/ M&8$9A.BHL']0IMB]T2)HKL#U1M2,!.N+<$P!]D1T>/\,1N>S8$._"-Y, M#[M;',WNTHL!H0?J-4Q!C=E+3?4[?*_Q*_0\DB^OH<5!?9EAT-&EU,(92FW0 M8:74BD,>W!;!X(;^]>D,-@L@,0DX(6#B/'0\_'[[G;GMG__CP\_,:;.;W$%K M-_[CX&W_=O"B!$?;)[;\,9`KHTW'I98+>_4#MGWVE]Y8L/.ZK& MX*1$'0JE11 MT*/E.JZV"VZ+'F!W\C28>9H_CI[&/X'P+HP0^=OS`SJP$*>Y#=V(\<,'=8GR M5^6%0*X]Z*BJ1MS%NT-'QP",OX)K M?I'=N7K\C+)3%]#>@44%K]ME=3`<\)RYZD,)LV/.CPK#P@]&M%DX1EW"PS[=.DE^,KSHR_>]E#UP%V:K(XT6#4) M$Y$Z^%6`1A'LUE0CPMBL0#I"@#[J#1%DY?AC!-4=A.D#1.TA:A`QBXX$ERY( M60\EW;F"6MBP:)H3)%ZW`[+3;[==X7X]$>V3CTGZNF/']=Q1?_'(P$6RV)"I MH/<@T(1W0QT*>7I/=?QP)[8A_.(="EPOVV8E;?6I;=>Y9Z]2[R]CF]'`6E?+& M6S!+%D^C`KLE%]:CV&,K;!6[/@6)\C9]D<9J>NZG'V3CV2_RK$\+>X05B'L1 M9Q9UQVO09$G MSK1W02_JS)G^4Q/.&0QN)2:B"G9[X@EU+E\<6E7T?(\JL9>$='Y8"2Q[6T_# ME_?9NS48H*IH/T=BY*S.QPCO_(A\\(+`)[XZ]J(G.G9`7["."!M"=(CVP#]& MM^=;V!M9Z/V$"XY;Z/`4H^-:FS&]'W55O&,X\STZ1:NG"'&+PO@^22V`3O'A M6]!P.3S!XCIC]AA]92_^QQ'/(&O4.K/5$*CQDB/"X94.8/IC!;$W_.X+C^>2 MEU9PXUC:"CTJ=;'#D),1T%?H*WWI*%>J[:RD"Q\8*L9D4FK2B)#4 M*V\N0[K"6)\YY?)J[N3E;;&G7!]K_#F::<2@3%K$H?2UNRRJM+D.C[@PT6!2 M*J?%)0&R>F/39TRS1CTFE;+29A# M&?H2L;=NTJ;>VBKFB/"A(,]13,D?RXA*Z6EG7$]HJ:$3KFS(96_B%^B'U<-8 M+3PQW/BR`*==8*ELK+F/$B#J!;LI4VPU<%0GA!5_//+Z=_(P?T3^1X<_R9/_ M#U!+`P04````"`#6@P=%F(@`"TR,#$T,#8S,%]P M&UL550)``/SX>-3\^'C4W5X"P`!!"4.```$.0$``.U=67/C.))^WXC] M#U[/Z[I+I-\DF0H!Y_VEP#O_^-__O,__OY?!PW>25+< MH_R_]Z[1,RC(-_?+ZO.#`\J1P?SWG^B/^P2#/2(ZQ]6_G_8?RW+^T^'A\_/S MJY?[(GN%BH?#-Z]?OSULJ/=7Y/3;2;EF:!/_>%A_V2:%DJ)A3M5*-T5G$N)_ M79**;"C92C^_K4B//G[\>%A]NR;%$QXA*?/H\%]?+V_31S!+-L1037S0JC>& M/^'JPTN4)F75ADI+[@DIZ'\'#=D!_>C@Z,W!VZ-71(E]TGY[>W4+%B@#-V"Z M1W__?'/1D3DO4)ED\.55BF:'E.!PGKT<3!)`4%09YJ=R.26;UT<_O'[W]C65^;<-ZZ&3^#2]QY;B:U97\1@A:_D5KX<*S%UJ,/=1 MA11BD$XDQ=JX`36SM4G&[";<."< MCB8O;2U>>FAMA^9V;V];S:$/S2=']JI37D?=,8+6\:]A=@6>K?R*T]GE;*77 MK(ZZ`UO5@;MH:[,#`[W;Z=S'6GH.'FB&?IG<@TQ=!5Y965%TBJ*)X4>:&!Z] MJVK9E>!>U3MJP.'KVQ;3KO2\`!CD995-TYR_4P?P4H)\LFE,*DEB1BIXG$_.\A*6RXM\BHI95=_C>UP62;H.L1E5KRK' MB(U\3=729SLTUZT]?B.)U*L']'0X`?"0ZDO_J!0_>'VT&G[\C7RTKLP=*991 M4?3U2I7^U]TJMQO]N.A6/RG2IC3R9Z_%NT.H%<7A/"E(>0?I(\S68)D6:&;1 M&$BIW76K]GL_[>E*V"O17K]D5$Q`\6G_:&NM>DQD3ZC\\RQYX#0K]_M6NS+? M1]>P,OT<6Y8I>M6T;[;NL->@@(A4=W)*(J_$<[ET'!=FZ*)KP>91PH<+]O-3_S?71-+M// ML9F9HE=-^VYK35M7\`8\0%JOO/R6S'@)@(RLU=!\LNC:6T-;QV;G2UBU_OLM MM_X)J7219!=DX/SR3[`4-K^`KM?^/;I(`2#7UPL">B)6$/BP-0B<+(JBDWN( M1P$JTA80Q*3184%3:T$"%."1PJ7H!@:&*#@)J M7;T$`T9`,]'S>MO=`9K-4'Y;HO3WVT=B2WRU**O])21/$?<-&DS]CD+*%"E, M#"SAIPN1RFM`M%D;.^R9\Y)\,/`$>[5+PPW$TP3?5ZVXP`? ML)!>??S;<9JB15[BZV29W&>`F)9\4BS`Y!(F]S"#)01X%7\%$_0>2EHUN5-) MCF'`FP7IH`6L:J=G*1Z'W")=CF"QP$?+(QNS,+'!H1XT7&C)WZPL$`-/`?FT M7C24&+"R7@D*##HK=>$A>E4^DK[4!*(\#CE$NQP["E&)6;8"T:[\S0I)C!#% M&)2Z/8V,EH4EGS:8GB<)?B2M3G^=_;&`3TE&ZH6/RY.D*)8D*_DER1;L^-** ME[&#)F]X1Y6V+7(SAL@I>3+;;J M]!FH;@LZN8BH@WW5;VWTPDJDJ1D8G,D8XD&9MMJV&),)V*RV1XBPB_R)*(&* M)=%(@"D>"8.B+DD\N)&H9HN4;I&;Q?<(L5'KJI5C:B67HJPR&$*D'9=&[BS% M"+>KXA<:=3YT"J8P!Y//("=_E-=9DM=:GJ."_K/Z'']#>2KMNJS+8;!F44X$ M<'2UCC%4+00VJ=:K'Z,$\G6!YJ`HEU2]:NJ`#&`7BI59 M.7$_(^<21X9(+9V=0">2$/4<9J/4"<+"_(=+(T#1BB8X>+3&;$*M;,9C[<*: M7#C2L5;?'[2[0.VN;P08,0LP2EV=@@NO=.L1U81(XO'$SRP MKGH+G0DV.;V\VQ[5A)E>.XH[;]-Y,JD\21?.F1X[>O4^TIB-\H<[4,Q.P7VI M!)NDW2G`*4L`"KC=X?4N)SQ&&-;2K!WFO7=13TRV=B.[5(8!'E!&% M,)U_+Y?Z.946NSB]4K"/R0OT-)4F]];35E+9\I1_R+FJ>!M$.108IDUX8GT0_\M@R[R)?86CJI0::&UNX`:BLP:E\A$B%XZ(E'6-+TCFI_ M@O(2Y@\@3\5@TN!@SQ+(.*(&F[XM/()/*G1SZ4F$'6=??P$&Q80,]'B$42-. MJ;E'H/%D;:Y5B1!?*B-8CNPL1W21(]'0*L/TO@+)FYM?(NR2;XF1JAF8J^DY MS!,2V)/L&F$HN?36AK47*758@R/62,/>;BRS<:V.K/XFK1V;6[`UN.5TF*>F MT)<>]6H!2?Z>0%'"^PQH+4=59?(6:]]>ECZ#'7Y M#'VB)Q3>SY(B)X,=?`V*ZGZ>SPF&*7'P4Y@M2E"O8IQ"G&8(+XCRBM[2L33& M5ZQ+"Q8]?@7PX9%4[9C`-7D`WQ:S>U!<3:O:MRX^8A01&-.M,,:6MH4%#TJN MD$*>#2J(99;5;$0H_DD`0'K`8#"Y134O0/[`NI@VJXVS(DFW]FO&7TV7P?W%55# M(*52`I\0%-QVB4V!@8ZBO8A@2G5.`OEOC`7#"9?"@+VZP)- MH:@?Y%`P$.E0Q`00L6KV\.B4&?5ND!MB`F)V>O_<*4%[AJJ+`\Y>YB#'HHBB MQ=-+-:0\,0'*1'V7I$0JQ7@7B:^(Q,U5OM"'-.C4^0V`L_L%Z1FK_0;UU5]@ MH$TC7.0U;M+RD>K^]@>8`U"0@>[* M8_JWT5ARMY!GQ!T+\NQ-8H<\(WG&VTG$S^>&NYUR#HJ$[L&J#4/'(8)^5D+) MWD?)HXP!DW+(W3[M$F+017U""ATO#P(:AB0DP,O7LH<*4VGK!PQ=* MQFU5S14(>P.+!32V-A]&C6G[BX.M[9:3_36%MORFI>)<'_B&RQJ2NNV3ALL%8ZKIGA*LKW/5$T()%3\R[) MYU''!#P]E1T&)Z+R6S'P;:17G_1TDP<]%;D*7E$&-DVE/0*,T\N:]+&2^!5P MB^D\W![3ZL(+`&Y!\013T*32],JY&35TC;NLJ@'YBRXJIN@AAW^"2?VR?'4U M'3$&N""-*!K-#R2%W5+E6TJX>X3K2H()7P=Y(#)C9F\>UF0.'J2&@A1R-*1H M;YO?ZG8.XFA6,^J+:K^O?7&WZ2.8+#)P-?6#FSO.TN569+%CNV%D!0]&)D/! M+9C;8>0X3.TVH61R5>]3-$M@KA=&^#SR8,+RC'.GS%=`SS/8[)?I0W8E:^^F:22.P,D4,TY2F!GQLKO[]'CC@YJ-45S! MIBESL_-X;#']^`6*!J(:''KQO.88*Z`Z^B"[#LT,1E1B]T5$J:01Q*IZC_1M MD@$LC4M".NXF]`[=6.$ACC>*!AXGRME!1R(CZK.D-*!/ZMG&S;U`Q MY24C[LUR\8GCP9:6NK:@$A4>]=4HZQQ&NK+")1+=1,A=RPBA$M.B6#*=HL4C M4IC/$]QK!*V&[+16W?#7RY$5A8^@Z][D[XI='V)"$20N17LOQHT#T^&TNO$U MAK)_W50]6(OWV]/#G=3]TC5OGS;>L#&OAN!$7E$&[R?IS`%NW9`F`HZ(CL5- MGRX6V"@TM$--OU#;)'U,H*&^<('Q`DQ.%_0,;3VG5"O[#3Q77XD['1-F7EC2 M8(X%?50R?+JI)7QBDA44^3A4 MXG?5EU=S:C1\]@(*.JLMNL32OB"3$"HH*&[DZMO(?V@52+6^'F#$F*[\U@.D MU>48A-^=!+2VA;R'93F/X(Z+UZ;8>`+%/0J/ M#H>IE=^.OH?)E9Z6WJ=7+.=7SO+@QY^M9U?$T-F=^15/P!'.L!Q93K&,`3>- MRE=3XX>_C7C%KVZ-^LEO,QUY*P(&IW*TA'$7";J':T:QUTUK9:R]G5%C]Y+* M;CQ9G:+*@#=LWOO;@!1"L.RV:%7Y]"K77B4 MH$JGA?MHMB.VMQ5G:+'CP;^TJ]JR_:WZO>'KV$P%FS_4X9RZ"ZS37+XZ[9?I!]FMIC^3/(45&=+7%);19$V::NPR/$$*M.QK$=3^AKYNE7)_CKD,2PC MM(YQ7"?%55$9KUXU::[`%?B$`:?X/(V8,UZ$FQO&%Y"U)%O/,XYD::.E9)U/ M'"_*1U300X)JI(HXQ`CM<^P$,A6&&`"1?8D-$HWWR(P$B?(M%-PT>94,6^Z7 MT2O2:.>,JLAXP>[1E/ZFV%VJM,"D*FA>)R?492!QI'+Y:?^USTOX`HZGIL&& M4IT,D,XIYBG,0&=/P!TZ2?#C=8&>(%'O\_)GTE`7^?H5E>.TA$\D<>P_22`; M2G@6)1MB>!,5=EFZYR"RM6DA,6]YFD,)O6->I3\B2+`?`A/UF0:N?I\JY(B!NG5%7ZZC2UX<]Y`4A:(![$V13!A'FS M(G;>6SQ8-E"78%;CR)^IOB9=7AT3JD<+KA&Q!RAA48T\/H,<3*'B96*+$AC/ M,2KANW$<>[L&\ANC"D=]IJ[=FUY-SV&>$%/F#](U'@T6=H`E9?EN_,#`T[7WQH3"G<+:?$JC]/B"1Q>+ED?VEA%?G*Q9">8>597P MV!_[8?0[3M,JNI'H">"3Y,XU$U8E:'FL.X=;I7T&ABY/OO$^!ULJ3N1R>UT[18D*K"Y!YF5=YI M'&YU"M,.P/+"=@[G%C;<4I"6URCJF2@R'N.-P=9S$-H;!^P+ZM_X8%Q0N-GO M`J4`3/`Y\0R36UJT^=B9;C5?\+C@@`1D;R%!*#"O3&=&6ET)VX7/D6P2%-B' M=OW8:..0?4%Z_B\M*)S_)\MF8W[ZQP(6@%2;=#7E\CI+\I)T&'2WW9PS]VE? M`!L1#`H8:VC0`0GR8#.S&"&I52=&&-3&>'YB7$ETH^HY*MJ1L5JMXUA+`7G# M4@2XURYEQ\!O9[U!/4"[2DV?^>KM>_TCEN-RA?Y@87/$E)I2>^3(9U..$5FV M'4&WH7T&@;.Z#NM'NSY$BU^!B;^C0FF[7'YH+UK@> MT?BJ,H0A??,WM'.V3NY0HYQGZ%GEACHLXH/R');@4-32"'D,1.IC5+UZ,!@T MEN]_O3*"AMK"$2/'IARFAOZWR$?0V-8[31R;T$3N;KS%["=7QVJEX&TI_8668AI+*#[1EU=,[Q--IO87P)7U,\@=P0^QTE5,;'.?5`)!. MZ#TE&>T>!-F831'LJ\5&142':@<+.>+93'+4;TKPE:I/];,=I`#)-D6PMY48 M%1$=DATLY(AD,\G6;P:4]$:$<4+YF'1-1;$DO9#LYE\C7BWP]GAW!+5RFPP" MUYY(QP<*1O&6W^!H%3YE\%WCU?CQ`[^(C?AIA,5\GE462;+&(A?Y%!6S&A.* MN4K+6=AJG,EJG!RW* M"`]+0Y@A/^82X52O-LU)/HM:C.EF':IA!O!Z0^#JJK75-D$.2/486HA4,<0* M/R-#^,&:2F34;Z+J+S^=H)Q\L""?K;[L(]5OH=8+_?Q"PR-^L)5)#2MN;962 M7Q?[]TM&,8V@O^K@[B6&A5IO@]YM+[&SXM86IZ1>8O-"RHB]A+/DX^XEAH5: M'Q;:;2^QL^+65@:E7O+!AY>$N1<8)^'>5UD=3J37-*,,IAI7^RH9V/NC)`S! M8M/G!$-\-6U#EPP/;^%##JL1^1SD,%HF:>P*6IQ"G&<*+`BCO'U)R]$Y`2#@"G@+I MU4H5;'18U+J/*5CH-":R,H#P>+]08'<+H$Q0[.X^?9H%<_CS!!;5VM?&LJKD M0X>%O0]9RA+NLFA.M51.K\6CH?Z8W%ZK19&=#02.+Q/9N8!9+BIVU\=EP$<= MV8=DOJ%2U=OK,?'>!9(PA7U6J5"2B>;^)BL4DJ,^F&=LZ3(B6JX M>=Y5#Z":7.R!&1579)`TLX(3%I6BHMX9URCMZ+:MRP&W(SHZWM=F#^[_A M3+RE8=QFY?6%[L`P>W(4;IQ=%/1T:W6)Q7$^^8;R9//)W>9).OP5S.Y!(?`= MRU+8$;EI*;Z&Z=>KAOD,T=TC&0K.P:*$*:;7>!1S5`\-N?K;,;<&[B;,P>.& M;2LC1T.)\@NSZC2#?I-JC.D,P?44_DDO2M3"I(JV#4$Q;?2(TS2#9X")I48] M2M^-*5GY/A_.XSEF3"W'TF$*[V':L[+&-K">EM61M(G,X?R!U&L"LP6]"O`6 MI(NBVL/Z+9F!4S1+8"[R"DTVUC>4;-X\I'7:B82]S:VFU:0//Q$TYFO[B1Y? M>%?1;3AD;P^1SRA$KSU'3V34BQI\6YR]I-F"#+[HC=(G:#9?U#:\FK*3EI^7 M_`*.7Z#P3=WA)6HYNR>)(W4DO_9$U@'7R`6]5+ISIZ2RLDX]GW3X>UE.E*/< M'@UG,-NB"8\U/V-6D=K##$U;TFR75$;R;LQM"HCJ$/V_R@CKC MU?1V<8_)D#3A/,^M(FOO4.:2!0.O14L@;7T9`.O+6N]+YLJ(>M:N_>+;"7%W[1.997>FWEL)ZQY(XPJ)VG#;6W!Q M-O^@5=V$WH@:T3K)M6X+$XF;H:6O//DKS``N40Y6[]MR\N%_^F*:*-GD3<>563T=RJRDLZQ,SH$BI!1YXFXRL^-M7`)OQ1X@O M%PLY@\]0>-1S6*3/FJ&\VDURG117195D3*J[,IJ>2Y!$&W"R3U+H<$8&6GNK M>!G5:8GU_UI>/)N!CF?4C,-L^^F6[7>#3U-VI.XPA&6].(RGBC7W^D;Y`*7] ML$UG`L5YP"40TB2"])+8<$L_&TVJ-P>6-`##ZH7@&T!7(HAB7\G/V6)60Z7^ MOMR<&6/7AYP+9!>1'`H<+R*EP<:;#;U$&)?:.%RJ/\!PYQ*27!<#>G5JI_09W!+[(/IHG/U%CP@&<197AEP<@,?'KEX MMR^DO>O6HI`(,>UL*V<4V]1@@]NW1UL'KO^5V]N$GLB_*A]!<8PQ*/&1(''1 M8Y*LX?*8(D.ME2V\K^;R)*Y1^>[#^U%$4S85(@.J?X.$N]5.3MG>+R.BC`Q& M^EH[1SBAF`U@_/2_@6[EP0BFD[]NY@FG.4GI5*JV2$2Z523!MUK8WF??5]#3 M_?55P=:SN6-X4&JMRJ\%+,$I>A8=$Q(3BC#3(HP6.2)E/>&G5;SM!.9(3IVM M5;I)GK\FI/LA(TQ,W.-J>D,L53SU-K*:,XIP)F&,%G>ZQO"$0XFX9E?3UF?` M?,O@/>&Z.S^%QDMN^.%3QOV MR9(+C!=@26K_BDY?6?&S,!8EWF4IJ$[VJ27(IDQ&YBFS1S5\GQ>5JD1[R)M`P[AVRHF%FV:=/LW#3[#HOQ3,HUGIUVABYV$/@V3+!W5.V&@(7F`A"53^<9#31@Z@@L>+3 M_NN-[[^.=G$.!`L:](HT\,>":'1&5T%5`4-%SG9X0O)PO3U3)>6SABIZAKA0V7K(7&]1MRX0U>G0Q2)VW-W#)0F,S7NYOAS]HJ&!FCR?2&$);[(Z_4'D9D&$<(:U[.0L86C/KC0EBRL%\,NN>M4 MGNNE$?C>>@A\H1SQ7FVI>]929R]S6#\#J/9!G^7SW,]/^?%YW@!V=74Z/U72 M\+577X!F!BAN4+][(]%DOWO(BE(5;/E M19X6M7$Y"YS;%=P^J;PEP5'X=;"6L/#E;=95PW_?1]S1>[-@OTTW/1=Q&YJ,U-0_:#66N^"%=T:,X0(7Y-07!'QN>,P MU@TQ`<6ME8;[_3B>+-?;O%OUWVE2@O7BHRB_W8)(-K,=5&04'AC`^B[9[*"U MU/#0C^/Q4.?\H#:$.+'?-$BV'&Q,:E,)[^-3LTK$Y=GV9PFI?#EZ-!N>91J(MV"(%M_U`-Q_^$I8^@ZOB3`V49T<4](K`"<\ M'Q9.9^[Y%"U:N:ZC.;6B;C.QBQF]S"R2(W&RIOPM;6\*CS9J%=G[S7)JM7>- MY-E(E1YBQ)F>KQ1(DF"N+4$3=Z.SIV8/*<"/GPYR4[B5%;^[/;WA86.RO]7D MQ(KYUM95Z9IC=]7>U-4W]`<=79!/_A]02P,$%`````@`UH,'17&=(ISP"``` M[T<``!``'`!P;'@M,C`Q-#`V,S`N>'-D550)``/SX>-3\^'C4W5X"P`!!"4. M```$.0$``.U]FE'V,>@ MJ;&\DIQ`__I[).-@@VT@85LRY65C2>=(Y_S.AS[9C[_,IK[Q!%Q0%MQ6ZB>G M%0,"A[DT&-]6(E$EPJ&T8@A)`I?X+(#;RAQ$Y9=/__GAXW^KU08'(L$UGJF< M&';?'A@-PD3X_87QX=GI:;WV^T-[H+M=$M/-Q%4:*+T< M2+C6A)F-N)\PGM=4\XB(%W+5ZLH7AC3Q92UN3$@Y>(4=7]6P-2$,6!!$TWQ: M5_*:G(=00Z(J4@&GS@O?9J85!A@KRQ5*=5WCS$>NF"RM,BV!:!71F5]"_'L[ M9=[0GV5(0\XD\>GLQ&%3)*]?G%Z=GR;$+M`L[`*UJOG]80< M_7A,2/C"XA$QTF(L&C(L1$I.1Y&$%N/3)G@D\M'&4?`M0G$\JK``'Z80R`Q! MJED2/@;9(5,0(7%@"[4P-@Q#1P<)`B20&(VZ+JD-0QIX;%&%EUB(9.V$A<$E!I&*IMB^M'.+OJA6R.)%_R$JYX.VJ%++0@!ZP3CX9 M[:H3LH#_?=51_0Q1`4-]//;MXK"-`P(U<@G@W$C=6#]=>NDTZ79IC4\X^1A5 MH\F<2&6/]"=.KH852"IQLL0XYU/MDA]KJSVL=AX)<+O!)_V]&J$+[@5)&>=* M%&S/F/6T?+Y%;8+NVT%WG)%8@JY+Y:"?(=(#Q`46J#>ZG:;5&5A-]37HMNVF M.<3"G=DV.PW+&'RVK.'@B'T^]H*Q-/BJ6([^^7;H#X;XY\'J#`=&MV5T>U;? M'-I(<+1#H1W"%4.$&RQQ\39+&!]ZA"/G!"1%M'X\6J;(,@[%Y:B;MQ,[0[]T8/S8$!<00]%_341J-\EU'7"]X,X';G"_IV MMW\$MP!<[VFZA%<5R@$^7P6X9=I]XXO9?K2,!\L3LN] M_+PT81L?AF3D@SCB7.3G;CWCZ%@L0_OB=/<5B?&A"9)0_VB$`F<7C*8WO(MR MN1ER4D[&[=4=G1OY8##/L(,GQ)'QN=%@TY`%6!`_'JVR::)UTS/M)GM6:IS_>#:S?'A7.ELI! MQU5E`SG5XZ;__QF&QG2G)V848ESK:"O7[U9G->)LB\YH!7`CKD$IT>J>$]SFF(';!SH=15SH1M$' M!^@33CH\_E+R+!7>B>G]8-''R9YP9]*$)_!9J%I01RL8TP"PIV!LS4((!'1@ M>>[R=2>FOQ4+%T:OAF(P(1SN34RI&4)-$%VE4H3YLA4%+KBVLF\(#IK3FH8^ MFP/TZ7@BQ6.H3"\IARPX;^WG_426'2`[1H.->R$RHCY5KRO1YWOQ4\MY#P?1 MV?9;1,,L2*]@?3^X-(B8^""$-0.NGI-T/9T8NJ'B2Z63373O)G0Z1.6XKM=% M/DTKXGNA(@C16._X1Q(U,ZO_A-(E;MA%PM!`.3EU*.$U/#/FM M:?O10,(8^#^LQ0-%?Y/H2CTRSP;D>LN[\;X&4V,Q1?<$)L?%[U@W8R[QJ-03 M;P\#3!T4C5.KY!W9%EZ)+AG&M=_3E/%.5):M:J(P].>X#)E2J:4&_@HR-;(XYQ*[+)/Y+B=^*5)9=A+)>L'8#7)'&KIV"Z>T]O9LL,4!- M,2^SX3-[`)6M4Z&RWI29@UPVQ37='K2*RV\3?X(6*E0@W7AP*O06UPEW2E"< M_4/`X1V!2T'&0Q:SKVJV"\_A*>S1OW#*+]6OF.3PU%G8HBW=(C.EF@Y._&37 MM2K[:OW!"9[\0DR?6ZG?AZ5^'F8N!DCMS;>BSAQ#2'4.=AC&0:D[.(ML,%4^ MU<$9+DG++1;QHI2=;CM8!;I!X923:CH\\>DXH!YUU%&"XZB%(/JYWF[B]JQ- M`U#BI8_WMJ0_M.`IE7N8O1O8AO85^KGR9C)7&Z-HI%'Z7IJFSD?T_<;+R:L^ M2EUSTNW(#\]QE7BCU7/FU![U;KXD6:S-];'S0MM%AS=2P$WR+\].?[1GVWL=,62.`Y!!.L M7:JLPW!7`$-\VVD',1"ZU"026H3R+\2/8-/US3Y'.I`CA"SJ\3.C^!X>B_\' M4$L!`AX#%`````@`UH,'14DT%M"80```!Q`"`!``&````````0```*2!```` M`'!L>"TR,#$T,#8S,"YX;6Q55`4``_/AXU-U>`L``00E#@``!#D!``!02P$" M'@,4````"`#6@P=%)#-SFHH*``#ZB@``%``8```````!````I('B0```<&QX M+3(P,30P-C,P7V-A;"YX;6Q55`4``_/AXU-U>`L``00E#@``!#D!``!02P$" M'@,4````"`#6@P=%[9?!]J\.``#US@``%``8```````!````I(&Z2P``<&QX M+3(P,30P-C,P7V1E9BYX;6Q55`4``_/AXU-U>`L``00E#@``!#D!``!02P$" M'@,4````"`#6@P=%1P+HQ(Q0``!LJP0`%``8```````!````I(&W6@``<&QX M+3(P,30P-C,P7VQA8BYX;6Q55`4``_/AXU-U>`L``00E#@``!#D!``!02P$" M'@,4````"`#6@P=%F(@``L``00E#@``!#D!``!02P$" M'@,4````"`#6@P=%<9TBG/`(``#O1P``$``8```````!````I(%+RP``<&QX M+3(P,30P-C,P+GAS9%54!0`#\^'C4W5X"P`!!"4.```$.0$``%!+!08````` ..!@`&`!0"``"%U``````` ` end XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

CURRENT ASSETS:

Cash and cash equivalents $ 71,144 $ 86,398

Accounts receivable - Trade 2,097 2,091

Other assets 1,988 1,457

Inventories 7,135 7,957

Total current assets 82,364 97,903

FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT 1,721 1,578

PROPERTY AND EQUIPMENT, NET 12,438 13,711

DEFERRED CHARGES 128 141

Total assets 96,651 113,333

Accounts payable and accruals:

Trade 3,592 5,254

Other 16,305 12,073

Deferred revenues 7,282 9,369

Total current liabilities 27,179 26,696

LONG TERM LIABILITIES:

Convertible notes 67,255 67,048

Deferred revenues 39,514 41,796

Liability in connection with collaboration operation 2,371

Liability for employee rights upon retirement 2,493 2,368

Total long term liabilities 109,262 113,583

Total liabilities 136,441 140,279

COMMITMENTS

CAPITAL DEFICIENCY (39,790) (26,946)

Total liabilities net of capital deficiency $ 96,651 $ 113,333

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableOtherCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_DeferredCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=21915240&loc=d3e1703-114919

+ Details

Name: us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e2417-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e2410-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=21915240&loc=d3e1703-114919

+ Details

Name: us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) (USD $)
6 Months Ended

Jun. 30, 2013

Jun. 30, 2014

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY) [Abstract]

Share-based compensation related to restricted stock award, forfeitures 1,667

Common Stock, par value $ 0.001 $ 0.001

Common Stock, Authorized 150,000,000 150,000,000

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares (or other type of equity) forfeited during the period.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (13,464) $ (11,158)

Adjustments required to reconcile net loss to net cash used in operating activities:

Share based compensation 577 2,499

Depreciation and write down of fixed assets 1,628 1,818

Financial income, net (mainly exchange differences) (133) (120)

Changes in accrued liability for employee rights upon retirement 102 93

Gain on amounts funded in respect of employee rights upon retirement (25) (14)

Amortization of debt issuance costs and debt discount 220

Changes in operating assets and liabilities:

Decrease in deferred revenues (including non-current portion) (4,369) (4,207)

Increase in accounts receivable and other assets (397) (406)

Decrease (increase) in inventories 822 (3,152)

Increase (decrease) in accounts payable and accruals (including long term ) 180 (3,048)

Net cash used in operating activities (14,859) (17,695)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment (371) (1,341)

Investment in restricted deposit (93)

Amounts funded in respect of employee rights upon retirement, net (101) (71)

Net cash used in investing activities (565) (1,412)

CASH FLOWS FROM FINANCING ACTIVITIES:

Exercise of options 31 30

Net cash provided by financing activities 31 30

EFFECT OF EXCHANGE RATE CHANGES ON CASH 139 168

NET DECREASE IN CASH AND CASH EQUIVALENTS (15,254) (18,909)

BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 86,398 52,035

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD 71,144 33,126

SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:

Purchase of property and equipment 170 304

Exercise of options granted to employees $ 12

X

- Definition

Cash due from broker assisted exercises of employee stock options.

+ References

No definition available.

+ Details

Name: plx_CashlessExerciseOfStockOptions

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.

+ References

No definition available.

+ Details

Name: plx_DepreciationAmortizationAndAssetImpairment

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Gain (loss) on amounts funded in respect of employee rights upon retirement.

+ References

No definition available.

+ Details

Name: plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase in liabilities for property, plant and equipment.

+ References

No definition available.

+ Details

Name: plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3098-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 70

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6414718&loc=d3e28014-114942

+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]

REVENUES $ 2,425 $ 2,264 $ 9,121 $ 5,832

COMPANY'S SHARE IN COLLABORATION AGREEMENT 261 800 948 1,200

COST OF REVENUES (1,605) (1,318) (5,678) (2,289)

GROSS PROFIT 1,081 1,746 4,391 4,743

RESEARCH AND DEVELOPMENT EXPENSES (7,076) (7,990) (15,228) (15,744)

Less - grants and reimbursements 2,114 1,532 4,199 3,963

RESEARCH AND DEVELOPMENT EXPENSES, NET (4,962) (6,458) (11,029) (11,781)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (1,566) (2,182) (5,277) (4,285)

OPERATING LOSS (5,447) (6,894) (11,915) (11,323)

FINANCIAL EXPENSES (874) (9) (1,789) (22)

FINANCIAL INCOME 202 66 240 187

FINANCIAL INCOME (EXPENSES) - NET (672) 57 (1,549) 165

NET LOSS FOR THE PERIOD $ (6,119) $ (6,837) $ (13,464) $ (11,158)

LOSS PER SHARE OF COMMON STOCK:

BASIC AND DILUTED $ (0.07) $ (0.07) $ (0.15) $ (0.12)

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:

BASIC AND DILUTED 92,820,897 92,297,522 92,754,640 92,241,505

X

- Definition

Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.

+ References

No definition available.

+ Details

Name: plx_GrantsAndReimbursementsReceivedOrReceivable

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The Company's share in collaboration agreement.

+ References

No definition available.

+ Details

Name: plx_OtherGainsLosses

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Research and development expenses, net.

+ References

No definition available.

+ Details

Name: plx_ResearchDevelopmentAndEngineeringExpenseNet

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENT (Details) (USD $)
In Millions, unless otherwise specified

Jun. 30, 2014

FAIR VALUE MEASUREMENT [Abstract]

Fair value convertible notes $ 70.2

X

- Definition

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Convertible Security

-URI http://asc.fasb.org/extlink&oid=6509036

+ Details

Name: us-gaap_ConvertibleDebtFairValueDisclosures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2014

Aug. 01, 2014

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Trading Symbol PLX

Entity Registrant Name PROTALIX BIOTHERAPEUTICS, INC.

Entity Central Index Key 0001006281

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 93,664,898

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: plx_DocumentAndEntityInformationAbstract

Namespace Prefix: plx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK TRANSACTIONS (Details) (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Class of Stock [Line Items]

Cash proceeds from exercise of options $ 31,000 $ 30,000

Certain Employee [Member]

Class of Stock [Line Items]

Exercise of options granted to employees (in shares) 55,362

Cash proceeds from exercise of options $ 43,000

Common stock issued in connection with exercise of options 56,122

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 26 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Research and Development Expense [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Share-based compensation $ 163 $ 719 $ 591 $ 1,589

General and Administrative Expense [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Share-based compensation $ (256) $ 413 $ (14) $ 910

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS
3 Months Ended

Jun. 30, 2014

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 5 – SUBSEQUENT EVENTS

On July 24, 2014, the Company's Board of Directors approved the grant of a 10-year option to purchase 150,000 shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $3.37 per share. The options vest over a three-year period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two year period, subject to certain terms and conditions. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's 2006 Stock Incentive Plan. The Company estimated the fair value of the option on the date of grant using the Black-Scholes option-pricing model to be approximately $293,000.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK TRANSACTIONS
6 Months Ended

Jun. 30, 2014

STOCK TRANSACTIONS [Abstract]

STOCK TRANSACTIONS

NOTE 4 – STOCK TRANSACTIONS

During the six months ended June 30, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS (Details) (Subsequent Events [Member], USD $)
0 Months Ended

Jul. 24, 2014

item

Subsequent Events [Member]

Subsequent Events [Line Items]

Term of option 10 years

Option granted (in shares) 150,000

Exercise price (in dollars per share) $ 3.37

Vesting period 3 years

Vest on the first anniversary of the grant date 50,000

Number of equal quarterly increments for remaining shares vest 8

Subsequent vesting period 2 years

Estimated fair value of option on the date of grant $ 293,000

X

- Definition

Represents the estimated fair value of option on the date of grant.

+ References

No definition available.

+ Details

Name: plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the number of equal quarterly increments for remaining shares vest.

+ References

No definition available.

+ Details

Name: plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements

Namespace Prefix: plx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the subsequent vesting period of equal quarterly increments for remaining shares vest.

+ References

No definition available.

+ Details

Name: plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently

Namespace Prefix: plx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options vested.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)
In Millions, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2009

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Protalix Bio Therapeutics Incorporation [Member]

Jun. 30, 2014

Pfizer Incorporation [Member]

Jun. 18, 2013

Protalix Ltd. [Member]

Dec. 31, 2009

Upon Filing of Pediatric Investigation Plan to EMA [Member]

Jun. 30, 2012

Upon FDA Approval [Member]

Significant Accounting Policies [Line Items]

Number of Subsidiaries 2

Pfizer Agreement, upfront payment received $ 60.0 $ 5.0

Milestone payment triggered 25.0

Pfizer Agreement, future revenues and expense sharing percentage 40.00% 60.00%

Supply commitment for entitled rights to be received 280

License and supply agreement potential future payment 12.5

Supply agreement maximum consideration payment 40

Revenue from sale of products $ 3.5

Common stock, par value per share $ 0.001 $ 0.001 $ 0.001 $ 0.001

Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive 18,778,154 7,356,464 18,844,777 7,413,383

X

- Definition

Collaborative arrangement profit sharing percentage.

+ References

No definition available.

+ Details

Name: plx_CollaborativeArrangementProfitSharePercentage

Namespace Prefix: plx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

License And Supply Agreement Potential Future Payment Based On Net Profits

+ References

No definition available.

+ Details

Name: plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name: plx_MilestonePayment

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of subsidiaries.

+ References

No definition available.

+ Details

Name: plx_NumberOfSubsidiaries

Namespace Prefix: plx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.

+ References

No definition available.

+ Details

Name: plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: plx_SignificantAccountingPoliciesLineItems

Namespace Prefix: plx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.

+ References

No definition available.

+ Details

Name: plx_SupplyCommitmentPerYear

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromCollaborators

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow from the sale of other assets as part of operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfOtherAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

SIGNIFICANT ACCOUNTING POLICIES (Policy)
6 Months Ended

Jun. 30, 2014

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

a. General

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx^® protein expression system (“ProCellEx”). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (“EMA”) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the “Subsidiaries.”

On May 1, 2012, the U.S. Food and Drug Administration (“FDA”) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the “Israeli MOH”) in September 2012, by the Brazilian Ministry of Health (the “Brazilian MOH”) in June 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.

Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO™ by Pfizer Inc. (“Pfizer”), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the “Pfizer Agreement”). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO™.

Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.

On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the “Brazil Agreement”) with Fundação Oswaldo Cruz (“Fiocruz”), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of 2014.

During the six months ended June 30, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.

To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.

Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.

In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.

An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.

In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.

In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.

Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.

Basis of Presentation

b. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.

Net loss per share

c. Net loss per share

Basic and diluted loss per share (“LPS”) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $0.001 per share (the “Common Stock”) outstanding for each period.

Diluted LPS does not include 7,413,383 and 18,844,777 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the six months ended June 30, 2013 and 2014, respectively, and 7,356,464 and 18,778,154 shares of Common Stock for the three months ended June 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.

X

- Definition

The accounting policy related to the nature of operations of the entity.

+ References

No definition available.

+ Details

Name: plx_NatureOfOperationsPolicyTextBlock

Namespace Prefix: plx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

INVENTORIES (Tables)
6 Months Ended

Jun. 30, 2014

INVENTORIES [Abstract]

Inventory

Inventory at June 30, 2014 and December 31, 2013 consisted of the following:

June 30, December 31,

2014 2013

(U.S. dollars in thousands)

Raw materials $ 1,845 $ 2,342

Work in progress 133 92

Finished goods 5,157 5,523

Total inventory $ 7,135 $ 7,957

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

INVENTORIES (Schedule of Inventory Components) (Details) (USD $)
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

INVENTORIES [Abstract]

Raw materials $ 1,845,000 $ 2,342,000

Work in process 133,000 92,000

Finished goods 5,157,000 5,523,000

Total inventory 7,135,000 7,957,000

Inventory write-down $ 1,600,000

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 34 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Beginning Balance $ (26,946) $ (3,357)

Share-based compensation related to stock options 190 645

Share-based compensation related to restricted stock award 387 1,854

Exercise of options granted to employees 43 30

Net loss for the period (6,119) (6,837) (13,464) (11,158)

Ending Balance (39,790) (11,986) (39,790) (11,986)

Common Stock [Member]

Beginning Balance 94 93

Beginning Balance (in shares) 93,551,098 93,489,809

Share-based compensation related to stock options

Share-based compensation related to restricted stock award

Share-based compensation related to restricted stock award (in shares) (1,667)

Exercise of options granted to employees ^[1] 1

Exercise of options granted to employees (in shares) 55,362 21,480

Net loss for the period

Ending Balance 94 94 94 94

Ending Balance (in shares) 93,606,460 93,509,622 93,606,460 93,509,622

Additional paid-in Capital [Member]

Beginning Balance 184,345 180,145

Share-based compensation related to stock options 190 645

Share-based compensation related to restricted stock award 387 1,854

Exercise of options granted to employees 43 29

Net loss for the period

Ending Balance 184,965 182,673 184,965 182,673

Accumulated Deficit [Member]

Beginning Balance (211,385) (183,595)

Share-based compensation related to stock options

Share-based compensation related to restricted stock award

Exercise of options granted to employees

Net loss for the period (13,464) (11,158)

Ending Balance $ (224,849) $ (194,753) $ (224,849) $ (194,753)

[1] Represents amount less than thousand

X

- Definition

Amount of recognized equity-based compensation during the period for restricted stock awards.

+ References

No definition available.

+ Details

Name: plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures

Namespace Prefix: plx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares

+ References

No definition available.

+ Details

Name: plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares

Namespace Prefix: plx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 35 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENT
6 Months Ended

Jun. 30, 2014

FAIR VALUE MEASUREMENT [Abstract]

FAIR VALUE MEASUREMENT

NOTE 3 – FAIR VALUE MEASUREMENT

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.

The fair value of the convertible notes as of June 30, 2014 is approximately $70.2 million based on a level 2 measurement.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 44 111 1 true 12 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.protalix.com/role/plx-daei Document and Entity Information true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.protalix.com/role/plx-ccbs CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.protalix.com/role/plx-ccsoo CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.protalix.com/role/plx-ccsoop CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY Sheet http://www.protalix.com/role/plx-ccsocisecd CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY false false R6.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) Sheet http://www.protalix.com/role/plx-ccsocisecdp CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) false false R7.htm 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.protalix.com/role/plx-ccsocf CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.protalix.com/role/plx-sap SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 102 - Disclosure - INVENTORIES Sheet http://www.protalix.com/role/plx-i INVENTORIES false false R10.htm 103 - Disclosure - FAIR VALUE MEASUREMENT Sheet http://www.protalix.com/role/plx-fvm FAIR VALUE MEASUREMENT false false R11.htm 104 - Disclosure - STOCK TRANSACTIONS Sheet http://www.protalix.com/role/plx-st STOCK TRANSACTIONS false false R12.htm 105 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.protalix.com/role/plx-se SUBSEQUENT EVENTS false false R13.htm 201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy) Sheet http://www.protalix.com/role/plx-sapp SIGNIFICANT ACCOUNTING POLICIES (Policy) false false R14.htm 302 - Disclosure - INVENTORIES (Tables) Sheet http://www.protalix.com/role/plx-it INVENTORIES (Tables) false false R15.htm 40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.protalix.com/role/plx-sapd1 SIGNIFICANT ACCOUNTING POLICIES (Details) false false R16.htm 40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details) Sheet http://www.protalix.com/role/plx-isoicd INVENTORIES (Schedule of Inventory Components) (Details) false false R17.htm 40301 - Disclosure - FAIR VALUE MEASUREMENT (Details) Sheet http://www.protalix.com/role/plx-fvmd FAIR VALUE MEASUREMENT (Details) false false R18.htm 40401 - Disclosure - STOCK TRANSACTIONS (Details) Sheet http://www.protalix.com/role/plx-std STOCK TRANSACTIONS (Details) false false R19.htm 40501 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.protalix.com/role/plx-sed SUBSEQUENT EVENTS (Details) false false All Reports Book All Reports Element us-gaap_ProceedsFromStockOptionsExercised had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS plx-20140630.xml plx-20140630.xsd plx-20140630_cal.xml plx-20140630_def.xml plx-20140630_lab.xml plx-20140630_pre.xml true true

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 71,144	$ 86,398
Accounts receivable - Trade	2,097	2,091
Other assets	1,988	1,457
Inventories	7,135	7,957
Total current assets	82,364	97,903
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	1,721	1,578
PROPERTY AND EQUIPMENT, NET	12,438	13,711
DEFERRED CHARGES	128	141
Total assets	96,651	113,333
Accounts payable and accruals:
Trade	3,592	5,254
Other	16,305	12,073
Deferred revenues	7,282	9,369
Total current liabilities	27,179	26,696
LONG TERM LIABILITIES:
Convertible notes	67,255	67,048
Deferred revenues	39,514	41,796
Liability in connection with collaboration operation		2,371
Liability for employee rights upon retirement	2,493	2,368
Total long term liabilities	109,262	113,583
Total liabilities	136,441	140,279
COMMITMENTS
CAPITAL DEFICIENCY	(39,790)	(26,946)
Total liabilities net of capital deficiency	$ 96,651	$ 113,333

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2014
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY) [Abstract]
Share-based compensation related to restricted stock award, forfeitures	1,667
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, Authorized	150,000,000	150,000,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,464)	$ (11,158)
Adjustments required to reconcile net loss to net cash used in operating activities:
Share based compensation	577	2,499
Depreciation and write down of fixed assets	1,628	1,818
Financial income, net (mainly exchange differences)	(133)	(120)
Changes in accrued liability for employee rights upon retirement	102	93
Gain on amounts funded in respect of employee rights upon retirement	(25)	(14)
Amortization of debt issuance costs and debt discount	220
Changes in operating assets and liabilities:
Decrease in deferred revenues (including non-current portion)	(4,369)	(4,207)
Increase in accounts receivable and other assets	(397)	(406)
Decrease (increase) in inventories	822	(3,152)
Increase (decrease) in accounts payable and accruals (including long term )	180	(3,048)
Net cash used in operating activities	(14,859)	(17,695)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(371)	(1,341)
Investment in restricted deposit	(93)
Amounts funded in respect of employee rights upon retirement, net	(101)	(71)
Net cash used in investing activities	(565)	(1,412)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of options	31	30
Net cash provided by financing activities	31	30
EFFECT OF EXCHANGE RATE CHANGES ON CASH	139	168
NET DECREASE IN CASH AND CASH EQUIVALENTS	(15,254)	(18,909)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	86,398	52,035
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	71,144	33,126
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Purchase of property and equipment	170	304
Exercise of options granted to employees	$ 12

FAIR VALUE MEASUREMENT (Details) (USD $) In Millions, unless otherwise specified	Jun. 30, 2014
FAIR VALUE MEASUREMENT [Abstract]
Fair value convertible notes	$ 70.2

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Trading Symbol	PLX
Entity Registrant Name	PROTALIX BIOTHERAPEUTICS, INC.
Entity Central Index Key	0001006281
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		93,664,898

STOCK TRANSACTIONS (Details) (USD $)	6 Months Ended
STOCK TRANSACTIONS (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Class of Stock [Line Items]
Cash proceeds from exercise of options	$ 31,000	$ 30,000
Certain Employee [Member]
Class of Stock [Line Items]
Exercise of options granted to employees (in shares)	55,362
Cash proceeds from exercise of options	$ 43,000
Common stock issued in connection with exercise of options	56,122

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2014
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 5 – SUBSEQUENT EVENTS On July 24, 2014, the Company's Board of Directors approved the grant of a 10-year option to purchase 150,000 shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $3.37 per share. The options vest over a three-year period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two year period, subject to certain terms and conditions. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's 2006 Stock Incentive Plan. The Company estimated the fair value of the option on the date of grant using the Black-Scholes option-pricing model to be approximately $293,000.

STOCK TRANSACTIONS	6 Months Ended
STOCK TRANSACTIONS	Jun. 30, 2014
STOCK TRANSACTIONS [Abstract]
STOCK TRANSACTIONS	NOTE 4 – STOCK TRANSACTIONS During the six months ended June 30, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.

SUBSEQUENT EVENTS (Details) (Subsequent Events [Member], USD $)	0 Months Ended
	Jul. 24, 2014 item
Subsequent Events [Member]
Subsequent Events [Line Items]
Term of option	10 years
Option granted (in shares)	150,000
Exercise price (in dollars per share)	$ 3.37
Vesting period	3 years
Vest on the first anniversary of the grant date	50,000
Number of equal quarterly increments for remaining shares vest	8
Subsequent vesting period	2 years
Estimated fair value of option on the date of grant	$ 293,000

SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended			6 Months Ended				1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2009	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Protalix Bio Therapeutics Incorporation [Member]	Jun. 30, 2014 Pfizer Incorporation [Member]	Jun. 18, 2013 Protalix Ltd. [Member]	Dec. 31, 2009 Upon Filing of Pediatric Investigation Plan to EMA [Member]	Jun. 30, 2012 Upon FDA Approval [Member]
Significant Accounting Policies [Line Items]
Number of Subsidiaries				2
Pfizer Agreement, upfront payment received			$ 60.0						$ 5.0
Milestone payment triggered										25.0
Pfizer Agreement, future revenues and expense sharing percentage						40.00%	60.00%
Supply commitment for entitled rights to be received								280
License and supply agreement potential future payment								12.5
Supply agreement maximum consideration payment								40
Revenue from sale of products				$ 3.5
Common stock, par value per share	$ 0.001	$ 0.001		$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive	18,778,154	7,356,464		18,844,777	7,413,383

INVENTORIES (Schedule of Inventory Components) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
INVENTORIES [Abstract]
Raw materials	$ 1,845,000	$ 2,342,000
Work in process	133,000	92,000
Finished goods	5,157,000	5,523,000
Total inventory	7,135,000	7,957,000
Inventory write-down	$ 1,600,000

FAIR VALUE MEASUREMENT	6 Months Ended
FAIR VALUE MEASUREMENT	Jun. 30, 2014
FAIR VALUE MEASUREMENT [Abstract]
FAIR VALUE MEASUREMENT	NOTE 3 – FAIR VALUE MEASUREMENT The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes as of June 30, 2014 is approximately $70.2 million based on a level 2 measurement.